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ABSTRACT 
Young women (18-30 years) are at high risk of weight gain and obesity. In Australia, young 
women are gaining weight more rapidly than other age and gender groups, including young men of 
similar age. Lifestyle changes such as moving away from the family home, cohabitation with 
friends or a partner, and for some young women, marriage and pregnancy increase the risk of 
weight gain. 
 
Recent evidence supports a link between obesity and disrupted iron metabolism, with the iron 
regulatory hormone hepcidin proposed as a key mediator. Chronic inflammation associated with 
obesity is believed to elevate circulating hepcidin concentration, which in turn, leads to reduced 
functional iron status. With iron deficiency already common in women of reproductive age, 
obesity-related iron disturbances may further contribute to iron inadequacy. Apart from fatigue, 
suboptimal iron status may lead to other reproductive, cognitive and mental health problems, some 
of which may also influence the capacity for young women to engage in and be successful with 
weight management. Energy-restricted diets used for weight management may further exacerbate 
this issue by providing insufficient dietary iron for women during this life stage.  
 
Despite growing literature on obesity, inflammation and iron metabolism, few dedicated studies 
have examined the influence of excess adiposity, weight loss, dietary iron intake and genetics on 
iron status in young overweight and obese women. Moreover, research utilising biochemical 
markers such as soluble transferrin receptor (sTfR), sTfR-ferritin index, and hepcidin that are 
appropriate for individuals with obesity and underlying inflammation is scarce. Hence, this thesis 
aimed to add to the current body of topic-related research by: (1) systematically reviewing the 
evidence on the relationship between obesity, inflammation and iron status in adults; (2) examining 
the prevalence of iron deficiency, severity of obesity-related iron disturbances and hepcidin 
concentration in young overweight and obese women; (3) assessing the impact of weight loss and 
manipulating protein and haem iron intake on iron status during a weight management intervention; 
 xv 
and (4) investigating the potential influence of the common transmembrane protease, serine 6 
(TMPRSS6) rs855791 polymorphism on hepcidin and body iron responses to altered protein and 
haem iron intake during energy restriction. 
 
A systematic search of the literature found 31 studies that measured iron status in obese 
individuals, 10 of which reported data from non-obese comparison groups. Findings from the 
systematic review indicated that obese individuals, particularly those with a body mass index 
(BMI) >35 kg/m
2
, exhibit biochemical alterations that are consistent with an elevated level of 
inflammation. These alterations include higher haemoglobin and serum ferritin concentration, and 
lower transferrin saturation. A small number of studies showed a tendency for greater sTfR and 
hepcidin levels in the obese although research is required to substantiate this data which has only 
been reported in a limited number of studies. 
 
A cross-sectional study was conducted as a part of this thesis to examine links between excess 
adiposity, inflammation and iron status in a sample of young healthy overweight and obese women. 
In the 114 participants recruited to this study, mean age and BMI were 22.3 years and 33.7 kg/m
2
 
respectively. Mean sTfR was within the normal range [1.61 (SD: 0.44) mg/l]. Median hepcidin 
concentration was low [6.40 (IQR: 7.85) ng/ml], and median C-reactive protein (CRP) indicated 
mildly elevated levels of inflammation [3.58 (IQR: 5.81) mg/l]. BMI was negatively associated 
with serum iron (coefficient=-0.379; p=0.008) and transferrin saturation (coefficient=-0.588; 
p=0.009), but positively associated with CRP (coefficient=0.127; p<0.001) in multivariate 
modelling. Hypoferritinaemia (serum ferritin <15.0 µg/l) was found in 17% of participants, most of 
whom also had hepcidin concentrations <5 ng/ml suggesting the presence of simple iron deficiency 
rather than inflammatory-related disturbances. 
 
A subset (n=36) of these participants later completed a 12-month randomised controlled trial 
comparing two iso-energetically restricted (5600 kJ/day) diets with contrasting macronutrient and 
haem iron content on iron status. The higher-protein, higher-haem iron diet (HPHI) provided 32% 
 xvi 
protein and 12.2 mg iron daily, while the lower-protein, lower-haem iron diet (LPLI) provided 20% 
and 9.9 mg respectively. Following 12 months of intervention, participants on the HPHI diet 
exhibited higher ferritin (HPHI: 52.0; LPLI: 39.0 µg/l; p=0.021) and lower sTfR-ferritin index 
(HPHI: 0.89; LPLI: 1.05; p=0.024) although median concentrations remained within normal range 
for both diet groups. Improvements in iron status accompanied successful losses of ≥10% initial 
weight, which was more apparent in LPLI participants who showed greater serum iron (HPHI: 
13.5; LPLI: 20.0 µmol/l; p=0.002), transferrin saturation (HPHI: 19.4%; LPLI: 29.8%; p=0.001) 
and lower sTfR (HPHI: 1.92; LPLI: 1.24 mg/l; p=0.034) at 12 months. This was likely to be a 
reflection of either stronger compliance to the dietary prescription or the potential influence of iron 
regulatory changes unrelated to significant hepcidin reduction. 
 
A final exploratory study was undertaken to examine the potential influence of the common 
TMPRSS6 rs855791 genetic polymorphism on iron status at baseline and following 12 months of 
energy restriction using the HPHI and LPLI diets. A total of 76 and 27 participants from the cross-
sectional and longitudinal weight loss studies were included in this analysis respectively. In the 
cross-sectional cohort, the iron-lowering thymine (T) allele was significantly associated with lower 
serum iron (coefficient=-3.116; p=0.047) and higher hepcidin (coefficient=0.607; p=0.023) at 
baseline. After completing 12 months of intervention using the HPHI diet, T hetero- and 
homozygotes had lower serum iron (p=0.028) and transferrin saturation (p=0.043) than individuals 
who were homozygous for the cytosine (C) allele. Intriguingly, an equivalent trend was not 
observed in those following the LPLI diet, suggesting that rs855791-associated iron variability may 
be dependent on dietary haem iron and/or protein intake. Furthermore, rs855791 was not associated 
with serum ferritin (HPHI: p=0.89; LPLI: p=0.91), although a significant diet × time effect 
(p=0.026) was observed. 
 
Outcomes from this series of studies highlight simple iron deficiency as a major nutritional issue in 
healthy overweight and obese young women. Suboptimal iron status is particularly problematic in 
this population as young women frequently engage in unhealthy and restrictive dietary practices 
 xvii 
that limit iron intake, and menstrual iron losses accompanying polycystic ovary syndrome can be 
higher in overweight and obesity. Although nutrient-rich energy-restricted diets used in the 12-
month longitudinal study allowed reasonable maintenance of iron homeostasis in most young 
women, greater protein and haem iron intake may be useful in those who have higher physiological 
requirements for iron. Weight loss per se may also be beneficial towards normalising the mild 
obesity-related iron disturbances observed although the mechanism for this is currently unclear. 
Evaluation of potential genetic influences revealed that the TMPRSS6 rs855791 polymorphism can 
significantly influence individual iron variability. However, this significant genetic impact appears 
to diminish with limited protein and haem iron intake, with dietary factors playing a more 
important role in determining storage and functional iron status. 
 
This thesis supports the use of serum ferritin as an indicator of iron deficiency in young overweight 
and obese women not burdened with obesity-related comorbidities. However, measurement of 
additional markers such as sTfR, sTfR-ferritin index and CRP should be considered in those with 
class II obesity or above (BMI >35 kg/m
2
) as inflammatory-related iron disruptions may be more 
pronounced. As simple iron deficiency is clearly a problem in this population with dieting 
potentially further reducing nutrient intake, performance of initial iron deficiency screening in 
young women who seek weight management advice is justified. For those identified to be at 
greatest risk of suboptimal iron status during weight management, higher-protein and haem iron 
diets can be recommended for superior maintenance of iron homeostasis. Contrary to expectations, 
the levels of inflammation and hepcidin were lower in this cohort than in previous studies of the 
obese. This was likely a result of the absence of obesity-related comorbidities. Hence, the impact of 
inflammatory-related iron disturbances was not able to be thoroughly examined in this thesis. 
Future research in larger, more severely obese cohorts evaluating the influence of comorbid 
conditions such as cardiovascular disease, metabolic syndrome and type 2 diabetes is needed to 
clarify the relative contribution of excess adiposity to inflammatory and iron disturbances. 
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CHAPTER 1. 
Introduction  
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INTRODUCTION 
Obesity and iron deficiency are both individually major disease burdens around the world.
1, 2
 
Young women are particularly vulnerable to weight gain and iron deficiency.
3-6
 Factors associated 
with weight gain in young women include moving away from the family home, reduced physical 
activity and high consumption of takeaway foods.
3, 4
 Regular menstrual iron loss increases the risk 
of iron deficiency in this age and gender group.
7
 Obesity and iron deficiency have generally been 
regarded as independent disease burdens, although an increasing amount of research over the past 
decade indicates that these conditions can interact, resulting in a greater iron deficiency risk in 
those who are overweight and obese.
8-10
 
 
The connection between obesity and reduced functional iron status was first documented in a 
cohort of adolescents by Wenzel et al in 1962.
11
 A year later, Seltzer & Mayer reported similar 
outcomes from a study comparing iron status between obese and non-obese adolescents.
12
 Both 
studies found an association between obesity and hypoferraemia (reduced serum iron 
concentration). In comparison to normal weight controls, obese adolescents were found to have 
significantly lower percent saturation of iron and higher unsaturated iron binding capacity as 
indicators of iron deficiency.
12
 Low physical activity levels and decreased muscle myoglobin 
concentration were proposed as potential causes, and were the first of various hypotheses that 
attempted to explain the iron disruptions observed in obese populations.
8, 13, 14
 
 
Micronutrient deficiencies often exist side-by-side with excessive energy intake in overweight and 
obese individuals.
15
 This has typically been attributed to poor diet quality secondary to frequent 
consumption of energy dense nutrient-poor foods.
15
 In the case of iron deficiency, other factors 
such as increased body surface area, expanded plasma volume, and menorrhagia accompanying 
polycystic ovary syndrome (PCOS) have been proposed as potential contributors to obesity-related 
hypoferraemia.
8, 9, 14
 The unremarkable nature of these factors meant that the connection between 
obesity and disturbed iron metabolism was probably overlooked for many years. 
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Since the discovery of the key iron regulatory hormone hepcidin in 2000,
16
 a new wave of interest 
has illuminated on another potential mechanism underpinning obesity-related iron disruption. 
Notably, a study in 2007 by Yanoff et al demonstrated significant associations between obesity, 
inflammation, hypoferraemia and elevated serum ferritin.
8
 Hepcidin, which inhibits gut iron 
absorption and induces sequestration of body iron stores, was proposed as a key mediator of the 
iron disturbances observed in this study.
8
 The clinical implications of these findings were 
important, as it demonstrated that using routine biochemical indices to assess iron status (such as 
serum iron and ferritin) was unsuitable for obese individuals with underlying inflammation. It also 
emphasised the relevance of utilising alternative non-acute phase reactant iron markers, such as 
soluble transferrin receptor (sTfR), in this population. Subsequent studies dedicated to the topic 
have found similar disruptions to iron metabolism,
9, 10, 17, 18
 with more recent research also reporting 
higher serum hepcidin in the obese.
9, 13, 19
 
 
In addition to obesity-related iron investigations, another area of research that has undergone rapid 
expansion since 2000 is the genetics of hepcidin and iron status. A growing number of single 
nucleotide polymorphisms (SNP) are being identified as moderators of hepcidin and iron marker 
concentration,
20-23
 with some resulting in extreme iron-related pathologies.
24, 25
 The rs855791 
polymorphism in the transmembrane protease, serine 6 (TMPRSS6) gene is one of the more 
common SNPs that have been reported to be significantly associated with iron status in the general 
population.
20, 26-28
 Individuals with the iron-lowering allele of this SNP exhibit lower concentrations 
of some markers such as haemoglobin and serum iron,
21, 26
 and a higher concentration of serum 
hepcidin.
29
 Hence, the risk of iron deficiency may potentially be greater in individuals with this 
genetic predisposition for lower iron status.
20
 
 
Despite young women being especially vulnerable to developing obesity and iron deficiency,
3, 6
 
few studies have utilised appropriate biomarkers, including sTfR and hepcidin, to examine the 
impact of excess weight or weight loss on iron status in this population. In the handful of dedicated 
studies that have done so, issues related to study design have limited the generalisability of 
Chapter 1: Introduction 
4 
outcomes to the wider population of young, healthy overweight and obese women.
9, 30, 31
 Some of 
these issues include the selection of a non-representative sample such as mildly overweight military 
recruits,
30
 significant confounding from obesity-related comorbidities, and the use of bariatric 
surgery as the primary method of weight loss.
9, 31
 As food and energy restriction, which is a more 
common strategy for weight loss in young women, can compromise nutrient intake particularly for 
iron,
32
 the importance of appropriately assessing iron alterations during energy restriction and 
weight loss is particularly highlighted. Furthermore, the potential impact of enhancing protein and 
haem iron intake, as well as the influence of SNP rs855791 on iron status of young women during 
energy restriction are currently unexplored areas of research which warrant clinical investigation. 
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THESIS AIMS 
The primary objective of this thesis was to address the paucity of research assessing relationships 
between obesity, inflammation and iron status in young healthy women. This thesis contains a 
series of studies in this target population that examine the associations between excess weight, 
weight loss, dietary protein and haem iron intake, as well as genetics on iron and hepcidin status. 
The specific aims of each study are to: 
1. systematically review the evidence on the relationship between obesity, inflammation and 
iron status in adults; 
2. examine the prevalence of iron deficiency, severity of obesity-related iron disturbances, and 
hepcidin concentration in a community sample of young, healthy overweight and obese 
Australian women; 
3. assess the impact of two energy-restricted diets with contrasting protein and haem iron 
content, and weight loss on iron status during a clinical weight management trial; and 
4. investigate the influence of the common TMPRSS6 rs855791 polymorphism on iron and 
hepcidin status, as well as physiological iron responses to altered protein and haem iron 
intake during energy restriction. 
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SPECIFIC HYPOTHESES 
1. Obese populations would present with higher levels of serum ferritin, sTfR and hepcidin, 
reflecting poorer functional iron status and greater sequestration of body iron stores when 
compared to non-obese control groups. 
2. Young, healthy overweight and obese Australian women would have significant 
inflammatory-mediated iron disturbances such as increased serum ferritin, sTfR and 
hepcidin. These disturbances would contribute to a higher iron deficiency prevalence than 
when the routine definition of hypoferritinaemia is used alone. Furthermore, increasing 
severity of obesity would also be significantly associated with a greater level of 
inflammation and a poorer iron profile. 
3. Higher intake of protein and haem iron during energy restriction would facilitate better 
maintenance of iron status than conventional diets containing less of these nutrients. 
Additionally, weight loss induced by these diets would lead to biochemical alterations that 
reflect lower inflammation and inflammatory-mediated iron disruptions. 
4. The iron-lowering allele of the TMPRSS6 SNP rs855791 would be associated with both a 
poorer baseline iron profile and a greater decrement in iron status during dietary energy 
restriction. Individuals carrying the iron-lowering allele of rs855791 and who are prescribed 
a lower-protein and haem iron diet would exhibit the least favourable iron profile. 
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SIGNIFICANCE OF THIS RESEARCH 
In young women, excess weight can potentially exacerbate the risk of iron deficiency, a condition 
which is already prevalent in this population. Outcomes from this series of studies will provide a 
greater insight into the biochemical alterations that mediate this risk in overweight and obese young 
women. This project will extend the current body of topic-related literature into (1) evaluating the 
potential reversibility of obesity-mediated iron disruptions with weight loss; (2) assessing the 
benefit of enhanced protein and haem iron intake during dietary energy restriction on maintaining 
iron status and (3) exploring the nutrigenetic impact of SNP rs855791 on iron alterations during 
planned weight reduction. These outcomes will potentially guide the design of optimal patient care 
plans in clinical practice for maintaining iron homeostasis in healthy overweight and obese women, 
particularly while undergoing supervised weight management to treat existing and/or prevent 
obesity-related comorbidities later in life. 
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THESIS OUTLINE 
Chapter 2 reviews the background literature on obesity, inflammation, hepcidin and iron status. It 
discusses the clinical implications of obesity-related iron disruptions on assessing iron status, and 
the health of young overweight and obese women. Furthermore, this chapter explores the current 
evidence on how weight loss, dietary energy restriction and genetics interact with iron and 
inflammatory status in this population. 
 
Chapter 3 reports a systematic review of current literature related to obesity-related iron disruption. 
It compares iron and inflammatory markers between obese and non-obese control groups across 
different studies in order to clarify the association between obesity, iron and inflammatory status in 
adult populations. 
 
Chapter 4 reports findings from a cross-sectional study conducted in young, healthy overweight 
and obese women. This study examines the prevalence of iron deficiency and discusses the 
contribution of inflammation and hepcidin to iron disturbances and deficiency observed in this 
population. 
 
Chapter 5 presents the iron-related outcomes of a 12-month randomised controlled trial conducted 
in overweight and obese young women. This trial compares the efficacy of two energy-restricted 
diets contrasting in macronutrient and haem iron content on weight loss and iron status. It also 
investigates whether a higher magnitude of weight loss induces greater improvements in iron status 
by comparing iron alterations between participants who successfully lost <5% and ≥10% of initial 
weight. 
 
Chapter 6 observes baseline iron status and iron alterations in a subset of participants from the 
cross-sectional study and clinical trial who were genotyped for the TMPRSS6 SNP rs855791. This 
study examines the association between rs855791 genotype and various iron traits, and explores the 
potential influence of this SNP on iron response to the two diets reported in Chapter 5. 
Chapter 1: Introduction 
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Chapter 7 summarises the key findings from the systematic review, as well as the cross-sectional, 
longitudinal intervention and genetic studies. This chapter also provides the nutritional implications 
and limitations of this thesis, as well as future directions for research. 
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LITERATURE REVIEW 
Overweight and obesity as an independent health issue in young women 
Over the past few decades, obesity has rapidly become an epidemic affecting a large proportion of 
the global population. In Australia, findings from the 2007-08 National Health Survey estimated 
that almost two-thirds (61%) of adults are classified as either overweight or obese.
33
 This issue is 
particularly problematic in young women as rates of overweight and obesity in those aged between 
18-24 years have increased rapidly from 26% to 35% within the past 20 years.
5
 Research of global 
obesity trends also indicates an increased risk for further weight gain in those who are already 
classified as overweight. Between 1980 to 2000 there has been a 5.4 point shift in body mass index 
(BMI) from 29.7 to 37.7 kg/m
2
 at the 95
th
 percentile for Australian women between the ages of 18-
30 years.
3
 The speed and magnitude of this shift was by far the greatest in Australia when 
compared to age-matched women in the United States and the United Kingdom.
3
 Furthermore, the 
absence of an equivalent trend in young Australian men highlights the vulnerability of young 
women to weight gain.
3
 
 
The greater risk of weight gain in this age and gender group has been attributed to factors related to 
major lifestyle change such as moving away from the family home, cohabitation and pregnancy.
34-
37
 These changes in addition to behavioural factors such as frequent consumption of takeaway 
foods,
4
 reduced inclination to be physically active,
34
 and binge eating and drinking tendencies have 
all been linked with weight gain in young women.
38
 With the rising incidence of obesity, young 
overweight and obese women are exposed to the risks of developing obesity-related comorbidities 
and lifestyle diseases, both immediately and later in life. 
 
Health effects of overweight and obesity 
Obesity is well established as a risk factor for many common lifestyle diseases such as 
cardiovascular disease, type 2 diabetes, osteoarthritis and various types of cancer.
39
 In 2003, high 
body mass was responsible for 8% of the total burden of disease and injury in Australia,
40
 with the 
overall cost to the Australian society and government estimated at $58.2 billion in 2008.
33
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In young women, overweight and obesity is associated with other health risks specific to this 
demographic. Body image is an important part of self-esteem in this population,
41
 and young 
overweight and obese women have been reported to be at increased risk of mental health problems. 
The odds ratios of developing depressive symptoms in overweight (odds ratio: 1.2) and obese (odds 
ratio: 1.3) women aged 18-27 years when compared to those in the healthy weight range have been 
shown to be higher in The Australian Longitudinal Study on Women's Health.
42
 Furthermore, 
overweight and obesity in this population may adversely affect reproductive health. The link 
between obesity and polycystic ovary syndrome (PCOS) is well known,
43
 and there is increasing 
evidence to suggest that excess weight can impact deleteriously on other fertility and obstetric 
outcomes.
44-46
 The risk of obesity and metabolic disease in the offspring of obese mothers is also 
known to be elevated.
44-48
 Hence, the early treatment and prevention of excess weight gain are 
particularly relevant for this population. 
 
Obesity and inflammation 
Obesity-related chronic disease often develops later in life. However, prior to manifestation of 
overt disease outcomes, excess adiposity is known to induce chronic systemic inflammation,
49, 50
 a 
condition which is believed to directly influence progression of disease precursors such as insulin 
resistance, impaired glucose tolerance and atherosclerosis.
51, 52
 Circulating levels of 
proinflammatory cytokines and acute phase proteins such as tumour necrosis factor-α (TNF-α), 
interleukin-6 (IL-6) and C-reactive protein (CRP) have all been reported to be higher in the obese 
when compared to non-obese comparison groups,
53-55
 with BMI also known to be positively 
correlated with inflammatory status.
49, 56, 57
 The location of body fat deposits play an important role 
in influencing level of inflammation.
49
 IL-6 production has been shown to be three-fold higher in 
abdominal compared to subcutaneous adipocytes in vitro,
58
 whereas in vivo measurement of 
inflammation in bariatric surgery patients indicated 50% greater IL-6 production in visceral versus 
subcutaneous fat deposits.
59
 Portal vein IL-6 (which is primarily derived from visceral fat) was also 
directly correlated to CRP, demonstrating the significant impact of abdominal fat on whole body 
inflammation.
59
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In human adults, the majority of excess fat is stored in the body as white adipose tissue.
49
 
Previously, white adipose tissue was believed to be a metabolically inert fat depot, whereas it is 
now recognised as a highly active endocrine organ.
49
 Adipose tissue is known to secrete a 
repertoire of bioactive proteins including adipokines and proinflammatory cytokines which 
contribute significantly to obesity-related inflammation.
60
 Some of these bioactive proteins include 
but are not limited to: leptin, resistin, monocyte chemoattractant protein-1 (MCP-1), and the 
abovementioned cytokines TNF-α and IL-6.59 Despite extensive research over the past 60 years, the 
question of why excess adiposity triggers an inflammatory response remains poorly understood.
61
 
Current opinion proposes several mutually inclusive explanations including macrophage 
infiltration, adipose tissue hypoxia and endoplasmic reticulum stress.
61
 Macrophage infiltration 
may arise as a result of local cellular hypoxia to facilitate remodelling and angiogenesis of adipose 
tissue.
62, 63
 In murine ex vivo studies, infiltrated macrophages were shown to account for 
approximately 50% and the majority of all adipose-derived IL-6 and TNF-α respectively.64, 65 The 
high demand for structural and functional proteins for maintaining massively hypertrophied 
adipocytes is also thought to be a considerable burden on the endoplasmic reticulum (a major site 
of protein synthesis) and thus, contributes to the greater level of inflammation in obesity.
66
 
 
Obesity, inflammation and micronutrients 
In addition to the increase in chronic disease risk, obesity is also associated with the disruption of 
micronutrient metabolism.
67
 Abnormal levels of certain vitamins and minerals (e.g. vitamins A, D, 
folic acid, calcium, iron and zinc) in obesity have been extensively reviewed,
68, 69
 with some 
nutrients reported to be directly linked with inflammation.
68
 The transient drop in micronutrient 
concentration with inflammation can be explained partly as an evolutionary adaptation in host 
defence. In acute infection, a normal immune response induces nutrient depletion due to the 
activation of antioxidative processes and immune cell proliferation.
70
 Micronutrient storage pools 
are also redistributed away from the circulatory system to limit their bioavailability to invading 
pathogens.
71-73
 Specifically, the sequestration of iron in reticuloendothelial macrophages occurs 
with acute infection (see later: Regulation of hepcidin).
74
 While obesity does not constitute an 
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infectious state, obesity-related inflammation appears to cause a similar functional iron 
deficiency,
75
 although the question of why this occurs remains to be elucidated. 
 
Iron deficiency as an independent health issue in young women 
Iron deficiency with or without anaemia is a major global health issue.
76
 Of all the nutrient 
deficiency syndromes, iron deficiency is the most common, affecting a large number of individuals 
across both industrialised and non-industrialised nations.
76
 Although no accurate figures exist for 
its global prevalence, the World Health Organisation (WHO) estimates that most preschool 
children and pregnant women in non-industrialised countries and at least 30-40% of the population 
in industrialised countries are iron deficient.
76
 Of those affected by this nutrient deficiency, a 
significant proportion include women of reproductive age due to regular menstrual iron loss.
7
 In 
2000, an Australian population-based study estimated that over 20% of women between 25-50 
years were either iron deficient or had marginally low iron status.
77
 Furthermore, the WHO also 
estimates an anaemia prevalence of 12.4% and 15% in pregnant and non-pregnant Australian 
women respectively.
78
 As women of reproductive age have such a high physiological demand for 
iron, it is not surprising that the Australian recommended dietary intakes (RDI) for iron are the 
greatest in this age and gender group (Table 2.1).
79
 
 
Table 2.1. Comparison of Australian nutrient reference values for pregnant and non-pregnant 
women aged 19-30 years, postmenopausal women aged >50 years and men aged >18 years 
Population 
Nutrient reference values 
Estimated average 
requirement (EAR) 
Recommended dietary 
intake (RDI) 
   
Women   
     Premenopausal (19-30 years) 8 mg/day 18 mg/day 
     Pregnant (19-30 years) 22 mg/day 27 mg/day 
     Postmenopausal (>50 years) 5 mg/day 8 mg/day 
Men (>18 years) 6 mg/day 8 mg/day 
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Health effects of iron deficiency 
Iron deficiency impacts adversely on health across all age groups. It can influence growth, 
cognitive development and behaviour in children, and reduced physical performance, work 
productivity and immune function in both children and adults.
76, 78
 Recent literature also indicates a 
possible effect of iron deficiency on impaired cognitive performance and increased depressive 
symptoms in adults.
80-82
 
 
Similar to overweight and obesity, iron deficiency is an important issue in women of reproductive 
age as there are additional health implications specific to this population. Maternal iron deficiency 
(especially iron deficiency anaemia) during pregnancy can adversely affect the health of both the 
mother and the child. Negative health outcomes to the mother include increased risk of pre-term 
delivery,
83, 84
 post-partum depression and poorer mother-to-infant interaction,
85, 86
 whereas greater 
susceptibility to fat accumulation, metabolic syndrome and cardiovascular dysregulation and 
compromised cognitive development have been reported in offspring.
87-89
 These adverse health 
effects emphasise the importance of regular monitoring and maintenance of iron homeostasis in 
women of reproductive age. 
 
Clinical assessment of iron status 
Biochemical markers such as haemoglobin, serum iron, transferrin saturation, total iron binding 
capacity (TIBC) and serum ferritin are routinely used to assess the iron status of individuals in 
clinical settings.
90, 91
 Deviation of these biomarkers from their reference range provides clinicians 
with an indication of iron abnormalities (Table 2.2). In the case of simple iron deficiency, onset is 
characterised by depletion of storage iron resulting in reduced serum ferritin (stage I iron 
deficiency). As the condition progresses to complete exhaustion of iron stores, iron deficient 
erythropoiesis occurs as iron supply to erythropoietic cells decrease which is reflected by a 
reduction in serum iron and transferrin saturation, and a rise in TIBC (stage II iron deficiency). 
With continued negative iron balance, the condition eventually progresses into iron deficiency 
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anaemia as senescent erythrocytes are no longer adequately replaced owing to low iron supply 
(stage III iron deficiency).
92-96
 
 
Table 2.2. Typical reference ranges for routine biochemical markers of iron status 
Biochemical marker Reference range
a
 
  
Haemoglobin (g/l) 120- 150 
Serum iron (µmol/l) 10 - 30 
Transferrin saturation (%) 15 - 50 
Total iron binding capacity (µmol/l) 42 - 80 
Serum ferritin (µg/l) 15 - 150 
aReference ranges based on premenopausal women over 18 years of age 
(South Western Sydney Local Health District Pathology Service, 
Sydney, Australia) 
 
Routine iron indices are useful in most cases although external factors such as diurnal variation 
(serum iron, transferrin saturation and TIBC can exhibit changes throughout the day) limit accuracy 
and validity of iron status assessment.
76
 Similarly, studies have observed that inflammation can 
decrease serum iron and transferrin saturation and elevate serum ferritin.
76
 The anaemia of 
inflammation (AI) or anaemia of chronic disease is an example of where inflammatory status can 
significantly affect the concentration of routine iron biomarkers. Anaemia of inflammation is a 
common condition in individuals with chronic disease, characterised by low haemoglobin and 
serum iron concentration despite the presence of sufficient body iron stores.
97, 98
 In clinical practice, 
AI can easily be misinterpreted as iron deficiency anaemia, especially if inflammatory status is not 
assessed, due to the similar biochemical presentation of the two conditions (Table 2.3).
90
 Obesity 
itself has recently been suggested to affect iron metabolism via inflammation.
8, 18
 Hence, the use of 
multiple indices that include alternative markers such as soluble transferrin receptor (sTfR), sTfR-
ferritin index (sTfR-F) and hepcidin are required to more accurately assess iron status of 
individuals with underlying inflammation (see later: Clinical implications of obesity and iron 
deficiency).
76
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Table 2.3. Comparison of biochemical alterations with iron deficiency and anaemia of 
inflammation 
Biochemical marker Iron deficiency Anaemia of inflammation 
   
Haemoglobin normal to ↓ ↓ 
Serum iron ↓ ↓ 
Transferrin saturation ↓ normal to ↓ 
Serum ferritin ↓ normal to ↑ 
sTfR ↑ normal 
sTfR-ferritin index ↑ ↓ 
CRP normal to ↓ ↑ 
CRP, C-reactive protein; sTfR, soluble transferrin receptor 
Adapted from Wians et al. Am J Clin Pathol 2001; 115: 112-8 and Beguin. Clin Chim Acta 
2003; 329: 9-22 
 
Hepcidin: a link between obesity and iron deficiency 
Role of hepcidin in iron metabolism 
Hepcidin is a 25-amino acid peptide hormone first isolated from plasma and urine in 2000 and 
2001 respectively.
16, 99
 Since its discovery, extensive research has been undertaken to elucidate its 
function and mechanism of action in the human body.
98
 
 
Hepcidin is synthesised primarily by hepatocytes and is a key regulator of iron status. It induces 
degradation of the iron exporter ferroportin from the cell membrane in three primary locations: 
duodenal enterocytes, hepatocytes and reticuloendothelial macrophages (Figure 2.1).
97
 The 
presence of ferroportin at these physiological sites is crucial as: (1) duodenal enterocytes are 
responsible for delivering iron from the gut; (2) the liver is a major iron storage depot; and (3) the 
reticuloendothelial system is responsible for recycling iron from senescent erythrocytes.
97, 100-103
 
Consequently, a reduction in the membrane density of ferroportin results in diminished dietary iron 
absorption and sequestration of hepatic and reticuloendothelial iron stores from the systemic 
circulation.
97
 This subsequently leads to hypoferraemia as the amount of bioavailable iron becomes 
limited.
97, 104
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Figure 2.1. Main target sites and regulators of hepcidin [Red crosses denote hepcidin-mediated 
inhibition of cellular iron export via ferroportin (FPN), which consequently lead to the blocking of 
intracellular iron efflux from hepatocytes, duodenal enterocytes and reticuloendothelial 
macrophages into the hepatic portal and systemic circulation; hepcidin itself is primarily regulated 
by a number of signals including iron, inflammation, hypoxia, erythropoiesis and possibly leptin; 
figure adapted from Collins et al. J Nutr 2008; 138: 2284-8 and Ganz. Best Pract Res Cl Ha 2005; 
18: 171-82] 
 
The importance of hepcidin for iron homeostasis is particularly evident in individuals with 
hepcidin-related pathologies. Complete ablation of hepcidin synthesis leads to iron overload 
secondary to inadequate attenuation of dietary iron uptake.
100, 105
 On the contrary, hepcidin 
overproduction results in microcytic iron-refractory iron deficiency anaemia that is unresponsive to 
regular oral iron therapy (see later: Genetic factors affecting iron status).
106, 107
 Research into these 
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pathological disorders has paved the way for further investigations into the biological and genetic 
mechanisms involved in regulating hepcidin production. 
 
Regulation of hepcidin 
The current body of research has identified several biological pathways responsible for regulating 
hepatic hepcidin production: (1) iron feedback regulation; (2) requirement for iron based on 
hypoxia and erythropoietic demands; and (3) regulation by inflammation. 
 
In iron feedback regulation, hepcidin is produced to limit unnecessary iron uptake when body iron 
stores are abundant.
97
 In vitro evidence indicates that hepatocytes possess the ability to sense and 
respond to the presence or absence of iron.
98
 The iron-sensing mechanism appears to be related to 
the protein complex formed by interactions between transferrin receptors 1 and 2 and the hereditary 
haemochromatosis (HFE) protein on the hepatocyte membrane. When transferrin-bound iron 
(holotransferrin) attaches to this protein complex, downstream bone morphogenetic protein-sons of 
mothers against decapentaplegic (BMP-SMAD) and/or mitogen-activated protein kinase (MAPK) 
signalling occurs to initiate hepcidin expression.
74
 
 
In addition to iron-driven feedback regulation, hepcidin is also regulated by oxygen demand and 
erythropoiesis. Under conditions of low oxygen (e.g. anaemia or hypoxia), hepcidin production is 
suppressed to allow for increased iron absorption and mobilisation to facilitate erythrocyte 
production.
100, 108
 Beta-thalassemia (major and intermedia) resulting in increased but ineffective 
erythropoiesis is a classic example of iron overload caused by inappropriate erythropoiesis-driven 
hepcidin suppression.
109
 Based on earlier research, oxygen-sensing hypoxia-inducible factors (HIF) 
were believed to play a crucial role in feedback regulation,
97, 110
 although more recent evidence 
indicates a greater involvement of erythroid precursors from the bone marrow (bone marrow being 
the site of erythropoiesis).
98
 At present, much is still unknown about the specific iron sensing and 
signalling mechanisms that control hepcidin production. Proteins involved in the crosstalk between 
different iron processing organs also remain largely unexplored. 
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Aside from the abovementioned homeostatic pathways, inflammation is also known to modify 
hepatic hepcidin production via Janus kinase/signal transducer and activator of transcription-3 
(JAK/STAT-3) signalling.
97, 103
 As mentioned previously, the inflammatory-mediated increase in 
circulating hepcidin and subsequent iron sequestration is believed to be related to host defence (see 
earlier: Obesity, inflammation and micronutrients).
97, 102
 Evidence from animal and human studies 
show increased susceptibility to infection in iron-overloaded individuals,
100, 111
 with in vitro 
research demonstrating a direct stimulatory effect of IL-6 and other proinflammatory cytokines 
such as interleukin-1β (IL-1β) on hepcidin expression.112-114 Hepcidin is also believed to be the 
primary mediator of reduced functional iron status under non-infectious inflammatory conditions 
such as obesity and anaemia of inflammation (AI) (see later: Hepcidin in anaemia of inflammation 
and obesity: the similarities and differences).
8, 115
 
 
Although yet to be widely established as a regulator of hepcidin synthesis, a 2007 study reported a 
stimulatory effect of leptin on hepcidin expression. Exposure of human hepatoma cells to leptin in 
vitro was demonstrated to induce significant elevation of hepcidin expression via JAK/STAT-3 
signalling.
116
 This data corroborates previous research where a significant correlation between 
serum leptin and hepcidin in obese children was observed,
19, 117
 and indicates the possibility that an 
alternative stimulus to inflammation for explaining hepcidin elevation in obesity. 
 
Hepcidin in anaemia of inflammation and obesity: the similarities and differences 
Inflammation, hypoferraemia and increased serum ferritin concentration are observed in both AI 
and obesity. Therefore, earlier research proposed that the underlying biological mechanisms behind 
obesity-related iron disruption may be similar to AI.
8, 19
 However, with the growing number of 
studies reporting serum hepcidin in obese populations, considerable differences have been found to 
distinguish the two separate conditions. 
 
The first of these differences relate to the magnitude of hepcidin elevation. In clinical populations 
with multiple myeloma and chronic renal failure, studies have reported extremely elevated levels of 
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hepcidin when compared to healthy controls.
118, 119
 In contrast, while serum hepcidin in morbidly 
obese women was observed to be nine-fold higher than non-obese age and haemoglobin-matched 
controls,
9
 this concentration remained markedly below the levels reported in individuals with 
chronic disease (Table 2.4). Measurement of hepcidin in overweight and obese children also found 
a mean concentration that was only 40-50% higher than normal weight controls.
13, 19
 
 
Table 2.4. Comparison of adult serum hepcidin concentration between populations of healthy 
obese and chronically ill individuals 
Population 
Serum hepcidin (ng/ml) 
Ganz et al 
(2008)a,b 
Małyszko et al 
(2005)c 
Tussing-Humphreys et al 
(2010a)a 
    
Healthy (weight non-discriminatory) 65.0 53.3 - 
Healthy (BMI <27 kg/m2) - - 9.70 
Obese (BMI >37 kg/m2) - - 88.0 
Inflammation (CRP >100 mg/l) 550.0 - - 
Multiple myeloma 300.0 - - 
CRF (not requiring dialysis) 250.0 - - 
CRF (haemodialysis) - 205.7 - 
BMI, body mass index; CRF, chronic renal failure CRP; C-reactive protein 
aResults reported as medians 
bResults estimated from graphical presentation using a ruler 
cResults reported as means 
 
As a result of this disparity in hepcidin elevation, true iron status is also different between AI and 
obesity. Iron sequestration in AI only causes a functional deficiency as iron stores are redistributed 
away from the systemic circulation into hepatic and reticuloendothelial cells.
97, 120
 However, liver 
biopsies obtained from obese bariatric surgery patients indicate the presence of minimal hepatic 
iron stores reflective of a truly iron depleted state.
9, 121
 As reticuloendothelial macrophages process 
a considerably larger amount of iron compared to duodenal enterocytes (20-25 mg vs. 1-2 mg per 
day respectively; Figure 2.1), Tussing-Humphreys et al (2010a) hypothesised that moderate 
hepcidin elevation with obesity may be sufficient to inhibit dietary iron absorption while allowing 
some mobilisation of iron from storage sites. This continual usage of body iron stores with minimal 
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dietary iron replenishment presumably leads to negative iron balance, which over a prolonged 
period of time, may result in true iron deficiency.
9
 
 
In addition to the abovementioned dissimilarities, there is some, but inconsistent evidence to 
suggest that the physiological site of hepcidin production may be different between obese 
individuals and those with AI. Serum hepcidin is primarily secreted by the liver, but in 2006 higher 
hepcidin protein and mRNA were detected in adipose tissue samples obtained from obese women 
(compared to normal weight controls) which suggests a role for adipose tissue in hepcidin 
synthesis.
121
 Although hepcidin expression occurred at a much smaller scale to hepatocytes, the 
sheer size of adipose tissue deposits was thought to contribute substantially to hepcidin 
concentrations in the obese.
121
 However, contradicting results have recently emerged where 
analysis of the abdominal subcutaneous adipose tissue blood supply in lean and obese individuals 
showed zero net release of hepcidin.
122
 
 
Clinical implications of obesity and iron deficiency 
Problems associated with the use of routine iron studies 
The interaction between obesity and iron metabolism is an important issue with significant clinical 
implications, one of which relates to the accuracy of routine iron biomarkers in overweight and 
obese individuals. Since obesity is recognised as a proinflammatory condition, the reliability of 
routine clinical iron indices is questionable as inflammatory-mediated disruptions to serum iron, 
transferrin saturation and serum ferritin can complicate detection of iron abnormalities.
8, 76, 115
 In 
clinical settings where hypoferritinaemia (low ferritin) is often used as the primary indicator of iron 
deficiency, overestimation of true iron status can occur in individuals with obesity-related 
inflammation. While supplementary analysis of acute phase proteins and proinflammatory 
cytokines such as CPR, α-1-acid glycoprotein, alpha-1-antichymotrypsin, IL-6 and TNF-α can 
provide an indication of inflammatory status,
96
 a number of alternative iron biomarkers have been 
shown to be important for gauging iron status in those with underlying inflammation. 
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In recent years, there has been increasing utilisation of an alternative iron marker soluble 
transferrin receptor (sTfR) in obesity research. Soluble transferrin receptor is a useful indicator of 
iron deficiency under inflammatory conditions as it is not influenced by infection or inflammation, 
and it does not vary with age, gender or pregnancy.
76
 Soluble transferrin receptor concentrations 
however, can become elevated in haematological disorders (those involving altered erythropoietic 
activity) such as haemolytic anaemia, β-thalassemia and sickle cell anaemia.76, 123 Hence, care must 
be taken to eliminate the presence of such conditions before sTfR can be employed as a marker of 
iron status. 
 
Some studies have also explored the potential of using sTfR to ferritin ratios.
94, 124
 In particular, the 
sTfR-ferritin index (sTfR-F) (calculated by dividing sTfR by log ferritin) has been reported to be 
especially valuable for assessing iron status under both inflammatory and non-inflammatory 
conditions.
125
 The sTfR-ferritin index is useful for distinguishing true iron deficiency from AI 
whereby a ratio of <0.8-1.0 with concurrent anaemia is indicative of AI, and a ratio of >1.5-2.0 the 
presence of true iron deficiency.
125, 126
 Unfortunately, neither sTfR or sTfR-F are frequently used in 
routine clinical practice which may be attributed to the cost associated with its measurement, as 
well as the lack of standardised reference ranges and cut-offs.
2
 
 
Nutrient adequacy of energy-restricted diet plans for obese individuals 
During dietary weight management, restriction of food intake is essential for achieving negative 
energy balance. Nutrient intake during periods of energy restriction can be compromised, 
especially if the dietary intervention is poorly designed.
127
 Body image dissatisfaction in young 
women can often drive fad dieting and adoption of unhealthy weight loss strategies such as 
elimination of core food groups, which increase the risk of nutrient deficiency.
128-130
 Of all 
nutrients, the dietary requirement for iron (EAR: 8 mg/day; RDI: 18 mg/day) is one of the most 
difficult to meet in women of reproductive age.
131
 Furthermore, a 2010 study demonstrated that 
meeting recommended iron intakes can be even more challenging during periods of energy 
restriction.
32
 Dietary modelling of a 6000 kJ/day higher-protein (33% daily energy) meal plan that 
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included red meat three times a week was only able to meet 81% of the RDI (Appendix D1).
32
 In 
fact, manipulation of this meal plan to incorporate red meat on all days of the week still did not 
satisfy the recommended requirement for iron (95% of the RDI). Therefore, monitoring and 
addressing iron deficiency is crucial in overweight and obese young women as iron deficiency risk 
may be further exacerbated by suboptimal dietary iron intake. 
 
Efficacy of weight management programmes in obese individuals 
Many lifestyle and behavioural weight management interventions rely primarily on food intake 
restriction and an increase in physical activity, both of which require substantial levels of self-
control and motivation. As iron deficiency is known to influence fatigue, exercise capacity and 
psychological health,
6, 76, 132-134
 compliance to prescribed diet and exercise regimens may be 
adversely affected by iron deficiency. To date however, the psychological impact of low iron status 
on motivation and compliance to weight management interventions has not been explored. 
 
Impact of weight loss on iron status 
As evidence suggests a significant inverse association between obesity and iron status, it would be 
logical to hypothesise that weight loss can bring about beneficial changes to iron status in 
overweight or obese individuals. The impact of weight reduction on iron status has been examined 
in a number of studies, the majority of which evaluated the impact of bariatric surgery-induced 
weight loss on overall nutritional status. Intriguingly, iron alterations reported after bariatric 
surgery have been inconsistent despite massive weight and/or inflammatory reduction reported 
across most studies.
135-142
 
 
Aside from bariatric surgery-based research, outcomes from earlier dietary weight loss studies have 
been equally conflicting. Two studies adopting rigorous energy restriction using very low energy 
diets (VLED) observed an acute decrease in circulating iron concentration.
143, 144
 This drop was 
reported to occur immediately following commencement of energy restriction irrespective of iron 
intake and supplementation,
143, 144
 although iron recovery was superior in the supplemented 
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groups.
144
 On the other hand, no decline in serum iron and transferrin saturation was observed with 
VLED-induced weight loss in children (mean age was 12.6 years).
145
 Most studies involving 
moderately restrictive diets demonstrated good maintenance of iron status following 
implementation of a hypocaloric diet for six to 24 weeks,
145-147
 although one study did report 
reduced iron status following 15 weeks of 50% energy restriction.
80
 Of all of the abovementioned 
dietary energy restriction studies, only one measured sTfR (which increased with a VLED 
intervention),
144
 and none reported hepcidin as all except one predated the discovery of the 
hormone. 
 
Since 2010, a small number of weight loss studies incorporating serum hepcidin have emerged. 
One study monitored sTfR and hepcidin status in a cohort of obese premenopausal women 
undergoing bariatric surgery,
31
 while two examined hepcidin alterations in children and adults 
following dietary energy restriction.
117, 148
 Two of these studies showed some improvements in 
serum hepcidin,
31, 117
 while the other reported a significant increase following 12 weeks of weight 
loss.
148
 Tussing-Humphreys et al (2010b) also showed a decrease in sTfR six months following 
bariatric surgery.
31
 However, issues relating to study design and the target population have limited 
the generalisability of these findings to the healthy overweight and obese population where dietary 
weight management practices are commonly utilised. Some of these issues include the recruitment 
of a paediatric sample,
117
 and confounding effects of obesity surgery on decreased gastric acid 
secretion which is required for conversion of molecular iron to absorbable ferrous iron, decreased 
surface area for nutrient absorption and reduced tolerance to red meat.
149
 
 
Genetic factors affecting iron status 
Apart from major environmental factors that influence iron status, genetics is also an important 
determinant of individual iron variation.
150
 The past decade has seen a rise in the number of animal 
and human studies investigating genetic influences on hepcidin expression and iron status. Studies 
examining hepcidin-linked mutations have focused on a number of key genes such as: HAMP 
(hepcidin gene); HFE (hereditary haemochromatosis protein gene); HJV (hemojuvelin gene); TfR2 
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(transferrin receptor 2 gene); SLC40A1 (ferroportin gene); and TMPRSS6 (matriptase-2 gene) that 
underpin many iron-related pathologies.
151-154
 The excess or shortage of hepcidin that result from 
genetic mutations can phenotypically manifest as iron overload or deficiency disorders.
150
 
 
The majority of genetic research since the discovery of hepcidin has been dedicated to studying 
iron overload disorders.
150
 Various mutations in the coding and non-coding regions of the HAMP, 
HFE, HJV and TfR2 genes have been linked with blunted hepcidin production leading to various 
types of hereditary haemochromatosis. For example, the R56X nonsense mutation of HAMP 
(rs104894695) and the G320V missense mutation of HJV (rs74315323) were identified in 
individuals with early-onset juvenile haemochromatosis.
155, 156
 Furthermore, pathogenic variants of 
the TfR2 (Y250X; rs80338880) and HFE (C282Y; rs1800562) genes are known to cause adult-
onset hereditary haemochromatosis,
24, 157
 the latter of which is very common and accounts for 
>95% of all hereditary haemochromatosis cases in European populations.
24, 158
 
 
Iron overload can very occasionally occur in individuals without defective hepcidin secretory 
mechanisms. Gain-of-function mutations have been identified in the ferroportin gene (SLC40A1) 
whereby individuals lack the ability to respond appropriately to the presence of hepcidin, 
essentially causing hepcidin resistance.
159, 160
 The C326S mutation has been associated with the 
most severe iron overload phenotype of all currently identified ferroportin mutations, and has been 
found to inhibit hepcidin-ferroportin binding completely.
159
 The resulting uncontrolled ferroportin-
mediated flux of iron across duodenal enterocytes leads to hyperabsorption of dietary iron and 
inappropriately high iron levels.
161
 
 
In contrast to iron overload disorders, variants in the TMPRSS6 gene have been found to cause 
hepcidin over-expression and iron deficiency.
25, 151, 162
 In mice, a chemically-induced TMPRSS6 
mutation dubbed the ‘mask’ phenotype has been shown to bring about iron deficiency anaemia 
characterised by low circulating and splenic iron together with other symptoms such as alopecia.
162
 
Point mutations in the TMPRSS6 locus have been identified in humans as the cause for iron 
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refractory iron deficiency anaemia unresponsive to oral iron administration.
151, 163-165
 
Mechanistically, the TMPRSS6 gene encodes a membrane serine protease called matriptase-2. 
Based on earlier in vitro research, the pathway by which matriptase-2 regulates hepcidin expression 
is believed to be related to its role in hemojuvelin degradation.
101, 166
 As hemojuvelin is a co-
receptor to BMP-SMAD mediated hepcidin expression,
167
 matriptase-2 deficiency presumably 
leads to accumulation of hemojuvelin on hepatocyte membranes and aberrant downstream 
signalling for hepcidin production.
106
 In vivo research however, has yielded contradictory outcomes 
as a 2011 study analysing liver homogenates from TMPRSS6 knockout mice unexpectedly 
observed a reduced level of hemojuvelin when compared to wild-type mice.
168
 Evidently, the 
impact of TMPRSS6/matriptase-2 on body iron metabolism remains to be clarified. 
 
The impact of genotype on iron variability in the general population has also been examined in a 
number of genome-wide association,
20, 21, 26, 169-174
 and smaller genetic studies.
22, 23, 28, 153, 175-178
 
Among them, substantial attention has been paid to single nucleotide polymorphisms (SNP) in the 
TMPRSS6 locus of healthy individuals. The synonymous rs4820268 SNP is one example of a 
common genetic variant that is strongly associated with serum iron in individuals of European and 
Indian ancestry.
21
 Another common polymorphism in linkage disequilibrium with rs4820268 is the 
SNP rs855791 (involving a non-synonymous alanine to valine change).  SNP rs855791 has been 
significantly correlated to several erythrocyte and iron traits such as haemoglobin, serum iron, 
transferrin saturation, ferritin and sTfR.
20, 26-28, 172, 175-177
 The comparability of results across 
European, Australian, North American and Chinese populations demonstrates the significant 
impact of this particular SNP on individuals with different ethnic backgrounds. 
 
Although the associations between rs855791 and haematological and iron traits have been reported 
extensively, little research has examined its influence on human serum hepcidin levels or iron 
responses to altered energy and haem iron intake. The lack of research on rs855791-hepcidin 
associations is surprising given that hepcidin is theorised to be a major link between TMPRSS6 
genotype and iron status. At present, only two studies (both of which report results from a single 
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common sample) have measured serum hepcidin in a population genotyped for rs855791.
29, 175
 The 
outcomes of these studies suggest that individuals homozygous for the alanine-coding allele are 
able to more effectively inhibit hepcidin production (and thus increase serum iron and transferrin 
saturation) than individuals homozygous for the valine-coding allele.
29
 Moreover, these iron 
variations could only partly be explained by hepcidin, suggesting the existence of novel hepcidin-
independent pathways for iron regulation via TMPRSS6/matriptase-2.
175
 Clearly, despite the rapid 
growth of research related to the genetics and mechanisms of iron regulation over the past decade, 
there is much that remains unknown about the determinants of iron variability between individuals. 
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SUMMARY 
Obesity and iron deficiency are both major public health issues around the world with profound 
health implications, particularly for young women. In the past five years, a growing amount of 
evidence supports a link between these two disease burdens which may be mediated by 
inflammation and the key iron regulatory hormone hepcidin. Since the discovery of hepcidin in 
2000, extensive research has contributed to a rapid increase in our understanding of the hormone 
and its physiological function in the human body. However, much about the mechanisms and 
genetics of hepcidin regulation remains to be elucidated. 
 
As inflammation and hepcidin are the common denominators in AI and obesity-related 
hypoferraemia, earlier studies suggested that iron disruptions in the two conditions may occur in a 
similar fashion. However, newer research incorporating the measurement of serum hepcidin in the 
obese indicates otherwise. Nevertheless in clinical practice, both AI and obesity-related 
inflammation can lead to inaccurate estimation of iron status, especially if routine biomarkers such 
as serum ferritin are used. Hence, it is important that alternative markers such as sTfR, sTfR-F and 
hepcidin are assessed simultaneously when underlying inflammation is suspected. 
 
Young women are a population already vulnerable to weight gain and iron deficiency, with recent 
evidence in premenopausal obese women also indicating true iron deficiency secondary to mildly 
elevated hepcidin levels. The risk of iron inadequacy may be further exacerbated by dieting (which 
is common practice in overweight and obese young women), low protein and haem iron intake, and 
a genetic predisposition for lower iron status resulting from the TMPRSS6 SNP rs855791. Despite 
this, dedicated research on obesity-related iron disruption in young women is limited, which 
emphasises the importance of extending the current body of topic-related literature focussed on this 
population. 
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ABSTRACT 
A growing number of studies suggest a potential link between obesity and altered iron metabolism. 
The purpose of this systematic review was to examine existing literature on iron status in obese 
populations. A comprehensive literature search was conducted. Included studies recruited 
participants ≥18 years with a body mass index ≥30 kg/m2 and provided descriptive statistics for 
haemoglobin or ferritin at a minimum. There were 31 studies meeting all eligibility criteria, of 
these 12 examined iron status in free-living obese individuals and 19 reported baseline iron status 
of bariatric surgery candidates. Non-obese comparison groups were employed by 10 (32%) 
manuscripts. In these, seven obese groups reported higher mean haemoglobin concentration; six 
reported significantly higher ferritin concentration; and four significantly lower transferrin 
saturation. Due to insufficient data, it was not possible to make conclusions regarding mean 
differences for soluble transferrin receptor (sTfR) and hepcidin which were reported in only five 
and two studies respectively. Existing evidence suggests a tendency for higher haemoglobin and 
ferritin concentration and lower transferrin saturation in obesity. Alteration of iron biomarkers in 
obese populations may be a result of obesity-related inflammation and/or related comorbidities. 
Further research incorporating measurement of inflammatory cytokines, sTfR and hepcidin is 
required to confirm the impact of obesity on iron status. 
Keywords: obesity, iron deficiency, inflammation, hepcidin 
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INTRODUCTION 
Obesity and iron deficiency are independently both major disease burdens affecting significant 
proportions of the global population. A connection between obesity and iron deficiency was first 
suggested in 1962 when a low mean serum iron concentration was reported in an obese adolescent 
cohort by Wenzel et al and subsequently in 1963 by Seltzer & Mayer.
11, 12
 The association was 
apparently initially overlooked and attributed to physical inactivity, poor dietary intake and higher 
iron requirements from larger blood volume and body surface area in the obese.
8, 12, 14
 Many later 
studies also reported low iron status in obese cohorts but the association was again largely ignored 
until the discovery of hepcidin, an iron regulatory hormone involved in controlling gastrointestinal 
iron absorption and circulation. A study by Yanoff et al (2006) demonstrating an association 
between obesity, the inflammatory marker C-reactive protein (CRP) and iron deficiency reignited 
scientific enquiry.
8, 97
 A number of recent manuscripts support earlier findings of an association 
between obesity and iron deficiency in both adults,
10, 18
 as well as children and adolescents.
13, 19, 179
 
 
Clinically, iron deficiency may further add to the burden of obesity and complicate weight 
management. Iron deficiency has been associated with fatigue, depression and reduced exercise 
capacity and this may reduce the efficacy of behavioural weight management programmes which 
aim to increase physical activity and improve motivation and psychological well-being.
6, 132-134
 
Restricted energy diets used for weight management may also be low in iron, particularly for 
women during reproductive years where requirements are higher.
32
 Treatment of iron deficiency 
including improved dietary iron intake and/or iron supplementation may not be efficacious in 
obesity, as obesity-related inflammation may alter iron absorption and circulation, a situation 
similar to the anaemia of chronic disease.
57, 115
 Unfortunately, the independent effect of iron 
deficiency on weight management and the treatment of hypoferraemia in obesity are yet to be 
adequately evaluated. 
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The objective of this paper was to systematically review publications relevant to the relationship 
between obesity and iron status. Importantly, we aimed to identify specific markers in iron 
metabolism that may be differentially affected by obesity, which may inform further hypothesis 
driven research. 
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METHODS 
Eligibility criteria 
Participants 
Studies recruiting non-pregnant or lactating participants of either gender, ≥18 years with a body 
mass index (BMI) ≥30 kg/m2 were considered. Where age and BMI ranges were not provided, 
studies were accepted if the mean age and BMI were ≥18 years and ≥30 kg/m2 respectively. In 
studies failing to report mean BMI, only those involving bariatric surgery candidates exhibiting 
overt obesity were accepted. To minimise the influence of potential confounders on iron 
metabolism, studies were rejected if participants had undergone previous bariatric surgery, or if 
they were conducted in countries undergoing nutrition transition where iron deficiency secondary 
to gastrointestinal parasitic infection may exist. 
 
Outcome measures 
To be included, studies were required to report descriptive statistics for haemoglobin or 
serum/plasma ferritin at a minimum. Due to lack of standardisation in iron deficiency definitions, 
studies reporting only prevalence data without descriptive statistics for each iron biomarker were 
excluded as variable haematological cut points for iron deficiency made data incomparable 
between studies. 
 
Literature search 
The search was performed using the electronic databases All EBM Reviews Multifile (via OvidSP), 
AMED (via OvidSP), APAIS-Health (via Informit Online), CINAHL (via EBSCO), EMBASE, 
MEDLINE (via OvidSP), OLDMEDLINE (via OvidSP), PRE-MEDLINE (via OvidSP), 
PsychINFO (via OvidSP), PubMed, SCOPUS, SPORTDiscus (via EBSCO), Web of Science (via 
ISI Web of Knowledge) from the earliest record to July 2013. 
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The search strategy used for MEDLINE and subsequently adapted for other electronic databases 
combined terms covering areas of obesity and iron deficiency (Appendix A1). Each electronic 
database search did not include language restrictions, and the search terms used included: anemi* 
(where * was used for truncation); anaemi*, iron deficien*; iron deplet*; obes*, overweight, 
abdominal obesity, morbid obesity. 
 
Study selection 
After elimination by title and/or abstract and removal of duplicates, the search results were 
screened by one reviewer (HLC) against participant recruitment criteria. Manuscripts matching the 
participant recruitment criteria were retrieved and independently evaluated by two reviewers (HLC 
and RC). Abstracts containing all information required for eligibility were included. In cases where 
abstracts and journal articles contained insufficient information or information presented in 
alternate formats, attempts were made to contact authors for further information. Reference lists of 
all eligible studies were handsearched for additional articles. To minimise publication bias, 
attempts to contact authors of eligible articles were made to obtain any relevant unpublished data. 
In multiple articles containing similar authorship and suspected of utilising duplicated or 
overlapping participant groups, only the most relevant study was included in this systematic 
review. 
 
Data extraction 
Data related to study and participant characteristics (age, BMI or any indication of weight in 
bariatric surgery studies where BMI was unavailable), mean and standard deviation (SD) of 
haematological markers (haemoglobin and/or ferritin concentration) were extracted independently 
by two reviewers (HLC and RC). The same protocol was applied in the extraction of additional 
haematological or inflammatory markers including transferrin saturation, soluble transferrin 
receptor (sTfR), serum hepcidin, CRP and corresponding data for non-obese control groups with 
BMI between 18.5-29.9 kg/m
2
 when available. In longitudinal and intervention studies, only 
baseline data was extracted. In studies where data were stratified or grouped into separate 
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categories (e.g. BMI strata or treatment groups), all relevant categories were extracted. Control 
group strata were pooled for mean differences analyses except in studies where adjusted mean 
differences between obese groups and normal weight controls (with BMI between 18.5-24.9 kg/m
2
) 
were reported in order to maintain confounder adjustment. 
 
In studies where haematological markers were presented in units outside of the conventional 
system, conversion to conventional units was performed for ease of comparison.
18, 180-182
 Means 
were estimated from median and range,
183
 and SD were calculated from 95% confidence intervals 
and standard errors.
184
 Where mean and SD could not be estimated using mathematical formulae, 
data was extracted as reported in the manuscript. In studies providing individual data points or data 
in graphical form, mean and SD were calculated or measured using a ruler independently by two 
reviewers (HLC and RC). 
 
Assessment of methodological quality 
To identify potential sources of bias, study quality was assessed independently by two reviewers 
(HLC and RC) using the following quality checklist adapted from items often used for assessment 
of epidemiological studies
185, 186
: (1) was the study population sufficiently described (age, gender 
and menopausal status)?; (2) were the sampling procedures sufficiently described (sampling frame 
(e.g. electoral register, convenience sample) and how was sample size determined)?; (3) was the 
participant exclusion criteria appropriate (e.g. did studies exclude participants based on abnormal 
haematological values)?; (4) were outcomes (anthropometric and haematological) measured using 
appropriate methods?; and (5) were important confounders accounted for through exclusion, data 
separation or statistical adjustment (gender, age/menopausal status, ethnicity, dietary iron intake, 
oral contraceptive use, blood donation, iron treatment, alcohol consumption, menorrhagia or 
amenorrhoea, haemorrhage or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic disease)? 
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Several assumptions were made in the quality assessment process due to variation in descriptions 
of study design and participant characteristics. Studies that conducted a complete physical 
examination or similar were assumed to have measured (not self-reported) anthropometric values, 
and studies that described participants as generally healthy, non-users of most medications or 
similar were assumed to be free of chronic diseases. 
 
Summary measures and synthesis of results 
Important study characteristics including study design, participant characteristics (gender and 
menopausal status), sample sizes, outcome variables and covariates used in statistical adjustment 
were summarised and presented in tabulated form. 
 
Data for each outcome variable (haemoglobin, ferritin, transferrin saturation, sTfR, hepcidin and 
CRP) were also summarised and presented in tabulated form. Data from non-bariatric surgery 
studies were tabulated separately from bariatric surgery studies to minimise potential bias from 
comorbidities related to severe obesity. Forest plots were generated to evaluate mean differences 
and 95% confidence intervals in haemoglobin concentration, ferritin concentration and transferrin 
saturation between obese and non-obese groups in studies with appropriate data. Data from 
bariatric surgery studies was identified in the forest plots where appropriate. 
 
Meta-analyses of mean differences were not performed due to substantial methodological 
heterogeneity in participant selection criteria, adjustment of important confounders and laboratory 
methodologies between studies. 
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RESULTS 
Study selection and characteristics 
A flowchart summarising the number of manuscripts identified and subsequently included or 
excluded is presented in Figure 3.1. The electronic database search yielded 13944 manuscripts. 
Following screening, elimination of ineligible manuscripts, removal of duplicates and 
handsearching, a total of 27 full manuscripts and four abstracts describing 31 studies were included 
in this review. 
 
 
 
Figure 3.1. Flowchart for identification and inclusion of relevant studies 
 
Records identified through 
database searching 
n = 13944 
 
Full-text articles excluded 
n = 96, with reasons: 
 
Irrelevant focus: n = 7 
Review: n = 6 
Pregnant subjects: n = 1 
Low mean age: n = 2 
Low mean BMI: n = 3 
Previous bariatric surgery: n = 3 
Post-bariatric surgery: n = 2 
Nutrition transition country: n = 19 
Inadequate/inappropriate data: n = 39 
Duplicate: n = 10 
Unable to retrieve: n = 4 
 
 
Additional records identified 
through other sources 
n = 0 
 
Records after 
duplicates removed 
n = 9237 
 
 
Records screened 
n = 9237 
 
Full-text articles 
assessed for eligibility 
n = 124 
 
Studies included in 
qualitative synthesis 
n = 31 
 
Additional records identified 
through handsearching 
n = 3 
 
 
 
Records excluded 
n = 9113 
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Table 3.1 and Table 3.2 summarise important characteristics extracted from each included study, 
separated according to the non-bariatric or bariatric surgery focus. Of the included studies, less than 
half (n=12; 39%) examined iron status of free-living obese populations.
8, 10, 17, 77, 80, 143, 148, 187-191
 
Majority of included manuscripts (n=19; 61%) were studies investigating the nutritional status of 
severely obese bariatric surgery candidates with reported pre-surgery data.
9, 121, 135, 137-140, 142, 192-202
 
Of the 12 non-bariatric surgery studies included, seven were cross-sectional, two were case-control, 
and three were longitudinal intervention studies. Of the 19 bariatric surgery studies, three were 
cross-sectional, eleven were prospective, three were retrospective and two were randomised 
controlled trials. Just over a third (n=10) of all studies contained non-obese control groups. 
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Table 3.1. Relevant characteristics of included non-bariatric surgery studies 
Author 
(Country) 
Study design Gender 
Menopausal 
status 
Participants 
Obese group 
outcomes 
Control group 
outcomes 
Covariates included in 
statistical adjustment 
        
Ahmed et al, 2008 
(Australia) 
Cross-sectional Both Both Male               (Normal): n = 219 
Female <50 y (Normal): n = 219 
Female ≥50 y (Normal): n = 197 
Male               (Overweight): n = 315 
Female <50 y (Overweight): n = 101 
Female ≥50 y (Overweight): n = 170 
Male               (Obese): n = 149 
Female <50 y (Obese): n = 107 
Female ≥50 y (Obese): n = 132 
Age, BMI, ferritin Age, BMI, ferritin None reported 
Anna et al, 2009 
(USA) 
[Abstract] 
Cross-sectional Male N/A BMI <25: n = 694 
BMI 25.1 – 30: n = 855 
BMI 30.1 – 35: n = 452 
BMI >35: n = 241 
Age, BMI, Hb Age, BMI, Hb None reported 
Ausk & Ioannou, 2008 
(USA) 
Cross-sectional Both Both BMI <25: n = 6059 
BMI 25 – 30: n = 5108 
BMI 30 – 35: n = 2366 
BMI 35 – 40 : n = 850 
BMI ≥40: n = 465 
Age, BMI, Hb, 
ferritin, Tsat 
Age, BMI, Hb, 
ferritin, Tsat 
Mean differences adjusted for: 
gender, menopausal status, 
ethnicity, age, educational 
attainment, alcohol intake, smoking, 
dietary iron intake, blood donation 
Beard et al, 1997 
(USA) 
Intervention Female Not reported VLED 1758 kJ/day: n = 14 
VLED 2763 kJ/day: n = 17 
VLED 3349 kJ/day: n = 12 
Age, BMI, ferritin, 
Tsat 
N/A None reported 
Fricker et al, 1990 
(France) 
Cross-sectional Female Premenopausal Obese: n = 20 
Non-obese: n = 20 
Age, BMI, Hb, 
ferritin, Tsat 
Age, BMI, Hb, 
ferritin, Tsat 
None reported 
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Author 
(Country) 
Study design Gender 
Menopausal 
status 
Participants 
Obese group 
outcomes 
Control group 
outcomes 
Covariates included in 
statistical adjustment 
        
Hamalainen et al, 2012  
(Finland) 
Case-control Female Not available MetS: n = 170 Age, BMI, Hb, 
ferritin, sTfR, CRP 
N/A Age, smoking, physical activity, 
inflammation 
Kretsch et al, 1998 
(USA) 
Intervention Female Premenopausal n = 14 Age, BMI, Hb, 
ferritin, Tsat 
N/A None reported 
Lecube et al, 2006 
(Spain) 
Case-control Female Postmenopausal Obese: n = 50 
Non-obese: n = 50 
Age, BMI, Hb, 
ferritin, Tsat, sTfR 
Age, BMI, Hb, 
ferritin, Tsat, sTfR 
None reported 
Micozzi et al, 1989 
(USA) 
Cross-sectional Female Not reported n = 8234 Age, BMI, Hb, Tsat Age, BMI, Hb, Tsat Age 
Murer et al, 2012 
(Switzerland) 
[Abstract] 
Intervention Both 
(assumed) 
Not reported n = 32 Age, BMI, ferritin, 
sTfR, hepcidin, CRP 
N/A None reported 
Świtoniak & Król, 1992 
(Poland) 
Cross-sectional Female Not reported Normal weight: n = 69 
Overweight: n = 85 
Obese: n = 62 
Age, BMI, Hb, Tsat Age, BMI, Hb, Tsat None reported 
Yanoff et al, 2007 
(USA) 
Cross-sectional Both Not reported Obese: n = 234 
Non-obese: n = 172 
Age, BMI, Hb, 
ferritin, Tsat, sTfR, 
CRP 
Age, BMI, Hb, 
ferritin, Tsat, sTfR, 
CRP 
Gender, ethnicity, age, 
socioeconomic status 
BMI, body mass index; CRP, C-reactive protein; Hb, haemoglobin; MetS, metabolic syndrome; N/A, not applicable; sTfR, soluble transferrin receptor; Tsat, transferrin saturation; VLED, very-low-energy diet 
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Table 3.2. Relevant characteristics of included bariatric surgery studies 
Author 
(Country) 
Study design Gender 
Menopausal 
status 
Participants 
Obese group 
outcomes 
Control group 
outcomes 
Covariates included in statistical 
adjustment 
        
Aasheim et al, 2009 
(Sweden, Norway) 
Randomised 
controlled trial 
Both Not reported GBP group: n = 31 
DS group: n = 29 
Age, BMI, Hb, CRP N/A None reported 
Amaral et al, 1984 
(USA) 
Prospective Both Not reported Male: n = 18 
Female: n = 132 
Age, per cent ideal 
body weight, Hb 
N/A None reported 
Anty et al, 2008 
(France) 
Prospective Female Both n = 178 Age, BMI, Hb, 
ferritin, Tsat 
N/A None reported 
Bekri et al, 2006 
(France) 
Cross-sectional Both Not reported Lean controls: n = 9 
Obese: n = 8 
Obese with diabetes: n = 7 
Obese with NASH: n = 10 
Age, BMI, Hb, 
ferritin, Tsat, CRP 
Age, BMI, CRP None reported 
Belgaumkar et al, 2011 
(UK) 
[Abstract] 
Prospective Both Not reported n = 19 Age, BMI, Hb, 
ferritin 
N/A None reported 
Brolin et al, 1998 
(USA) 
Randomised 
controlled trial 
Female Premenopausal Placebo group: n = 27 
Intervention group: n = 29 
Age, weight, Hb, 
ferritin, Tsat 
N/A None reported 
Cooper et al, 1999 
(Australia) 
Prospective Both Not reported n = 17 (in biochemical analysis) Age, BMI, Hb, 
ferritin 
N/A None reported 
Coupaye et al, 2009 
(France) 
Prospective Both Not reported AGB group: n = 21 
GBP group: n = 49 
Age, BMI, Hb, 
ferritin, Tsat, CRP 
N/A None reported 
de Luis et al, 2013 
(Spain) 
Prospective Female Not reported BMI 35-40: n = 11 
BMI 40-45: n = 28 
BMI 45-50: n = 40 
BMI >50: n = 36 
Age, BMI, Hb, 
ferritin 
N/A None reported 
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Author 
(Country) 
Study design Gender 
Menopausal 
status 
Participants 
Obese group 
outcomes 
Control group 
outcomes 
Covariates included in statistical 
adjustment 
        
Ernst et al, 2009 
(Switzerland) 
Prospective Both Not reported n = 232 Age, BMI, Hb, 
ferritin 
N/A None reported 
Gasteyger et al, 2006 
(Switzerland) 
Prospective Female Premenopausal n = 36 Age, BMI, Hb, 
ferritin 
N/A None reported 
Ortiz Espejo et al, 2011 
(Spain) 
Retrospective Both Not reported n = 35 Age, ferritin N/A None reported 
Palomar et al, 2005 
(Spain) 
Prospective Both Both n = 35 Age, BMI, Hb, 
ferritin, Tsat 
N/A None reported 
Payne & DeWind, 1969 
(USA) 
Prospective Both Not reported n = 80 Age, weight, Hb N/A None reported 
Skroubis et al, 2006 
(Greece) 
Retrospective Both Both RYGBP group: n = 79 
BPD group: n = 95 
Age, BMI, Hb, 
ferritin 
N/A None reported 
Smith et al, 2013 
(UK) 
[Abstract] 
Cross-sectional Both Not reported Normoglycaemic: n = 216 
Pre-diabetic: n = 237 
Diabetic: n = 223 
Age, BMI, ferritin, 
Tsat 
N/A None reported 
Thurnheer et al, 2012 
(Switzerland) 
Prospective Both Not reported Male: n = 98 
Female: n = 257 
Age, BMI, Hb, 
ferritin 
N/A None reported 
Toh et al, 2009 
(Australia) 
Retrospective Both Not reported RYGBP group: n = 103 
SG group: n = 46 
Age, BMI, Hb, 
ferritin 
N/A None reported 
Tussing-Humphreys 
et al, 2009 
(USA) 
Cross-sectional Female Premenopausal n = 20 Age, BMI, Hb, 
ferritin, Tsat, sTfR, 
hepcidin, CRP 
Age, BMI, Hb, 
ferritin, Tsat, sTfR, 
hepcidin, CRP 
Ethnicity 
AGB, adjustable gastric banding; BMI, body mass index; BPD, biliopancreatic diversion; CRP, C-reactive protein; DS, duodenal switch; GBP, gastric bypass; Hb, haemoglobin; N/A, not applicable; NASH, non-
alcoholic steatohepatitis; RYGBP, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; sTfR, soluble transferrin receptor; Tsat, transferrin saturation 
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Participant gender and menopausal status varied across studies with 18 mixed gender, 12 female 
and one male only study. Of the 12 studies examining iron indices in female only participants, five 
focused specifically on premenopausal and one on postmenopausal women. The studies by Ahmed 
et al and Anty et al utilised the age cut-off of 50 years to differentiate menopausal status in female 
participants, but evidence to confirm menstruation status was not provided.
77, 137
 
 
Concentrations of haemoglobin and ferritin in addition to transferrin saturation were the most 
frequently reported haematological markers. Few studies reported sTfR (n=5) or serum hepcidin 
(n=2).
8, 9, 17, 148, 189
 
 
Most of the extracted data were presented as mean and SD although some studies reported means 
or medians in combination with either range, 95% confidence interval or interquartile range. 
 
Comparison of laboratory methodologies used in the analysis of haemoglobin concentration 
showed mostly automated methods of measurement. Ferritin analysis was comparatively more 
varied, although automated immunoassays were the most common method of analysis. Of the five 
studies examining sTfR, two utilised immunoassays
8, 9
 one used particle-enhanced nephelometry,
17
 
and another study used a particle enhanced immunoturbidimetric assay.
189
 In the two studies 
reporting hepcidin, Tussing-Humphreys et al utilised a hepcidin specific immunoassay,
9
 whereas 
the method employed by Murer et al was not reported.
148
 However, a previous study by the same 
research team suggests that a combined weak cation exchange chromatography and time-of-flight 
mass spectrometry method may have been used.
13
 
 
Methodological quality 
A descriptive assessment of methodological quality is presented in Appendix A2. Overall study 
quality was moderate with most studies (n=25) unable to meet at least three of the five important 
quality items (Appendix A2). Non-bariatric surgery studies were generally of higher quality with 
30% of studies (n=3) meeting at least three quality items. Most bariatric surgery studies (with the 
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exception of Tussing-Humphreys et al
9
) were poorer quality [with only 5% of studies (n=1) 
meeting at least three quality items]. 
 
Main quality related issues for all studies were linked to both study and outcome level bias. Some 
confounders were frequently accounted for (e.g. gender, age/menopausal status, ethnicity), but 
other important confounders (e.g. acute infection, amenorrhoea/menorrhagia, oral contraceptive 
use, iron treatment/supplementation, obesity-related comorbidities) were often not considered even 
in studies where iron status was a primary outcome. The study by Ausk & Ioannou based on data 
from The National Health and Nutrition Examination Survey III (NHANES III) contained one of 
the most comprehensive confounder adjustment lists, but still failed to account for oral 
contraceptives use and iron treatment/supplementation.
10
 A few (n=4) studies excluded participants 
with anaemia or abnormally high or low ferritin which likely biased results.
17, 77, 80, 190
 In addition, 
some studies (n=2) used ferritin as the sole biomarker for assessment of iron status with few 
utilising the more recently discovered markers sTfR and hepcidin. This may have resulted in 
potential underestimation of iron deficiency due to elevation of serum ferritin through obesity-
related chronic inflammation.
57, 77, 141, 203
 
 
Results of individual studies 
Summaries of the data extracted for each non-bariatric or bariatric surgery study are presented in 
Appendices A3 to A6. Haemoglobin and transferrin saturation showed higher consistency with 
lower SD when compared to ferritin concentration which was highly variable (large SD) even in 
studies with large sample size and multiple confounder adjustment.
10
 Too few studies used sTfR or 
hepcidin for robust conclusions to be drawn. 
 
Forest plots were used to illustrate the mean differences in concentration of haemoglobin and 
ferritin as well as transferrin saturation between obese and non-obese control groups. There were 
10 obese groups from seven included studies reporting data for haemoglobin.
8-10, 17, 187, 188, 191
 Of 
these, seven groups tended to have higher (with four showing significantly higher) haemoglobin 
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-15 -10 -5 0 5 10 15
Mean haemoglobin differences and 95% CI (g/l) 
 
Control higher                                                    Obese higher 
Study Gender (menopausal status) 
Anna et al, 2009 (BMI 30.1-35) M 
Anna et al, 2009 (BMI >35) M 
Fricker et al, 1990 F (Premenopausal) 
Tussing-Humphreys et al, 2009 F (Premenopausal) 
Świtoniak & Król, 1992 F (Premenopausal) 
Lecube et al, 2006 F (Postmenopausal) 
Ausk & Ioannou, 2008 (BMI 30-35) Mixed 
Ausk & Ioannou, 2008 (BMI 35-40) Mixed 
Ausk & Ioannou, 2008 (BMI >40) Mixed  
Yanoff et al, 2007 Mixed 
concentrations in the obese when compared to non-obese controls (Figure 3.2). Larger studies and 
those in women all showed higher haemoglobin concentration in obese groups with the exception 
of the study by Yanoff et al
8
 The two remaining obese groups from Anna et al showing similar and 
non-significantly lower haemoglobin concentration were those with all male participants.
187
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Summary of mean haemoglobin differences between obese and non-obese groups with 
95% confidence intervals (CI) arranged according to gender and menopausal status (Dashed line 
denotes results from a bariatric surgery study; BMI, body mass index; M, male; F, female) 
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-100 -75 -50 -25 0 25 50 75 100
Mean ferritin differences and 95% CI (µg/l) 
 
Control higher                                                    Obese higher 
Study Gender (menopausal status) 
Ahmed et al, 2009 (Male) M 
Ahmed et al, 2009 (Female <50 y) F (Premenopausal) 
Fricker et al, 1990 F (Premenopausal) 
Tussing-Humphreys et al, 2009 F (Premenopausal) 
Ahmed et al, 2009 (Female ≥50 y)
 
 F (Postmenopausal) 
Lecube et al, 2006 F (Postmenopausal) 
Ausk & Ioannou, 2008 (BMI 30-35) Mixed 
Ausk & Ioannou, 2008 (BMI 35-40) Mixed 
Ausk & Ioannou, 2008 (BMI >40) Mixed 
Yanoff et al, 2007 Mixed 
All except one of the obese groups from six studies reported higher ferritin concentrations 
compared to non-obese controls (Figure 3.3).
8-10, 17, 77, 188
 In three groups this difference did not 
reach statistical significance (two of which were male or postmenopausal female). The only group 
reporting slightly lower ferritin concentration in the obese was also a postmenopausal female 
group.
77
 NHANES III data found a marked increase in ferritin concentration in higher (35-40 kg/m
2
 
and > 40 kg/m
2
) compared to lower (30-35 kg/m
2
) BMI strata in the obese.
10
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Summary of mean ferritin differences between obese and non-obese groups with 95% 
confidence intervals (CI) arranged according to gender and menopausal status (Dashed line denotes 
results from a bariatric surgery study; BMI, body mass index; M, male; F, female) 
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-20 -15 -10 -5 0 5 10
Mean transferrin saturation differences and 95% CI (%) 
 
Control higher                                                    Obese higher 
Study Gender (menopausal status) 
Świtoniak & Król, 1992 F (Premenopausal) 
Fricker et al, 1990 F (Premenopausal) 
Tussing-Humphreys et al, 2009 F (Premenopausal) 
Lecube et al, 2006 F (Postmenopausal) 
Ausk & Ioannou, 2008 (BMI 30-35) Mixed 
Ausk & Ioannou, 2008 (BMI 35-40) Mixed 
Ausk & Ioannou, 2008 (BMI >40) Mixed 
Yanoff et al, 2007 Mixed 
A trend for lower transferrin saturation in seven of eight obese groups was also observed (Figure 
3.4).
8-10, 17, 188, 191
 Of the eight groups, four showed significantly lower transferrin saturation levels 
in the obese compared to the corresponding control groups. Observation of the NHANES III data 
showed a stepwise decrease in transferrin saturation with increasing levels of obesity (Figure 3.4).
10
 
 
Mean differences in sTfR, hepcidin and CRP between obese and controls were not computed as 
few studies reported these biomarkers. When reported, sTfR was slightly and hepcidin and CRP 
markedly elevated in the obese (Appendices A5 and A6).
8, 9, 17, 121
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Summary of mean transferrin saturation differences between obese and non-obese 
groups with 95% confidence intervals (CI) arranged according to gender and menopausal status 
(Dashed line denotes results from a bariatric surgery study; BMI, body mass index; M, male; F, 
female) 
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DISCUSSION 
To our knowledge, this is the first manuscript to systematically review studies reporting iron status 
in obese cohorts. The obese tended to have higher haemoglobin and ferritin concentrations and 
lower transferrin saturation compared to the non-obese. The higher ferritin and lower transferrin 
saturation is consistent with the mechanism of obesity-related inflammation.
204
 However, 
assessment of other biomarkers such as sTfR (which is elevated in iron deficiency) and hepcidin 
(which is elevated in inflammatory states) in concert with clearly defined obesity populations are 
required to clarify the causal relationship between obesity and disturbed iron metabolism. Future 
investigations in different BMI and waist strata with care to measure and adjust for known 
confounders (e.g. gender, menopausal status, dietary treatment/supplementation) are also required. 
 
Traditionally, routine iron biomarkers such as haemoglobin, transferrin saturation and ferritin have 
been used to gauge iron status in individuals. However, in the presence of inflammation, the typical 
presentation of iron status is altered which can complicate detection of abnormalities in the clinical 
setting. Additional to routine iron studies, sTfR is useful in inflammatory states as unlike ferritin, it 
is not an acute-phase reactant.
8
 Other measurements such as the sTfR-ferritin index have also been 
reported to be valuable indicators of iron status in this circumstance.
94, 205
 
 
Recent interest in iron metabolism in chronic inflammatory states such as obesity has focused on 
hepcidin. Hepcidin is a 25 amino acid peptide hormone synthesised primarily by the liver and is a 
key regulator of iron homeostasis. It induces the internalisation and degradation of ferroportin in 
duodenal enterocytes, hepatocytes and macrophages which result in the inhibition of gastro-
intestinal iron absorption and release of iron stores from the liver and reticuloendothelial system.
97, 
206
 This review identified only two studies measuring serum hepcidin in adults, one of which 
showed it to be higher in the obese.
9
 Similar results were also reported in a paediatric population 
where mean serum hepcidin concentrations were higher in obese compared to non-obese children 
irrespective of dietary iron intake.
13
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The mechanisms resulting in increased circulating hepcidin concentration in obesity remain to be 
fully explained. There are considerable data demonstrating the proinflammatory cytokine 
interleukin-6 (IL-6) as a stimulator of hepcidin expression through signalling and activation of 
signal transducer and activator of transcription-3 (STAT-3) which binds to the promoter region of 
the hepcidin gene (HAMP) inducing mRNA transcription.
101, 103, 153
 Increases in inflammatory 
cytokines including IL-6 have been well documented in obesity and may contribute to significant 
increases in systemic hepcidin concentrations.
56, 57, 207
 There is also in vitro evidence suggesting the 
adipokine leptin (which is known to be markedly increased in obesity) may also stimulate hepcidin 
expression through the STAT-3 pathway.
116
 Furthermore, hepcidin mRNA has been shown to be 
expressed in adipose tissue which may also significantly contribute to elevated local and systemic 
concentrations in obese individuals with large adipose deposits. However, studies examining 
hepcidin mRNA expression in hepatic vs. adipose tissue have provided conflicting results.
9, 121
 
 
Studies included in this review show a trend towards higher haemoglobin concentrations in some 
obese groups. There are comorbidities more common in the obese which may raise haemoglobin 
and explain the trend illustrated in Figure 3.2. Obese individuals are at greater risk of chronic tissue 
hypoxia secondary to obstructive sleep apnoea and other obesity-related respiratory conditions 
which may lead to polycythaemia.
208, 209
 This rise is of course dependent on adequate iron 
availability, and the higher haemoglobin concentrations observed in the obese suggest that 
adequate iron is available for erythropoiesis. 
 
Higher ferritin concentrations were observed in all but one of the obese cohorts (Figure 3.3). 
Chronic inflammation associated with obesity is known to elevate this marker and may explain the 
higher mean ferritin concentrations observed in the obese groups.
57, 94, 203
 The rise in ferritin from 
the BMI strata of 35-40 kg/m
2
 onwards reported in the NHANES III dataset may reflect the impact 
of obesity-related inflammation on ferritin concentration.
10
 The inflammatory cytokine CRP was 
most frequently reported in the included studies and levels are consistent with obesity-related 
inflammation.
57
 However, additional studies designed to specifically investigate the association 
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between obesity-related inflammation and iron biomarkers such as ferritin are needed to confirm 
this relationship, and to determine how body fat distribution and degree of obesity may alter ferritin 
concentration. 
 
Lower transferrin saturation indicates decreased circulating protein bound iron.
103
 In obesity, lower 
transferrin saturation may be due to impaired iron absorption or decreased release from the 
reticuloendothelium – both of which fit with the inflammatory hepcidin hypothesis.97 Decreased 
transferrin saturation coupled with increased ferritin is suggestive of an inflammatory state. The 
progressive decline with increasing obesity suggests a biological link and may support the 
hypothesis that there is the underlying abnormality of iron absorption and iron storage release 
characteristic of the anaemia of inflammation.
115
 
 
Participants undergoing bariatric surgery tend to be more obese and have a higher frequency and 
severity of obesity-related comorbidities.
210
 Iron status in this population may therefore not 
accurately reflect what occurs in less severely obese cohorts. Due to the lack of studies with control 
groups and heterogeneity across all studies, it is difficult to conclude what effect the degree of 
obesity and comorbidity had on markers of iron status. However, results from pre-bariatric and 
healthy obese cohorts appear to be similar. Although not assessed by this review there are 
numerous reasons why the obese could also have simple iron deficiency. This may result from 
inadequate micronutrient intake, particularly in bariatric surgery patients and those with poor 
dietary habits or as a result of reduced energy diets in which iron is typically a limiting nutrient.
32
 
Menorrhagia associated with polycystic ovary syndrome and gastro-oesophageal reflux with 
oesophagitis are also two potential causes of iron deficiency that are more prevalent in the obese 
population.
211, 212
 Furthermore, chronic negative iron balance secondary to mild hepcidin elevation 
and partial mobilisation of iron stores has also been proposed to increase the risk of simple iron 
deficiency in the obese. 
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Particular challenges surround the detection of abnormalities in iron status. Conventional reference 
intervals quoted for ferritin, transferrin saturation, sTfR and other biomarkers are based on 
reference groups defined by the lack of anaemia. Patients with subclinical abnormalities in iron 
status without anaemia may be included in these reference groups, leading to a widening of 
reference intervals and decreased sensitivity of the biomarkers.
94
 Similar challenges also exist in 
the definition of hypoferraemia in obesity. Currently, the degree to which obesity-related 
inflammation alters iron metabolism remains unclear. Inflammatory elevation of ferritin leads to 
reduction in its sensitivity as an indicator of iron status,
205
 and some iron replacement studies have 
suggested alternate ferritin cut points for identifying disturbances in iron status in the presence of 
inflammation but further validation is required, particularly in obese populations.
205, 213
  
 
At present, there are insufficient well-designed studies with non-obese control groups comparing 
ferritin, sTfR, hepcidin and CRP simultaneously to offer firm evidence about the abnormalities of 
iron metabolism in the obese. There is a need for more dedicated studies employing control groups 
and wider use of additional iron biomarkers in future research in order to more accurately compare 
iron and inflammatory status between obese and non-obese populations. This study also revealed a 
large heterogeneity in gender and menopausal status between studies which may have biased 
results. Other sources of possible bias stem from the small, non-random, convenience samples 
recruited in the majority of studies (particularly bariatric surgery studies) that may not accurately 
reflect iron status of the wider population and the lack of adjustment for important confounders 
(e.g. acute infection, oral contraceptive use, iron treatment/supplementation). Despite this, most of 
the smaller studies were consistent with results of the NHANES III data.
10
 
 
In conclusion, this review highlights (1) the considerable challenge in identifying abnormalities of 
iron metabolism in the obese, (2) the need for further research, particularly well-designed topic-
focused studies with appropriate adjustment of important confounders, wider use of novel iron 
biomarkers and inflammatory markers such as sTfR, hepcidin and CRP, in addition to existing 
routine iron markers in future studies, and (3) the need for validated markers or algorithms able to 
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differentiate between disruptions in true or functional iron status secondary to obesity-related 
inflammation. Despite the limitations of heterogeneous methodologies and populations in the 
studies examined, this systematic review supports evidence for obesity associated disturbances in 
iron metabolism, the mechanisms for which are currently undefined. 
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ABSTRACT 
Background & Aims: Evidence suggests obesity-related inflammation alters iron metabolism 
potentially increasing the risk of iron deficiency. This cross-sectional study aimed to investigate 
iron, hepcidin and inflammatory status in young, healthy overweight and obese women. Methods: 
114 young (18-25 years), healthy comorbidity-free women with a body mass index (BMI) ≥27.5 
kg/m
2
 were recruited. Biochemical data were analysed using mean ± standard deviation or median 
(interquartile range) and multivariate modelling. Biochemical markers were also stratified 
according to varying degrees of overweight and obesity. Results: Anaemia (haemoglobin <120 g/l) 
and iron deficiency (serum ferritin <15.0 µg/l) were prevalent in 10% and 17% of participants 
respectively. Mean/median soluble transferrin receptor was 1.61 ± 0.44 mg/l; hepcidin 6.40 (7.85) 
ng/ml and C-reactive protein (CRP) 3.58 (5.81) mg/l. Multivariate modelling showed that BMI was 
a significant predictor of serum iron (coefficient=-0.379; standard error=0.139; p=0.008), 
transferrin saturation (coefficient=-0.588; standard error=0.222; p=0.009) and CRP 
(coefficient=0.127; standard error=0.024; p<0.001).Stratification of participants according to BMI 
showed those with ≥35.0 kg/m2 had significantly higher CRP (p<0.001) than those in lower BMI 
categories. Conclusions: Increasing obesity was associated with minor disturbances in iron 
metabolism. However, overall outcomes indicated simple iron deficiency (hypoferritinaemia) was 
the primary iron-related abnormality with no apparent contribution of inflammation or hepcidin, 
even in those with BMI >35.0 kg/m
2
. This indicates that obesity alone may not be sufficient to 
induce clinically significant disturbances to iron metabolism as previously described. This may be 
attributed to the lack of comorbidity in this cohort. 
Keywords: iron, hepcidin, inflammation, iron deficiency, obesity, overweight 
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INTRODUCTION 
Obesity is regarded as a proinflammatory condition characterised by the presence of chronic, low 
grade systemic inflammation.
8, 10
 In the past decade, a growing number of studies have suggested 
that obesity-related inflammation can lead to an iron handling defect similar to anaemia of 
inflammation (AI),
10
 with hepcidin proposed as a key mediator.
8, 9, 13
 Our recent systematic review 
investigating the impact of obesity on iron status also reported elevated BMI to be associated with 
increased serum ferritin and reduced transferrin saturation.
214
 However the question of whether 
these alterations are due to inflammation-mediated functional deficiency or true iron deficiency 
remains unclear due to lack of data for soluble transferrin receptor (sTfR) and hepcidin.
214
 
 
At a population level, premenopausal women are at higher risk of iron deficiency. In Australia, it 
has been estimated that over 20% of women between 25-50 years are either iron deficient or have 
marginally low iron status.
77
 In addition to regular menstrual iron loss,
7
 low iron intake (which is 
often reported in this group) and restrictive dietary practices for weight loss in overweight women 
can also increase the risk of iron deficiency.
32, 215
 Overweight and obese young women may 
therefore have a combination of age, dietary and inflammatory-associated factors perturbing iron 
status. 
 
Currently, only a handful of dedicated studies on obesity-related iron deficiency have focused on 
adolescent girls or young women.
9, 30, 216
 One US study analysed serum hepcidin and reported it to 
be significantly higher in bariatric surgery candidates compared to non-obese women.
9
 Severe 
obesity however, is frequently associated with comorbidities (e.g. obstructive sleep apnoea, gastro-
oesophageal reflux and fatty liver disease) that influence haematological markers or increase blood 
loss,
214, 217, 218
 and findings from this study may not be applicable to the wider population of less 
severely obese young women who are not burdened with comorbid conditions. Furthermore, other 
studies performed in more representative populations have been limited by the absence of hepcidin 
measurement, with mixed outcomes further complicating interpretation. 
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This study aimed to clarify the relationship between obesity, inflammation and iron status and 
identify the prevalence and nature of iron deficiency in a cohort of young healthy overweight and 
obese women by using a broad range of iron markers including sTfR and hepcidin. 
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METHODS 
Ethics statement 
This study was registered with the Australian New Zealand Clinical Trials Registry (ID: 
ACTRN12613000072718) and approved by the Ethics Review Committee of the Sydney South 
West Area Health Service and the University of Sydney Ethics Committee. Signed, written 
informed consent was obtained from all participants (the participant consent form used is presented 
in Appendix B3). Ethics approval was obtained for the referral of participants to their family 
physician upon detection of abnormal pathology results and review by the study medical officer 
(KSS). 
 
Study design 
This cross-sectional study reports anthropometric and biochemical characteristics of a community 
sample of young overweight and obese women (the study protocol and information for participants 
are presented in Appendices B1 and B2). Participants included in this study responded to one of 
two advertisements: one for recruitment into this cross-sectional study and the other for recruitment 
into a related 12-month clinical weight loss trial (where a similar but more stringent eligibility 
criteria was enforced).
219
 This cross-sectional study reports the baseline characteristics of 
volunteers who responded to either advertisement and met the eligibility criteria outlined in this 
manuscript. A subset of these participants also met the recruitment criteria for entry into the weight 
loss trial and results from this trial have been published elsewhere (Appendices D4 and D5).
219
 
 
Participants 
Young women aged between 18 to 25 years with a measured BMI 27.5 kg/m2 were recruited. 
Exclusion criteria included: self-report of significant medical conditions [e.g. diabetes mellitus, 
disorders of the liver (including haemochromatosis) and kidney, autoimmune or metabolic diseases 
and malignancy] or use of medications that may influence weight, iron or inflammatory status; 
pregnancy or lactation; vegetarianism; zinc supplementation; smoking; and previous bariatric 
surgery. 
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Volunteers reporting iron supplementation or blood donation within three months prior to 
recruitment were asked to participate only following a three-month washout period. A two-week 
washout period was required prior to recruitment for self-reported vitamin, fish oil or mineral 
(other than iron or zinc) supplementation. 
 
Data collection 
Participants attended two appointments at the obesity clinic of a university teaching hospital in 
Sydney, Australia. The first visit involved anthropometric assessment and collection of medical and 
socio-demographic history including self-reported use of contraceptive medication and history of 
polycystic ovary syndrome (PCOS). Participants reported to the second visit following a 12-hour 
overnight fast for collection of a morning venous blood sample. Those reporting current or recent 
(week prior) acute infection had blood collection rescheduled to avoid infection-related 
inflammation. 
 
Height (to the nearest 0.1 cm) and weight (to the nearest 0.1 kg) were measured without shoes 
using a wall-mounted stadiometer (Hyssna Limfog AB, Hyssna, Sweden) and an electronic digital 
platform scale (Teraoka Seiko, Tokyo, Japan) respectively. Waist circumference was measured 
using a metal retractable tape (Lufkin W606PM; Cooper Industries, Sparks, USA) to the nearest 
0.1 cm and according to international guidelines.
220
 In participants who were subsequently 
recruited to the weight loss trial, baseline body composition was also measured by dual-energy x-
ray absorptiometry (DXA) (GE Healthcare, Chalfont St Giles, UK). Abdominal (android) fat was 
calculated according to the manufacturer’s instructions by taking the lower boundary at the pelvis 
cut; upper boundary above the pelvis cut by 20% of the distance between the pelvis and neck cuts; 
and lateral boundaries at the arm cuts (Figure 4.1). 
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Figure 4.1. Regions of android (abdominal) and gynoid fat as measured by dual-energy x-ray 
absorptiometry (DXA) 
 
Biochemical analysis 
Haemoglobin, serum iron, transferrin saturation and serum ferritin were analysed at a nationally 
accredited commercial diagnostic pathology laboratory. Stored frozen plasma was used to analyse 
sTfR, hepcidin and C-reactive protein (CRP). Haemoglobin was measured using the Sysmex 
Instrument (Roche Diagnostics Australia, Sydney, Australia). Serum iron, transferrin saturation and 
serum ferritin were measured using the Roche Modular E170 Immunoassay Analyser (Roche 
Diagnostics Australia, Sydney, Australia). The reference ranges used were 120-165 g/l for 
haemoglobin; 10.0-30.0 µmol/l for serum iron; 12.0-45.0% for transferrin saturation; and 15.0-
165.0 µg/l for serum ferritin. Plasma sTfR and CRP were analysed using commercial ELISA kits 
(R&D Systems, Minneapolis, USA). Reference ranges provided were 0.74-2.39 mg/l for sTfR; and 
0.11-4.52 mg/l for CRP. A conversion factor was applied to transform sTfR values from nmol/l to 
mg/l.
181
 The sTfR-ferritin index (sTfR-F) was used to identify participants with iron depletion 
(sTfR-F 1.80-2.20), iron deficient erythropoiesis (sTfR-F >2.20), and AI (sTfR-F <1.00 with 
concurrent haemoglobin <120 g/l).
94, 125
 Clinically elevated CRP was defined as >10.00 mg/l.
53
 
Plasma hepcidin was measured by an on-line extraction coupled to liquid chromatography-tandem 
mass spectrometry method using the Xevo TQ MS (Waters Corporation, Milford, USA).
221
 Inter-
Android region 
 
 
Gynoid region 
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assay accuracy was 95% with a coefficient of variation of 8.2%. Assay sensitivity was 2.00 ng/ml, 
and values below the detectable range were defined as 1.00 ng/ml. A reference range of 1.92-32.40 
ng/ml was used.
222, 223
 
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics 19 for Windows (IBM Corporation, 
Armonk, USA). Data are presented as percentages, mean ± standard deviation (SD) or median 
(interquartile range). 
 
The relationship between obesity, iron and inflammatory status was assessed using two 
multivariate multiple regression models via MANOVA. Pearson’s correlations between BMI and 
waist circumference as well as between BMI and the DXA variables (total body fat percentage, 
absolute fat mass and abdominal fat percentage) were assessed prior to running the models. The 
first regression model included BMI (as a representative anthropometric variable) and potential 
confounders [use of contraceptive medication, ethnicity (coded dichotomously as European or non-
European) and PCOS] as predictors for the response variables: haemoglobin, serum iron, 
transferrin saturation, serum ferritin, sTfR, sTfR-F, hepcidin and CRP. As DXA measurement was 
only conducted in a subset of participants, body composition was excluded from initial multivariate 
analysis to maximise the number of participants included in the first regression model. A second 
multivariate model including BMI, total body fat percentage and the aforementioned confounder 
variables was subsequently produced to evaluate the impact of body composition on the 
biochemical markers. Significance was set at 0.01 for the MANOVA models to protect against type 
1 error with regression coefficients and standard errors (SE) also reported. 
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Secondary analyses were carried out to investigate biochemical differences between varying 
degrees of overweight and obesity. This was done by stratifying BMI into three categories and 
comparing biochemical markers using one way ANOVA and Bonferroni-adjusted post hoc tests. 
For the regression models and secondary analyses, variables were assessed for normality with 
natural log transformations performed on the serum ferritin, sTfR-F, hepcidin and CRP variables. 
Significance for the post hoc tests was set at 0.05. 
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RESULTS 
A total of 114 overweight and obese women were recruited to this cross-sectional study. A 
summary of participant characteristics is presented in Table 4.1. Mean age and BMI were 22.3 ± 
2.3 years and 33.7 ± 4.4 kg/m
2
 respectively. Overall use of hormonal contraceptive medication was 
32% (n=36) [oral contraceptive pill (n=30), contraceptive implant (n=4), depot injection (n=1) or 
patch (n=1)]. PCOS was self-reported in 12% (n=15) of participants. DXA body composition 
information was obtained from a subset (n=69) of participants (Table 4.1). 
 
Table 4.1. Summary of participant characteristics 
Participant characteristic (n=114) 
Mean ± SD or 
percentage 
  
Age (years) 22.3 ± 2.3 
Ethnicity (%)  
      European 65.8% 
      Asian 12.3% 
      African 3.5% 
      South American 4.4% 
      Other 14.0% 
Contraceptive medication (%) 31.6% 
PCOS (%) 12.4% 
Weight (kg) 94.6 ± 13.3 
BMI (kg/m2) 33.7 ± 4.4 
Waist circumference (cm) 93.8 ± 10.0 
Total body fat (%)a 49.8 ± 4.5 
Absolute fat mass (kg)a 44.5 ± 7.6 
Abdominal fat (%)a 55.7 ± 4.3 
PCOS, polycystic ovary syndrome; SD, standard deviation 
aBody composition data obtained from 69 participants. Two participants were 
precluded from body composition analysis as the measurement equipment did 
not accommodate body weights of above 130 kg 
 
 
A summary of participant iron, hepcidin and inflammatory status is presented in Table 4.2. 
Anaemia (haemoglobin <120 g/l) was detected in 10%; (n=11) of participants with none having AI 
(sTfR-F <1.00). Iron deficiency anaemia was identified in seven of the anaemic participants who 
simultaneously had serum ferritin and/or transferrin saturation below normal range. The degree of 
anaemia was mild (107-114 g/l) in the remaining four participants, three of which had borderline to 
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low mean corpuscular volume. Microcytosis with normal iron parameters raises the possibility of 
thalassemia trait. Pathology results outside of the reference range and which were deemed of 
potential clinical significance by the study medical officer (KSS) were forwarded to the 
participant's family physician with their consent. 
 
Table 4.2. Summary of participant biochemistry 
Biochemical marker 
Mean ± SD or 
Median (IQR) 
Prevalence of 
abnormality 
   
Hb (g/l) 131 ± 8  
     Hb <120 g/l  9.6% 
Serum iron (µmol/l) 15.3 ± 6.8  
     Serum iron <10.0 µmol/l  21.9% 
Tsat (%) 22.5 ± 10.6  
     Tsat <12.0%  14.0% 
Serum ferritin (µg/l) 34.0 (37.0)  
     Serum ferritin <15.0 µg/l  16.7% 
sTfR (mg/l) 1.61 ± 0.44  
     sTfR >2.39 mg/l  6.1% 
sTfR-F 1.02 (0.65)  
     sTfR-F 1.80-2.20  6.1% 
     sTfR-F >2.20  7.0% 
     sTfR-F <1.00 + Hb <115 g/l  0.0% 
Hepcidin (ng/ml) 6.40 (7.85)  
     Hepcidin >32.40 ng/ml  0.9% 
CRP (mg/l) 3.58 (5.81)  
     CRP >10.00 mg/l  14.0% 
CRP, C-reactive protein; Hb, haemoglobin; IQR, interquartile range; 
SD, standard deviation;  sTfR, soluble transferrin receptor; sTfR-F, soluble 
transferrin receptor-ferritin index; Tsat, transferrin saturation 
 
Iron deficiency without anaemia (serum ferritin <15.0 µg/l) was present in just under 17% (n=19) 
of participants. As serum ferritin has been reported to be elevated in obesity,
214
 sTfR and sTfR-F 
were also used to assess iron status. By using elevated sTfR (>2.39 mg/l), 6% of participants were 
identified as iron deficient. Alternatively, when sTfR-F >1.80 was used, iron deficiency was 
present in 13% of the cohort. Individuals identified as iron deficient by these alternative methods 
were also identified by hypoferritinaemia alone. 
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Median hepcidin was 6.40 ng/ml with only one participant presenting with hepcidin (37.40 ng/ml) 
above the reference range (in this participant, all other biochemical measures of iron and 
inflammatory status were normal). Hepcidin concentration was below 5.00 ng/ml in 80% of 
participants with hypoferritinaemia. Median CRP (3.58 mg/l) was within the assay specified 
normal range. Clinically elevated CRP (>10.00 mg/l) was observed in 14% of participants. 
 
Multivariate multiple linear regression models were employed to assess the relationship between 
obesity, iron and inflammatory status. BMI and total body fat percentage were selected as 
representative predictors for the anthropometric and body composition measures respectively due 
to strong correlations between BMI and waist circumference (Pearson’s r=0.839) and between BMI 
and each DXA variable (all Pearson’s r>0.737). In the initial regression model (Table 4.3), BMI 
was a significant predictor of serum iron (coefficient=-0.379; SE=0.139; p=0.008), transferrin 
saturation (coefficient=-0.588; SE=0.222; p=0.009) and CRP (coefficient=0.127; SE=0.024; 
p<0.001). Following the inclusion of total body fat percentage as an additional predictor, the 
association between BMI and CRP remained (coefficient=0.149; SE=0.042; p=0.001), with no 
significant relationship observed between the DXA and iron variables. Use of contraceptive 
medication was a significant confounder of iron but not hepcidin status in both regression models. 
Its confounding effect on the first model is shown in Table 4.3. 
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Table 4.3. Results from the first multivariate model used to assess the associations between BMI, inflammation, iron and hepcidin status 
Predictor variable 
Wilks’ lambda 
p value 
Response variable p value 
Hb Serum iron Tsat Serum ferritin
a
 sTfR sTfR-F
a
 Hepcidin
a
 CRP
a
 
          
BMI <0.001 0.907 0.008 0.009 0.039 0.833 0.264 0.318 <0.001 
Contraception <0.001 0.600 <0.001 0.006 0.134 0.002 0.007 0.147 <0.001 
Ethnicity 0.026 0.124 0.417 0.161 0.553 0.011 0.196 0.723 0.914 
PCOS 0.682 0.361 0.957 0.759 0.335 0.602 0.361 0.412 0.288 
R2  0.032 0.181 0.140 0.083 0.148 0.108 0.043 0.347 
BMI, body mass index; CRP, C-reactive protein; Hb, haemoglobin; PCOS, polycystic ovary syndrome; sTfR, soluble transferrin receptor; sTfR-F, soluble 
transferrin receptor-ferritin index; Tsat, transferrin saturation 
aNatural log transformation performed on the serum ferritin, sTfR-F, hepcidin and CRP variables 
  
Chapter 4: Iron and Inflammation in Overweight Young Women 
69 
Secondary analyses of biochemical data stratified according to World Health Organization BMI 
classifications were also performed to examine iron, hepcidin and inflammatory status with 
increasing degrees of overweight and obesity (Table 4.4).
1
 Classes II (35.0-39.9 kg/m
2
) and III 
(≥40.0 kg/m2) obesity were combined into a single category (defined as ≥35.0 kg/m2) as the 
number of participants with higher levels of obesity were small, and this BMI threshold was 
reported to be associated with substantial iron disturbances in our recent systematic review.
214
 
Serum iron (p=0.029), transferrin saturation (p=0.042), ferritin (p=0.021) and CRP (p<0.001) were 
significantly different between BMI categories, with CRP showing a significant increment between 
categories two and three (p<0.001) in the post hoc analysis (Table 4.4). 
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Table 4.4. Biochemical differences between varying categories of overweight and obesity 
BMI 
category 
BMI 
(kg/m
2
) 
n 
Age  
(years) 
Biochemical marker 
Hb Serum iron Tsat Serum ferritin
a
 sTfR 
sTfR-F
a
 
Hepcidin
a
 CRP
a
 
(g/l) (µmol/l) (%) (µg/l) (mg/l) (ng/ml) (mg/l) 
            
1 27.5-29.9 28 22.0 ± 2.1 132 ± 8 17.2 ± 6.3 25.9 ± 11.3 31.0 (34.0) 1.64 ± 0.47 1.03 (0.68) 5.25 (8.28) 1.62 (4.15) 
2 30.0-34.9 48 21.7 ± 2.3 130 ± 10 16.0 ± 7.4 22.9 ± 10.9 30.5 (31.0) 1.61 ± 0.49 1.02 (0.80) 6.30 (7.70) 1.62 (4.15) 
3 ≥35.0 38 23.1 ± 2.3 130 ± 8 13.0 ± 6.0b 19.3 ± 9.1b 46.0 (49.0)b 1.58 ± 0.35 0.99 (0.43) 9.20 (9.78) 6.24 (8.17)b,c 
Mean ± SD or median (interquartile range) 
BMI, body mass index; CRP, C-reactive protein; Hb, haemoglobin; sTfR, soluble transferrin receptor; sTfR-F, soluble transferrin receptor-ferritin index; Tsat, transferrin saturation 
aNatural log transformation performed on the serum ferritin, sTfR-F, hepcidin and CRP variables 
bBiochemical concentration significantly different from BMI category 1 in Bonferroni-adjusted post hoc analysis (p<0.05) 
cBiochemical concentration significantly different from BMI category 2 in Bonferroni-adjusted post hoc analysis (p<0.05) 
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DISCUSSION 
This study describes iron status in a cohort of healthy overweight and obese young women by using 
a broad range of iron biomarkers. Unlike studies in older or more severely obese populations, 
selection of this cohort allowed for examination of obesity, inflammation and iron handling 
associations independent of potential confounding from significant comorbidity. Young overweight 
women are of specific interest as they are at risk of iron deficiency.
32
 As suboptimal iron status 
even in the absence of anaemia is reported to adversely affect physical performance, mental health 
and cognitive function,
42, 76, 81
 success with dietary and behavioural weight management 
programmes may be reduced secondary to the effects of iron deficiency.
214
 Adverse effects from 
maternal iron deficiency anaemia on birth outcomes,
76
 offspring cognitive development,
76
 and 
increase risk for post-partum depression also highlight the importance of iron adequacy in this 
population.
85
 
 
Results from this study indicate the presence of obesity-related inflammation, and mild iron 
disruptions such as reduced serum iron and transferrin saturation with increasing BMI. In line with 
data from the US National Health and Nutrition Examination Survey III,
10
 no cases of AI were 
identified in our participants. Contrary to our expectations however, simple iron deficiency 
(hypoferritinaemia) was the most common iron-related abnormality (17%). 
 
Median hepcidin in this cohort was well below the concentration reported in morbidly obese 
bariatric surgery candidates in the US (88.02 ng/ml).
9
 Our hepcidin data was in fact, consistent with 
the non-obese (BMI <27.0 kg/m
2
) control group of this US study as well as levels reported in 
healthy, non-anaemic premenopausal female blood donors.
9, 224
 The lowest hepcidin concentrations 
were observed in those with the lowest iron stores. This is consistent with normal suppression of 
hepatic hepcidin secretion in the iron depleted state to allow for greater iron absorption and 
mobilisation.
74
 It is likely that low iron intake was a major contributing factor to the high 
prevalence of simple iron deficiency observed,
32
 although this cannot be confirmed as dietary iron 
intake was not assessed. Nevertheless, there was no apparent contribution of obesity-related 
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inflammation to the prevalence of iron deficiency observed, as evidenced by the modest rate (14%) 
of clinically elevated CRP, low median hepcidin and failure of sTfR and sTfR-F to detect a greater 
percentage of participants with iron deficiency. 
 
Iron but not hepcidin status of young female military recruits has been reported previously.
30
 This 
study concluded that a critical level of adiposity may be required for significant inflammation, 
hepcidin elevation and iron disturbances to occur which was partially supported by this study.
30
 In 
our subset of participants with a higher degree of obesity (BMI >35.0 kg/m
2
), mean hepcidin 
concentration remained in the lower normal range despite significantly greater CRP compared to 
those who were less obese. Given the healthy state of our cohort, this result indicates that a greater 
level of comorbidity (which is more often seen in older and severely obese individuals) may also be 
required to elicit substantial hepcidin elevation. 
 
This study is primarily limited by the absence of dietary iron intake assessment. As baseline data 
collection procedures were primarily intended for screening and recruitment into the weight loss 
trial, assessment of dietary intake was only conducted upon commencement of the weight loss 
intervention. Iron intake variation however, is not likely to have affected the main finding of this 
study which was that obesity-related inflammation in the absence of comorbidity did not elicit 
significant hepcidin-mediated iron disruptions. Furthermore, body composition was only measured 
in a subset of participants and this may have compromised statistical significance of regression 
outcomes between the DXA and iron variables. 
 
This study adds to the body of literature on excess weight, iron and inflammatory status in young 
women inclusive of the markers sTfR, sTfR-F and hepcidin. Results support a positive relationship 
between obesity and inflammation, with mild disruptions to some iron markers such as serum iron 
and transferrin saturation. However, simple iron deficiency as reflected by low ferritin remains the 
major iron-related abnormality in this cohort. There was no apparent contribution of inflammation 
and hepcidin to iron deficiency prevalence, which may be attributed to the absence of comorbidity 
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in this sample. As true iron deficiency has been shown to compromise reproductive and mental 
health, cognitive function and general wellbeing, this study highlights the importance of addressing 
simple iron deficiency in healthy overweight and obese young women. 
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Impact of diet and weight loss on iron status in 
overweight and obese young women 
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ABSTRACT 
Young women are at risk of iron deficiency with evidence suggesting obesity-related inflammation 
may exacerbate this risk. This study assessed iron and inflammatory status during a 12-month 
weight loss trial in young overweight (18-25 years; BMI ≥27.5kg/m2) women randomised to a 
higher-protein, higher-haem iron (HPHI; 32% protein; 12.2 mg/day iron) or lower-protein, lower-
haem iron (LPLI; 20%; 9.9 mg/day respectively) diet. Data: mean ± SD or median (range). In 
completers (HPHI: n=21; LPLI: n=15) HPHI participants showed higher ferritin [52.0 (7.0-139) vs. 
39.0 (6.0-71.0) µg/l; p=0.021] and lower soluble transferrin receptor-ferritin index (sTfR-F) [0.89 
(0.57-1.61) vs. 1.05 (0.44-3.40); p=0.024] although mean concentrations remained within normal 
range in both diets. C-reactive protein (CRP) [HPHI: 3.54 (0.08-13.26); LPLI: 4.63 (0.18-27.31) 
mg/l] and hepcidin [HPHI: 5.70 (1.00-25.60); LPLI: 8.25 (2.20-26.50) ng/ml] were not 
substantially elevated at baseline, and no between-diet differences were observed for CRP at the 
longitudinal time points. Compared to those with <5% weight loss, HPHI participants losing ≥10% 
initial weight showed lower sTfR-F [0.76 (0.40) vs. 1.03 (0.92); p=0.019] at six months. Impact of 
≥10% weight loss on iron was more apparent in LPLI participants who exhibited greater serum iron 
(20.0 ± 12.7 vs. 13.5 ± 6.3 µmol/l; p=0.002), transferrin saturation (29.8 ± 20.3% vs. 19.4 ± 9.1%; 
p=0.001) and lower sTfR (1.24 ± 0.52 vs. 1.92 ± 0.68 mg/l; p=0.034) at 12 months. This study 
shows that normal iron status can be maintained during 12 months of energy restriction. In the 
absence of elevated baseline inflammation and hepcidin, a more favourable iron profile in those 
with ≥10% weight loss may reflect stronger compliance or the potential influence of iron regulatory 
mechanisms unrelated to significant hepcidin reduction. 
Keywords: obesity, weight loss, young adult, iron 
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INTRODUCTION 
Young women are at an increased risk of weight gain and obesity.
3
 At this life stage, factors such 
as moving away from home, cohabitation and pregnancy are all associated with weight gain.
32, 34
 In 
addition to the deleterious effects on metabolic and reproductive health,
39, 48
 obesity is also linked 
with abnormal micronutrient metabolism, particularly for calcium, iron, zinc, vitamins A, D and 
folic acid.
68, 69, 225
 These micronutrient disturbances may contribute to the aetiology of obesity, as 
supported by studies showing leptin suppression in zinc deficiency,
68, 226
 or arise from excess 
adiposity such as the hypoferraemia of obesity.
9
 
 
Obesity-related alterations to micronutrient concentration are of particular concern in young 
women as: (1) requirement for nutrients such as iron are higher in this population;
32
 (2) obesity-
related inflammation may contribute to reduced micronutrient status,
214, 227
 although this was not 
observed for iron in our previous study conducted in a cohort of young women (Chapter 4);
228
 and 
(3) unhealthy eating habits can compromise nutrient adequacy.
229
 This was demonstrated in our 
aforementioned study of young overweight and obese women where despite minimal 
inflammatory- and hepcidin-mediated disturbances to iron metabolism, simple iron deficiency 
remained a prevalent (17%) health issue in this group.
228
 Dietary iron intake, particularly haem 
iron, is also often reported to be low in young women,
230-232
 and reduced food consumption during 
weight reduction can limit micronutrient intake (even when nutritionally balanced diets are used).
32
 
As iron has been reported as a limiting nutrient in energy-restricted diets for young women,
32
 
requirement for iron may be more easily met using animal-based, higher-protein meal plans that are 
nutrient dense and provide iron in the most bioavailable form.
32
 
 
Current literature examining micronutrient (particularly iron) alteration during medium to longer 
term (minimum six months) diet-induced weight loss is limited. Many studies focus on bariatric 
surgery-induced weight loss which can affect nutrient absorption.
149
 Some report favourable 
changes to iron and inflammatory status,
31, 137, 233
 although the impact of different degrees of weight 
loss on these biomarkers is unknown. With reduced iron and elevated inflammatory status all 
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correlated to increasing BMI,
68
 it is reasonable to assume that a larger reduction in excess weight 
will result in greater improvement of these markers. 
 
The objective of this study was to compare the effect of two energy-restricted diets with contrasting 
protein and haem iron content as well as differing degrees of weight loss (<5% vs. ≥10%) induced 
by these diets on iron and inflammatory status in young overweight and obese women. We 
hypothesise that participants who lose ≥10% of initial weight with either diet will have superior 
iron status and a lower level of inflammation than those on the same diet but who were less 
successful (<5%) with weight loss. Additionally, amongst the successful participants, those who 
lose ≥10% of weight via the higher-protein, higher-haem iron diet would show a more favourable 
iron profile compared to participants on a diet containing lower protein and haem iron content. 
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METHODS 
Study design 
This study examined iron and inflammatory status in young overweight women who completed a 
12-month single blind randomised controlled trial comparing the efficacy of two iso-energetically 
restricted diets (5600 kJ/day) differing in macronutrient and haem iron content (HPHI: higher-
protein, higher-haem iron diet; LPLI: lower-protein, lower-haem iron diet) on weight loss (the 
study protocol and information for participants are presented in Appendices B1 and B4).
219
 Due to 
the popularity of higher-protein diets, participants were blinded to the macronutrient distribution of 
the HPHI and LPLI diets to ensure a similar level of perceived therapeutic efficacy. This was 
achieved by informing participants that the two diets differed only in the type of meat prescribed 
(i.e. red or white). All participants were provided with an identical behaviour modification 
programme and a standard exercise prescription based on national activity guidelines.
234, 235
 
Participants attended counselling sessions weekly up to three months, fortnightly from three to six 
months and monthly from six to 12 months. 
 
Ethics 
This study was registered with the Australian New Zealand Clinical Trials Registry (ID: 
ACTRN12609000307202). All procedures were in accordance with the ethical standards of the 
Sydney South West Area Health Service Ethics Review Committee and the Human Research 
Ethics Committee of The University of Sydney. Signed and informed consent was obtained from 
all participants (the participant consent form used is presented in Appendix B5). 
 
Participants 
Healthy women aged 18-25 years with a measured BMI ≥27.5 kg/m2 were recruited. Exclusion 
criteria were applied to minimise confounding on weight loss outcomes.
219
 Since iron status was an 
important outcome of interest and animal protein was included in both diets, volunteers were 
ineligible if they had any haematological disorders, were anaemic (haemoglobin <120 g/l) or 
vegetarian. As iron deficiency without anaemia (serum ferritin <15.0 µg/l) is prevalent in this 
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population, iron deficient volunteers were advised to take the same ferrous fumarate supplement 
(10 mg elemental iron per day, five days a week) for three months and randomised upon 
normalisation of iron status and discontinuation of iron supplementation. Self-reported use of 
contraceptive medication was recorded due to its confounding effect on iron status.
236
 Recruited 
participants were required to cease all dietary supplements and blood donation for the entire 
duration of the trial. Volunteers reporting recent (week prior) acute infection had venepuncture (at 
baseline, six and 12 months) rescheduled to avoid infection-related inflammation. 
 
Dietary intervention, compliance and estimated dietary iron intake 
The HPHI diet provided 32% protein, 41% carbohydrate, 25% fat and 12.2 mg iron per day, 
whereas the LPLI diet provided 20% protein, 58% carbohydrate, 21% fat and 9.90 mg iron. Haem 
iron, estimated as 40% of total iron from meat, poultry, and fish,
237
 was calculated at 1.90 and 0.40 
mg/day for the HPHI and LPLI diets respectively. Both diet plans met the Australian estimated 
average requirement (EAR), but not the recommended dietary intake (RDI) for iron (HPHI: 68%; 
LPLI: 55%).
79
  Further details on the dietary prescriptions are presented in Appendices B6 and B7. 
A comparison of the nutrient composition of the two diets is shown in Appendix B8, and the seven-
day diet models used to do so are presented in Appendices B9 and B10. 
 
To monitor recent protein intake and compliance to the protein prescription, 24-hour urine samples 
were collected for measurement of urea/creatinine ratio (UCR).
238
 As studies have reported the 
need for at least 12 days of dietary data to estimate iron intake confidently,
239
 average iron intake 
was estimated using three-day food records collected at the end of the first, second, third, sixth and 
twelfth months totalling 15 days for trial completers. To maximise accuracy, training on how to 
record food intake using household measures was provided by a dietitian. Kitchen scales were also 
given to each participant. When required, recorded food portions were verified with the assistance 
of a visual aid.
240
 Nutrient analysis was performed using FoodWorks Version 6.0.25175 (Xyris 
Software, Brisbane, Australia). 
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Anthropometry 
Height (nearest 0.1 cm) and weight (nearest 0.1 kg; measured at every visit) were recorded using a 
wall-mounted stadiometer (Hyssna Limfog AB, Hyssna, Sweden) and digital platform scale 
(Teraoka Seiko, Tokyo, Japan) respectively. Waist circumference was measured at baseline, three, 
six and 12 months according to international guidelines.
220
 
 
Biochemical analysis 
Fasting morning venous blood samples were collected at baseline, six and 12 months. 
Haemoglobin, serum iron, transferrin saturation and serum ferritin were analysed at a nationally 
accredited commercial diagnostic laboratory. Reference ranges were 120-165 g/l for haemoglobin; 
10.0-30.0 µmol/l for serum iron; 12.0-45.0% for transferrin saturation; and 15.0-165.0 µg/l for 
ferritin. Plasma was stored for analysis of soluble transferrin receptor (sTfR) and C-reactive protein 
(CRP) using commercial ELISA kits (R&D Systems, Minneapolis, USA). Median inter-assay 
coefficients of variation reported in the kits were 5.70% and 6.60% for sTfR and CRP respectively. 
Reference ranges were 0.74-2.39 mg/l for sTfR and 0.110-4.52 mg/l for CRP, with clinically 
elevated CRP defined as >10.0 mg/l.
53
 sTfR results were converted from nmol/l to mg/l.
181
 The 
sTfR-ferritin index (sTfR-F), described as a useful indicator of iron status in inflammation was 
calculated.
94
 Plasma hepcidin was measured only at baseline using an on-line extraction coupled to 
liquid chromatography-tandem mass spectrometry method with the Xevo TQ MS (Waters 
Corporation, Milford, USA).
221
 Inter-assay accuracy was 95.0% with an 8.20% coefficient of 
variation. Assay sensitivity was 2.00 ng/ml with values below the detectable range defined as 1.00 
ng/ml. A reference range of 1.92-32.4 ng/ml was used.
222, 223
 
 
Statistical analysis 
Statistical analysis was performed using PASW Statistics 18 for Windows (IBM Corporation, 
Armonk, USA). As weight loss was the primary outcome of this trial, sample size was calculated 
on the basis of detecting a weight difference between the diet groups. Based on a significance level 
of 0.05 and 80% power, 28 participants were required in each diet to detect a 5 kg weight 
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difference. With attrition estimated at approximately 20%,
241
 a recruitment goal of 70 participants 
was established. 
 
In this study, data were analysed only for participants who completed to six and 12 months to 
determine true biochemical alterations associated with the dietary intervention which were not 
based on statistical assumptions used for treating missing data. Participants were categorised into 
non-responder (<5% loss of initial weight) and responder (≥10% loss of initial weight) groups 
within each diet to examine the influence of weight loss success on the biochemical markers. These 
cut-offs were selected as they have previously been used to reflect weight loss success,
242
 and 10% 
weight reduction is generally associated with important improvements in chronic disease risk 
factors.
243
 Categorising participants according to these cut-offs also allowed for a clear distinction 
between the two degrees of weight loss. 
 
Variables were assessed for normality with natural log transformations performed on the serum 
ferritin, sTfR-F, CRP and hepcidin variables. Baseline age, weight, BMI and the dietary 
compliance measures (UCR and dietary iron intake) were compared between the two diets using 
unpaired t-tests. Paired t-tests were used to assess anthropometric changes (from baseline) within 
each diet. Pearson’s tests were used to correlate dietary iron intake against serum ferritin 
concentration. Repeated measures ANOVA (adjusted for baseline BMI) was used to compare 
anthropometric changes between the diets. Biochemical differences between the diets and 
responder groups at baseline and the longitudinal time points (where the baseline value of the 
dependent variable was included as an additional covariate) were assessed using ANCOVA. All 
ANCOVA analyses were adjusted for baseline BMI and contraceptive medication, whereas 
ANCOVA tests comparing serum iron, transferrin saturation and ferritin concentrations were also 
adjusted for lnCRP (to account for potential inflammatory differences). Significance was set to 
p<0.05, with data presented as a percentage, mean  SD or median (range). 
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RESULTS 
A total of 71 participants (HPHI: n=36; LPLI: n=35) were recruited to the trial with 44 (HPHI: 
n=24; LPLI: n=20) completing to six and 36 (HPHI: n=21; LPLI: n=15) completing to 12 months. 
Reasons for high attrition in this trial have been described (Appendices D4 and D5).
219, 244
 Results 
reported in this study refer to six- and 12-month completers only. All baseline characteristics were 
similar between diets with the exception of higher BMI in HPHI participants (Table 5.1). Use of 
contraceptive medication was reported by 36%. At recruitment (prior to pre-trial iron 
supplementation), iron deficiency (ferritin <15.0 µg/l) was identified in six participants (17%; 
HPHI: n=4; LPLI: n=2). All participants presented with baseline hepcidin concentration within 
normal range and clinically elevated CRP (>10.0 mg/l) was observed in five (HPHI: n=1; LPLI: 
n=4) participants. As baseline hepcidin was unremarkable indicating minimal likelihood of 
substantial hepcidin-mediated iron disturbances, measurement of this marker at six and 12 months 
was not pursued. Mean values for all biomarkers were within normal range throughout the trial.
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Table 5.1. Comparison of participant age, anthropometric and biochemical characteristics between diets at baseline 
Baseline characteristic 
6-month completers at baseline 12-month completers at baseline 
HPHI diet (n=24) LPLI diet (n=20) p value HPHI diet (n=21) LPLI diet (n=15) p value 
       
Age (years) 22.4 ± 2.3 21.8 ± 2.2 0.339 22.4 ± 2.3 22.1 ± 2.1 0.678 
Weight (kg) 95.8 ± 9.1 92.9 ± 11.7 0.368 96.2 ± 8.9 92.5 ± 11.6 0.291 
Ethnicity (%)       
     European 83.3 75.0  81.0 86.7  
     Asian 4.17 10.0  4.76 6.67  
     African 0.00 5.00  0.00 6.67  
     South American 4.17 10.0  4.76 0.00  
     Other 28.33 0.00  9.52 0.00  
BMI (kg/m2) 34.3 ± 3.5 32.2 ± 3.6 0.063 34.6 ± 3.4 32.2 ± 3.6 0.047 
Hb (g/l) 131 ± 8 130 ± 9 0.797 132 ± 8 130 ± 10 0.456 
Serum iron (μmol/l) 13.5 ± 6.2 16.3 ± 7.2 0.344 14.0 ± 6.2 15.5 ± 6.2 0.749 
Tsat (%) 19.5 ± 8.5 24.7 ± 12.2 0.147 20.5 ± 8.4 23.9 ± 11.4 0.393 
Serum ferritin (μg/l)a 33.0 (89.0) 37.0 (185.0) 0.286 34.0 (80.0) 35.0 (82.0) 0.985 
     <15.0 μg/l (%) 16.7 10.0  9.52 13.3  
sTfR (mg/l) 1.56 ± 0.34 1.67 ± 0.61 0.445 1.55 ± 0.35 1.73 ± 0.66 0.356 
sTfR-F indexa 1.01 (1.52) 1.02 (1.60) 0.652 0.95 (1.50) 1.01 (1.42) 0.839 
Hepcidin (ng/ml)a 5.70 (24.6) 8.25 (24.3) 0.123 5.80 (24.6) 7.40 (24.0) 0.298 
CRP (mg/l)a 3.55 (13.2) 4.63 (27.1) 0.690 3.51 (13.2) 4.75 (13.0) 0.626 
     >10.0 mg/l (%) 4.17 20.0  4.76 13.3  
Mean  SD or median (range) 
CRP, C-reactive protein; HPHI, higher-protein and higher-haem iron; LPLI, lower-protein and lower-haem iron; sTfR, soluble transferrin receptor; sTfR-F, soluble transferrin receptor-ferritin 
index; Tsat, transferrin saturation 
Reference ranges – Hb: 115-165 g/l; serum iron: 10.0-30.0 µmol/l; Tsat: 12.0-45.0%; serum ferritin: 15.0-165 µg/l; sTfR: 0.74-2.39 mg/l; CRP: 0.11-4.52 mg/l; hepcidin: 1.92-32.40 ng/ml 
aNatural log transformation performed on the serum ferritin, sTfR-F, hepcidin and CRP variables
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Weight loss 
Both diets independently led to significant weight loss at six (HPHI: 9.31 ± 8.87%, p<0.001; LPLI: 
5.08 ± 5.99%; p=0.001) and 12 months (HPHI: 9.79 ± 13.0%, p=0.003; LPLI: 4.56 ± 7.15%, 
p=0.027). Between the diets, weight loss in HPHI was approximately double that of LPLI, although 
this was not statistically significant (Figure 5.1). Similar between-diet outcomes were observed for 
waist circumference at six (HPHI: -7.8 ± 1.3; LPLI: -3.7 ± 1.0 cm; p=0.30) and 12 months (HPHI: -
7.9 ± 1.8; LPLI: -2.4 ± 0.8 cm; p=0.36). Other anthropometric outcomes have also been published 
(Appendix D5).
219
 At six months, there were 18 non-responders (HPHI: n=8; LPLI: n=10) who had 
lost <5% of initial weight while 13 responders (HPHI: n=10; LPLI: n=3) achieved losses of ≥10%. 
By 12 months, 27 of the 36 participants who completed the trial had lost either <5% (HPHI: n=6; 
LPLI: n=8) or ≥10% (HPHI: n=9; LPLI: n=4) of weight. The distribution of responders and non-
responders was not significantly different between the diets (six months: p=0.127; 12 months: 
p=0.153). 
 
 
 
Figure 5.1. Percent loss of initial weight between the diets (Mean ± SE; HPHI, higher-protein and 
higher-haem iron; LPLI, lower-protein and lower-haem iron) 
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Dietary compliance and estimated iron intake 
No significant UCR difference was observed between the diets at baseline (HPHI: 33.5 ± 7.43; 
LPLI: 30.6 ± 6.94; p=0.194). At six months, UCR was significantly higher on the HPHI diet 
(HPHI: 38.4 ± 9.67; LPLI: 30.5 ± 7.31; p=0.023) which was consistent with the protein 
prescription. However, this difference was no longer significant at 12 months (HPHI: 35.0 ± 7.40; 
LPLI: 33.7 ± 5.49; p=0.547), indicating reduced compliance. 
 
As expected, mean estimated iron intake in HPHI was significantly higher than the LPLI diet (all 
p<0.001) and was close to the dietary prescription for both groups (Table 5.2). No significant 
intake differences were observed between responder groups in either diet (Table 5.3). All HPHI 
participants met the EAR for dietary iron while a number of participants on the LPLI diet did not 
(Table 5.2). Pearson’s tests revealed no significant correlations between dietary iron intake and 
serum ferritin (r=0.109; p=0.547 at 12 months). 
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Table 5.2. Comparison of biochemistry and micronutrient intake between the diets at six and 12 months 
Biochemical or 
intake variable 
6 months 
p  value 
12 months 
p  value 
HPHI diet (n=24) LPLI diet (n=20) HPHI diet  (n=21) LPLI diet (n=15) 
       
Hb (g/l) 130 ± 11 128 ± 7 0.318 132 ± 12 126 ± 11 0.075 
Serum iron (μmol/l) 14.3 ± 6.4 15.0 ± 4.5 0.564 15.6 ± 5.3 15.5 ± 8.8 0.242 
Tsat (%) 21.9 ± 10.3 22.1 ± 7.4 0.410 23.7 ± 8.6 23.5 ± 14.4 0.244 
Serum ferritin (μg/l)a 46.0 (107) 37.0 (141) 0.052 52.0 (132) 39.0 (65.0) 0.021 
     <15.0 μg/l (%) 12.5 5.00  9.52 20.0  
sTfR (mg/l) 1.50 ± 0.39 1.72 ± 0.69 0.335 1.46 ± 0.30 1.68 ± 0.71 0.145 
sTfR-F indexa 0.80 (1.58) 0.98 (2.55) 0.057 0.89 (1.04) 1.05 (2.96) 0.024 
CRP (mg/l)a 2.36 (14.9) 2.65 (21.8) 0.597 2.22 (25.8) 3.95 (12.0) 0.784 
     >10.0 mg/l (%) 12.5 20.0  14.3 6.67  
Iron intake (mg/day) 11.9 ± 2.7 8.3 ± 1.6 <0.001 11.4 ± 1.9 8.5 ± 1.5 <0.001 
     <EAR (%) 0.00 30.0  0.00 26.7  
     <RDI (%) 95.8 95.0  90.5 93.3  
Mean  SD or median (range) 
CRP, C-reactive protein; EAR, estimated average requirement; HPHI, higher-protein and higher-haem iron; LPLI, lower-protein and lower-haem 
iron; sTfR, soluble transferrin receptor; sTfR-F, soluble transferrin receptor-ferritin index; RDI, recommended dietary intake; Tsat, transferrin 
saturation 
Reference ranges – Hb: 115-165 g/l; serum iron: 10.0-30.0 µmol/l; Tsat: 12.0-45.0%; serum ferritin: 15.0-165 µg/l; sTfR: 0.74-2.39 mg/l; CRP: 
0.11-4.52 mg/l 
Nutrient reference values for iron – EAR: 8.00 mg/day, RDI: 18.0 mg/day 
aNatural log transformation performed on the serum ferritin, sTfR-F and CRP variables 
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Iron and inflammatory status between diets 
Comparison of iron and inflammatory markers between the diets is presented in Table 5.2. At 12 
months, HPHI participants showed changes reflective of increased iron stores with significantly 
higher ferritin [HPHI: 52.0 (132) vs. LPLI: 39.0 (65.0) µg/l; p=0.021] and lower sTfR-F [HPHI: 
0.89 (1.04) vs. LPLI: 1.05 (2.96); p=0.024]. In contrast, these markers remained stable in LPLI 
participants throughout the trial. CRP decreased from baseline in both diet groups, although no 
significant between-diet differences were observed. Use of contraceptive medication was a 
significant confounder of several iron markers including serum ferritin (p=0.032), sTfR (p=0.019) 
and sTfR-F (p=0.001) (confounding effect on 12-month data reported for brevity). 
 
Of the six (HPHI: n=4; LPLI: n=2) participants identified as iron deficient at recruitment, three 
(HPHI: n=2; LPLI: n=1) were able to maintain normal ferritin following 12 months of intervention. 
Conversely, in those with normal baseline iron status, four participants (HPHI: n=2; LPLI: n=2) 
developed iron deficiency upon trial completion and had to be referred to their family physician for 
follow-up treatment. The number of HPHI participants presenting with low ferritin decreased from 
baseline to 12 months whereas the opposite was observed in the LPLI diet group (Table 5.1 and 
Table 5.2).  
 
Iron and inflammatory status between responder groups 
Table 5.3 shows the biochemical comparisons between diet non-responders (<5% weight loss) and 
responders (≥10% weight loss). Within each diet at six months, HPHI responders showed 
significantly lower sTfR-F [non-responders: 1.03 (0.92) vs. responders: 0.76 (0.40); p=0.019] while 
LPLI responders exhibited a trend for higher ferritin [non-responders: 27.0 (133) vs. responders: 
69.0 (28.0) µg/l; p=0.053] and significantly lower sTfR [non-responders: 1.73 ± 0.72 vs. 
responders: 1.59 ± 0.93 mg/l; p=0.011]. By 12 months, the tendency for those with ≥10% weight 
loss to show a more favourable iron profile was only apparent in LPLI responders who had higher 
serum iron (non-responders: 13.5 ± 6.3 vs. responders: 20.0 ± 12.7 µmol/l; p=0.002), transferrin 
saturation (non-responders: 19.4 ± 9.1%; responders: 29.8 ± 20.3%; p=0.001) and lower sTfR (non-
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responders: 1.92 ± 0.68 vs. responders: 1.24 ± 0.52 mg/l; p=0.034). The HPHI diet appeared to 
have a greater impact on CRP reduction with successful weight loss than LPLI (p=0.085 at 12 
months), although not significantly so. Similar to the between-diet analysis, contraceptive 
medication was a significant confounder for transferrin saturation (p=0.031) in the HPHI diet and 
for serum iron (p=0.001), transferrin saturation (p=0.001) in the LPLI diet group.
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Table 5.3. Comparison of biochemistry and micronutrient intake between non-responders (<5% loss of initial weight) and responders 
(≥10% loss of initial weight) within the diets at six and 12 months 
Biochemical or 
intake variable 
HPHI diet LPLI diet 
Weight loss at 6 months p 
value 
Weight loss at 12 months p 
value 
Weight loss at 6 months p 
value 
Weight loss at 12 months p 
value <5% (n=8) ≥10% (n=10) <5% (n=6) ≥10% (n=9) <5% (n=10) ≥10% (n=3) <5% (n=8) ≥10% (n=4) 
             
Hb (g/l) 128 ± 11 129 ± 9 0.590 131 ± 14 133 ± 10 0.840 129 ± 7 134 ± 7 0.613 127 ± 11 129 ± 6 0.060 
Serum iron (μmol/l) 13.6 ± 8.5 15.8 ± 5.0 0.400 16.7 ± 6.3 14.1 ± 3.3 0.769 14.5 ± 3.7 17.0 ± 4.6 0.453 13.5 ± 6.3 20.0 ± 12.7 0.002 
Tsat (%) 19.6 ± 11.8 25.5 ± 9.1 0.878 24.7 ± 10.5 23.2 ± 5.7 0.608 21.9 ± 7.0 25.3 ± 9.0 0.161 19.4 ± 9.1 29.8 ± 20.3 0.001 
Serum ferritin (μg/l)a 42.0 (77.0) 59.5 (91.0) 0.137 51.0 (75.0) 70.0 (104.0) 0.172 27.0 (133.0) 69.0 (28.0) 0.053 27.0 (52.0) 51.5 (16.0) 0.263 
     <15.0 μg/l (%) 0.00 0.00  33.3 0.00  0.00 0.00  50.0 0.00  
sTfR (mg/l) 1.47 ± 0.37 1.32 ± 0.25 0.241 1.48 ± 0.31 1.32 ± 0.26 0.658 1.73 ± 0.72 1.59 ± 0.93 0.011 1.92 ± 0.68 1.24 ± 0.52 0.034 
sTfR-F indexa 1.03 (0.92) 0.76 (0.40) 0.019 1.04 (0.99) 0.63 (0.46) 0.145 1.06 (2.14) 0.62 (0.89) 0.050 1.12 (2.52) 0.67 (0.69) 0.223 
CRP (mg/l)a 5.43 (14.69) 0.92 (12.67) 0.145 3.78 (17.33) 1.06 (25.57) 0.085 2.17 (13.82) 5.16 (21.16) 0.310 3.45 (11.97) 5.14 (7.74) 0.830 
     >10.0 mg/l (%) 0.25 10.0  16.7 11.1  20.0 33.3  12.5 0.00  
Iron intake (mg/day) 11.8 ± 2.5 12.3 ± 3.4 0.953 12.3 ± 2.9 11.0 ± 1.1 0.244 8.9 ± 1.8 7.7 ± 1.9 0.299 8.7 ± 0.9 7.9 ± 1.8 0.911 
     <EAR (%) 0.00 0.00  0.00 0.00  10.0 33.3  25.0 25.0  
     <RDI (%) 100 90.0  83.3 88.9  90.0 100  87.5 100  
Mean  SD or median (range) 
CRP, C-reactive protein; EAR estimated average requirement; HPHI, higher-protein and higher-haem iron; LPLI, lower-protein and lower-haem iron; sTfR, soluble transferrin receptor; sTfR-
F, soluble transferrin receptor-ferritin index; RDI, recommended dietary intake; Tsat, transferrin saturation 
Reference ranges – Hb: 115-165 g/l; serum iron: 10.0-30.0 µmol/l; Tsat: 12.0-45.0%; serum ferritin: 15.0-165 µg/l; sTfR: 0.74-2.39 mg/l; CRP: 0.11-4.52 mg/l 
Nutrient reference values for iron – EAR: 8.00 mg/day, iron RDI: 18.0 mg/day 
aNatural log transformation performed on the serum ferritin, sTfR-F and CRP variables 
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DISCUSSION 
This study evaluated the impact of two energy-restricted diets with contrasting protein and haem 
iron content on iron and inflammatory markers in young women. Results showed that during 
medium to longer term energy restriction, the HPHI diet had a propensity for increasing iron stores 
more readily although serum ferritin was maintained within normal limits for most individuals on 
both diets. Responders on the LPLI diet who lost ≥10% of initial weight also showed a more 
favourable iron profile compared to non-responders who lost <5% of initial weight. 
 
Iron homeostasis in adults is essential for tissue oxygen delivery, cell growth and immune 
function,
76, 245
 with inadequate body iron impacting adversely on physical performance, work 
productivity and cognitive function.
76, 245
 The tendency for greater iron stores (ferritin) in the HPHI 
diet group was comparable to a similar study conducted in middle-aged women.
238
 The substantial 
proportion of individuals identified with iron deficiency (17%) at recruitment also highlights the 
clinical relevance of HPHI diets for maintaining iron status, particular in young women with higher 
requirements for this nutrient. 
 
Meeting age and gender-appropriate nutrient recommendations can be difficult for young women 
undergoing energy restriction.
32
 This was reflected in our study whereby the HPHI and LPLI diets 
did not reach the RDI for iron, even after detailed modelling and manipulation of the meal plans. In 
women with greater nutritional needs such as those who experience high menstrual iron losses,
7
 
adopting energy-restricted diets may become problematic. The persistence and new development of 
iron deficiency in a number of our participants was similar to a previous study describing an 
increase in nutrient deficiency with weight reduction via a nutritionally complete formula diet.
246
 
This highlights the importance of careful nutritional planning and monitoring during dietary weight 
management in young women, particularly if energy restriction is sustained over a prolonged 
period of time. 
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Contrary to our expectations, mean CRP and hepcidin concentration were not greatly elevated at 
baseline, which was most likely due to the modest obesity and absence of comorbidities in this 
cohort.
247
 Hence, diet therapy and weight loss would only have brought about a minor (if any) 
decrease in these markers. This finding indicates that unlike previous studies,
31, 117
 significant 
weight loss associated reductions in hepcidin may only occur in individuals who are severely obese 
and/or burdened with comorbid conditions and greater levels of inflammation.
31, 214, 248
 Despite low 
baseline hepcidin, higher circulating iron levels were still observed in LPLI responders who lost 
≥10% of weight. While a superior iron profile in LPLI responders vs. non-responders is likely to be 
the result of better diet quality and compliance, these findings do not rule out a possible standalone 
benefit of weight loss on iron status that is independent of significant hepcidin reduction. Higher 
haem iron intake may have masked the iron-related benefits of weight loss, which explains the 
absence of significant differences between responder groups in the HPHI diet. 
 
This study enrolled young women, a nutritionally vulnerable population for which limited clinical 
research is available. Limitations of this study include the high rate of attrition (leading to small 
sample size) and absence of longitudinal hepcidin assessment. Interestingly, similar difficulties 
with attrition was recently reported in a systematic review of weight management interventions in 
young adults,
37
 highlighting the inherent challenges of conducting research in this population. 
 
In conclusion, this study supports the use of well-designed energy-restricted diets for weight loss 
and reasonable maintenance of iron status in young, healthy, overweight and obese women. Despite 
insignificant changes to inflammatory status, loss of ≥10% initial weight was associated with a 
superior iron profile which was evident under conditions of limited haem iron intake. This may 
reflect greater diet quality and compliance, or the influence of iron regulatory pathway(s) 
independent of significant inflammatory hepcidin reduction. 
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ABSTRACT 
Although young women following energy-restricted diets are at increased risk of iron deficiency, 
weight management trials rarely examine the longitudinal impact of genetic polymorphisms on iron 
metabolism. This exploratory study examined how the TMPRSS6 rs855791 polymorphism 
influenced iron and hepcidin status in 76 young (18-25 years) women with BMI ≥27.5kg/m2, and in 
a subset of this cohort, iron responses to two 12-month iso-energetically restricted diets [higher-
protein, higher-haem iron (HPHI) vs. lower-protein, lower-haem iron (LPLI) diet] were explored. 
While all mean/median values were within normal range, individuals hetero- or homozygous for 
the T allele showed significantly lower serum iron (coefficient=-3.116; p=0.047) and higher 
hepcidin (coefficient=0.607; p=0.023) at baseline than those homozygous for the alternative C 
allele. Following 12 months of dieting, T hetero- and homozygotes were less able to maintain 
serum iron (p=0.028) and transferrin saturation (p=0.043) while on the HPHI, but not LPLI diet. 
Whilst rs855791 did not influence ferritin concentration (HPHI: p=0.89; LPLI: p=0.91), a 
significant diet × time effect was observed (p=0.026). In conclusion, this study confirms the iron-
lowering effect of the T allele on serum iron and hepcidin at baseline. Lower serum iron and 
transferrin saturation observed in T hetero- and homozygotes following the HPHI diet suggest that 
rs855791-associated iron variability may be dependent on haem iron and/or protein intake. These 
small but significant variations highlight the need for studies incorporating more polymorphisms 
and dietary patterns to evaluate gene-nutrient interactions that affect iron status during weight 
management. 
Keywords: TMPRSS6, iron deficiency, weight loss, young women 
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INTRODUCTION 
Young women are at increased risk of iron deficiency.
6
 Recent evidence indicates that obesity may 
exacerbate this risk secondary to inflammation and elevated hepcidin, resulting in unfavourable 
changes to iron metabolism.
8, 18, 249
 However, inflammation and hepcidin were not found to be 
significant contributors to iron abnormality in a recent study of young healthy overweight and 
obese women (Chapter 4).
228
 The primary issue observed was simple iron deficiency, suggesting 
that iron disruptions related to excess adiposity may be dependent on the degree of obesity and 
presence of obesity-related comorbidities.
214, 228
  Although iron deficiency is globally the most 
common nutrient deficiency with a high prevalence amongst young women,
76
 the influence of 
genetics on iron is rarely explored in longitudinal clinical trials, particularly in weight management 
interventions involving energy restriction where iron intake may be limited.
32
 
 
The rs855791 variant in the transmembrane protease, serine 6 (TMPRSS6) gene is a single 
nucleotide polymorphism (SNP) that has been identified to be strongly associated with iron status 
in healthy populations.
21, 26
 The TMPRSS6 gene encodes matriptase-2, a transmembrane serine 
protease that is involved in negative regulation of hepcidin production.
250
 The SNP rs855791 
involves a non-synonymous cytosine (C) to thymine (T) nucleotide substitution that corresponds to 
an alanine to valine change in the amino acid sequence. Mutations or variations in the TMPRSS6 
gene (such as SNP rs855791) resulting in blunted matriptase-2 activity, are believed to cause 
increased hepcidin expression and greater attenuation of iron absorption.
250
 Recent evidence 
indicates that rs855791 may also exert an unidentified hepcidin-independent effect on iron 
metabolism.
175
 
 
Genome-wide association studies have shown significant associations between rs855791 and 
various haematological and iron traits.
20, 26, 172
 However, no research to date has reported the effect 
of rs855791 on iron responses to dietary protein and haem iron manipulation during restricted 
energy intake. In order to gain a further insight into the impact of rs855791 on iron metabolism in 
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young overweight and obese women, we performed a number of exploratory analyses by: (1) 
comparing baseline iron and hepcidin status between young women of differing rs855791 
genotype, and (2) assessing how rs855791 genotype may influence iron-related responses to two 
iso-energetically restricted diets with contrasting protein and haem iron content. 
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METHODS 
Study design and participants 
This study reports results from young overweight and obese women recruited to two previous 
studies (a larger cross-sectional study and a subsequent randomised controlled trial) from which 
sufficient DNA was extracted from frozen blood samples. In the cross-sectional study (Chapter 4), 
iron, inflammatory and hepcidin status were analysed in a community sample of healthy women 
aged 18-25 years with a measured BMI ≥27.5 kg/m2.228 A subset of these participants then went on 
to complete a randomised controlled trial comparing the efficacy of two diets with contrasting 
macronutrient and haem iron content (Chapter 5). One of these diets was higher in protein and 
haem iron (HPHI diet), whereas the other was an iso-energetically restricted diet containing lower 
protein and haem iron content (LPLI diet).
251
 Exclusions were applied during participant 
recruitment to minimise confounding on weight, iron and inflammatory marker outcomes 
(Appendix B1).
228, 251
 
 
Briefly, the HPHI diet provided 32% protein; 41% carbohydrate; 25% fat and 12.2 mg iron daily, 
whereas the LPLI diet provided 20% protein; 58% carbohydrate; 21% fat and 9.9 mg iron 
(Appendix B8). Haem iron, estimated as 40% of total iron from meat, poultry, and fish,
237
 was 
calculated at 1.90 and 0.40 mg/day for the HPHI and LPLI diets respectively. Both diets met the 
Australian estimated average requirement but not the recommended dietary intake for iron (HPHI: 
68%; LPLI: 55%).
79
 Methods used for estimating dietary iron intake are described in Chapter 5. 
 
Biochemical analysis 
Haemoglobin, serum iron, transferrin saturation and serum ferritin were analysed at a nationally 
accredited commercial diagnostic laboratory. Plasma was frozen for retrospective analysis of 
soluble transferrin receptor (sTfR), hepcidin and C-reactive protein (CRP). Haemoglobin was 
measured using the Sysmex Instrument (Roche Diagnostics Australia, Sydney, Australia), with 
anaemia defined as haemoglobin <120 g/l. Serum iron, transferrin saturation and serum ferritin 
were measured using the Roche Modular E170 Immunoassay Analyser (Roche Diagnostics 
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Australia, Sydney, Australia). Reference ranges used were 120-165 g/l for haemoglobin; 10.0-30.0 
µmol/l for serum iron; 12.0-45.0% for transferrin saturation; and 15.0-165.0 µg/l for serum ferritin. 
Plasma sTfR and CRP were analysed using commercial ELISA kits (R&D Systems, Minneapolis, 
USA). Reference ranges used were 0.74-2.39 mg/l for sTfR; and 0.11-4.52 mg/l for CRP. sTfR 
values were converted from nmol/l to mg/l.
181
 Plasma hepcidin was measured only at baseline by 
on-line extraction coupled to liquid chromatography-tandem mass spectrometry using the Xevo TQ 
MS (Waters Corporation, Milford, USA).
221
 Inter-assay accuracy and coefficient of variation were 
95% and 8.2% respectively. Assay sensitivity was 2.00 ng/ml, with values below the detectable 
range defined as 1.00 ng/ml. The reference range used for hepcidin was 1.92-32.40 ng/ml.
222, 223
 
 
DNA analysis 
DNA was extracted from frozen packed cell samples using a Wizard® Genomic DNA Extraction 
Kit (Promega Corporation, Madison, USA) in accordance with the manufacturer’s instructions.  
 
A pair of forward and reverse oligonucleotide primers intended to amplify 167 base pairs 
surrounding the SNP rs855791 were generated using the primer design program Primer3,
252
 and 
verified using an in-silico polymerase chain reaction (PCR) tool.
253
 The custom primers were 
obtained from Sigma-Aldrich Australia. 
 
The 167 base pair sequence surrounding the target SNP was amplified and purified in five of the 76 
DNA samples by PCR and gel electrophoresis respectively. Gel-purified PCR products (or 
amplicons) were sent to an accredited national research facility (Australian Genome Research 
Facility Ltd, Sydney, Australia) for sequence determination using Sanger sequencing techniques 
(Applied Biosystems, Foster City, USA). Sequencing results were verified against published data 
with a sequence alignment tool.
254
 The remaining 71 genomic DNA samples were genotyped using 
TaqMan® SNP Allelic Discrimination on the 7500 Fast Real-time PCR System platform (Applied 
Biosystems, Foster City, USA). Three Sanger-sequenced DNA samples (one of each zygosity) 
were selected as positive controls in the TaqMan® genotyping analyses. Please refer to Appendix 
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C1 for further details on the: DNA extraction method; custom primer and DNA target sequences; 
PCR reaction set-up; amplicon purification method; and sequence determination and verification 
procedures. A broad explanation of the TaqMan® SNP Allelic Discrimination technique and 
output is presented in Appendices C2 and C3. 
 
Ethics 
Both the cross-sectional study and randomised controlled trial were registered with the Australian 
New Zealand Clinical Trials Registry (ACTRN12613000072718 and ACTRN12609000307202) 
and approved by the Ethics Review Committee of the Sydney South West Area Health Service and 
the University of Sydney Ethics Committee. Signed informed consent was obtained from all 
participants (the participant consent forms used for both studies are presented in Appendices B3 
and B5). 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 20 (IBM Corporation, Armonk, 
USA). Variables were assessed for normality with natural log transformations performed where 
appropriate. Descriptive data are presented as percentages, mean ± SD or median (interquartile 
range). To explore the differences in iron marker concentrations between differing genotype 
groups, univariate ANOVA was used to analyse the cross-sectional data based on the co-dominant 
(CC vs. CT vs. TT) and dominant [CC vs. combined CT and TT (defined as the ‘mixed group’)] 
genetic models. Confounders including BMI, waist circumference, lnCRP, ethnicity, self-reported 
use of hormonal contraceptives and polycystic ovary syndrome were incorporated as covariates. 
Using the longitudinal data, the impact of SNP rs855791 on iron alterations across three key time 
points of the clinical trial (baseline, six and 12 months) was assessed using the dominant genetic 
model only. This was performed using repeated measures ANOVA with effect size reported as 
partial eta-squared (ηp
2
). Significant confounders including percent loss of initial weight at 12 
months, mean dietary iron intake across 12 months and contraceptive medication use were included 
as covariates in all repeated measures analyses. 
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RESULTS 
Participants 
From the 114 participants recruited to the larger cross-sectional study, sufficient DNA for 
genotyping was extracted from 76 participants. T was the less frequent allele (0.44) with genotypic 
distribution in Hardy-Weinberg equilibrium (p=0.68). A comparison of the observed and 
theoretical genotype distributions (based on the global minor allele frequency) is presented in Table 
6.1.
255
 Of the 76 participants who were genotyped, 27 completed the 12-month weight management 
intervention with 15 randomised to the HPHI diet (CC: n=4; CT: n=9; TT: n=2), and 12 to the 
LPLI diet (CC: n=5; CT: n=6; TT: n=1). 
 
Table 6.1. Comparison of the observed and theoretical (based on the global minor allele frequency) 
genotype distributions 
Genotype 
(n=76) 
Genotype distribution 
Hardy-Weinberg 
p value 
Observed Theoretical
a
 
n % % 
     
C homozygote 22 29 36 
0.68 CT heterozygote 41 54 48 
T homozygote 13 17 16 
C, cytosine allele; T, thymine allele 
aTheoretical distribution obtained from the Database of Single Nucleotide 
Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology 
Information, National Library of Medicine. dbSNP accession:[rs855791], (dbSNP 
Build ID: [86/137]). Available from: http://www.ncbi.nlm.nih.gov/SNP/ 
 
A summary of baseline age, BMI and biochemical marker concentrations is presented in Table 6.2. 
The baseline characteristics of participants from whom DNA was extracted were similar to those 
with no available DNA. Furthermore, no significant differences were observed between 
participants who were only included in the cross-sectional analysis and those in the longitudinal 
trial (Table 6.2). 
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Table 6.2. Comparison of baseline biochemical markers between participants with/without 
available DNA and between participants recruited to the cross-sectional study only and those who 
completed the longitudinal trial 
Biochemical marker 
Participants 
without DNA 
(n=38) 
Participants 
with DNA 
(n=76) 
p value 
Participants with DNA 
p value  CSS 
(n=49) 
Clinical trial 
(n=27) 
       
Age (years) 22.5 ± 1.9 22.1 ± 2.5 0.35 22.0 ± 2.5 22.5 ± 2.4 0.82 
BMI (kg/m2) 33.8 ± 4.8 33.6 ± 4.2 0.81 33.5 ± 4.4 33.8 ± 3.8 0.77 
Hb (g/l) 131 ± 9 130 ± 9 0.80 130 ± 9 131 ± 8 0.50 
Serum iron (µmol/l) 14.9 ± 7.6 15.5 ± 6.5 0.67 15.3 ± 6.5 15.7 ± 6.0 0.40 
Tsat (%) 22.4 ± 11.7 22.5 ± 10.1 0.96 22.0 ± 10.3 23.2 ± 9.5 0.71 
Serum ferritinb (µg/l) 41.5 (44.0) 33.0 (31.0) 0.47 31.0 (34.0) 34.0 (26.0) 0.73 
sTfR (mg/l) 1.52 ± 1.47 1.65 ± 0.45 0.14 1.67 ± 0.42 1.60 ± 0.51 0.67 
sTfR-Fb  0.89 (0.74) 1.05 (0.59) 0.20 1.08 (0.59) 1.01 (0.40) 0.86 
Hepcidinb (ng/ml) 6.50 (11.0) 6.95 (8.00) 0.36 8.40 (9.25) 5.60 (4.60) 0.99 
Hepcidin/ferritin ratiob 0.20 (0.21) 0.20 (0.17) 0.63 0.21 (0.19) 0.15 (0.14) 0.64 
Hepcidin/Tsat ratiob 0.34 (0.56) 0.31 (0.48) 0.19 0.36 (0.55) 0.29 (0.21) 0.86 
Age (years) 3.59 (5.79) 3.85 (5.91) 0.83 3.52 (6.08) 3.85 (5.56) 0.77 
Mean ± SD or median (interquartile range) 
CSS, cross-sectional study; DNA, deoxyribonucleic acid; Hb, haemoglobin; sTfR, soluble transferrin receptor; sTfR-
F, soluble transferrin receptor-ferritin index; Tsat, transferrin saturation 
aRegression models adjusted for BMI, waist circumference, C-reactive protein, ethnicity, contraception and 
polycystic ovary syndrome 
bNatural log transformation performed for the serum ferritin, sTfR-F, hepcidin, hepcidin/ferritin and hepcidin/Tsat 
variables 
 
Baseline iron biomarkers of participants of differing rs855791 genotype 
Initial observation of baseline biochemical concentrations across the three genotypes indicated a 
tendency for lower serum iron and transferrin saturation with each additional T allele. The inverse 
was observed for serum ferritin, sTfR and hepcidin (both adjusted and unadjusted for ferritin and 
transferrin saturation) (Table 6.3). Univariate analysis using the co-dominant model (Table 6.3) 
showed that hepcidin/transferrin saturation ratio was significantly different between the three 
genotype groups (CC: coefficient=-0.741, SE=0.319; CT: coefficient=0.012, SE=0.305; p=0.007). 
Of all potential confounders, use of contraceptive medication had a significant impact on serum 
iron (coefficient=6.245; SE=1.756; p=0.001), transferrin saturation (coefficient=7.321; SE=3.103; 
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p=0.022), sTfR (coefficient=-0.339; SE=0.133; p=0.013) and sTfR-F (coefficient=-0.285; 
SE=0.133; p=0.036). 
 
A dominant genetic model was also adopted to explore the iron-lowering effect of the T allele. This 
was done by combining CT heterozygotes and T homozygotes into a single group (defined as the 
‘mixed group’) and analysing iron traits against C homozygotes. Using this alternative model, the 
mixed group had significantly lower serum iron (coefficient=-3.116; SE=1.532; p=0.047), higher 
hepcidin (coefficient=0.607; SE=0.260; p=0.023) and higher hepcidin/transferrin saturation ratio 
(coefficient=0.750; SE=0.226; p=0.002) than C homozygotes (Table 6.3). Higher sTfR 
(coefficient=0.225; SE=0.115; p=0.056) and hepcidin/ferritin ratio (coefficient=0.406; SE=0.203; 
p=0.050) exhibited by the mixed group were close to significance. The influence of contraceptive 
medication on serum iron (coefficient=6.004; SE=1.731; p=0.001), transferrin saturation 
(coefficient=7.150; SE=3.042; p=0.022), sTfR (coefficient=-0.353; SE=0.130; p=0.009) and sTfR-
F (coefficient=-0.296; SE=0.131; p=0.027) were similar to the co-dominant model. 
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Table 6.3. Co-dominant and dominant genetic analysis of biochemical differences between genotypes 
Biochemical marker
a
 
Co-dominant genetic model 
p value 
Dominant genetic model 
p value CC 
(n=22) 
CT 
(n=41) 
TT 
(n=13) 
CC 
(n=22) 
CT and TT / 
mixed group 
(n=54) 
        
Hb (g/l) 131 ± 7 131 ± 9 128 ± 10 0.573 131 ± 7 130 ± 9 0.437 
Serum iron (µmol/l) 17.5 ± 7.2 15.1 ± 6.3 13.4 ± 4.8 0.096 17.5 ± 7.2 14.7 ± 6.0 0.047 
Tsat (%) 24.0 ± 10.7 22.6 ± 10.2 19.7 ± 8.9 0.515 24.0 ± 10.7 21.9 ± 9.9 0.270 
Serum ferritinb (µg/l) 25.0 (34.0) 33.0 (42.0) 35.0 (19.0) 0.697 25.0 (34.0) 34.0 (36.0) 0.395 
     <15.0 μg/l (%) 18.0 19.5 7.7  18.0 16.7  
sTfR (mg/l) 1.59 ± 0.42 1.67 ± 0.49 1.72 ± 0.39 0.132 1.59 ± 0.42 1.68 ± 0.46 0.056 
sTfR-Fb 1.07 (0.65) 1.01 (0.59) 1.19 (0.55) 0.689 1.07 (0.65) 1.05 (0.59) 0.483 
Hepcidinb (ng/ml) 4.00 (5.00) 7.50 (8.95) 10.00 (7.45) 0.075 4.00 (5.00) 8.55 (8.30) 0.023 
Hepcidin/ferritin ratiob 0.18 (0.16) 0.20 (0.23) 0.27 (0.21) 0.141 0.18 (0.16) 0.21 (0.20) 0.050 
Hepcidin/Tsat ratiob 0.22 (0.26) 0.36 (0.47) 0.50 (0.36) 0.007 0.22 (0.26) 0.43 (0.45) 0.002 
Mean ± SD or median (interquartile range) 
CC, cytosine allele homozygote; CT, cytosine and thymine allele heterozygote; Hb, haemoglobin; sTfR, soluble transferrin receptor; 
sTfR-F, soluble transferrin receptor-ferritin index; TT, thymine allele homozygote; Tsat, transferrin saturation 
aRegression models adjusted for BMI, waist circumference, C-reactive protein, ethnicity, contraceptive medication use and polycystic 
ovary syndrome 
bNatural log transformation performed for the serum ferritin, sTfR-F, hepcidin, hepcidin/ferritin and hepcidin/Tsat variables 
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Effect of rs855791 on iron alterations induced by two energy-restricted diets differing in 
protein and haem iron content 
Due to small sample size and limited T homozygote representation, only the dominant genetic 
model was employed for analysis of longitudinal data (Figure 6.1). HPHI participants in the mixed 
group showed significantly lower absolute serum iron (ηp
2
=0.475, p=0.028) and transferrin 
saturation (ηp
2
=0.418, p=0.043) than C homozygotes on the same diet. A significant genotypic 
effect on serum iron (ηp
2
=0.110, p=0.38) and transferrin saturation (ηp
2
=0.118, p=0.36) was not 
observed in participants following the LPLI diet. 
 
Analysis of absolute serum ferritin concentration across 12 months showed no significant effect of 
SNP rss855791 within either diet (HPHI: p=0.89; LPLI: p=0.91). Both HPHI genotype groups 
exhibited increased ferritin concentration at 12 months, while a slight decrease in serum ferritin 
was observed in both LPLI genotype groups. Consequently, the effect of diet on absolute ferritin 
concentration was assessed using repeated measures ANOVA (covariates included: rs855791, 
contraceptive medication and percent loss of initial weight at 12 months), and a significant diet × 
time interaction (ηp
2
=0.160; p=0.026) was found. No significant SNP or diet effects were observed 
for absolute haemoglobin, sTfR or sTfR-F levels. Mean/median values for all biomarkers remained 
within normal range throughout the trial and across all diet and genotype groups. 
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Figure 6.1. Comparison of 12-month iron alterations induced by the higher-protein, higher-haem 
iron (HPHI) and lower-protein, lower-haem iron (LPLI) diets between C homozygotes and the 
mixed group (CT heterozygotes and T homozygotes) [Asterisks denote significant SNP effects on 
absolute serum iron and Tsat levels (p<0.05); mean ± SE; Hb, haemoglobin; sTfR, soluble 
transferrin receptor; sTfR-F, soluble transferrin receptor-ferritin index; Tsat, transferrin saturation; 
∆, change from baseline] 
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DISCUSSION 
The purpose of this study was to explore the influence of SNP rs855791 on iron metabolism in 
young overweight and obese women at baseline, and across a 12-month dietary intervention using 
either a HPHI or LPLI diet. Outcomes from the baseline analysis support current literature 
suggesting a significant relationship between rs855791, serum iron and hepcidin concentration. 
Furthermore, our longitudinal results indicate iron-related responses to altered protein and haem 
iron intake during energy restriction can vary across participants with differing rs855791 genotype. 
With young women at higher risk of iron inadequacy compared to other age and gender groups,
32
 a 
greater understanding of how SNP rs855791 may affect iron metabolism during dietary energy 
restriction can aid selection of suitable diets that minimise the risk of suboptimal iron status. 
 
A more novel angle of this research involves the adoption of a candidate gene approach to 
assessing longitudinal effects of rs855791 on iron status during energy restriction. Analysis of the 
longitudinal data showed that participants with one or both copies of the T allele (i.e. the mixed 
group), and who were following the HPHI diet exhibited lower serum iron and transferrin 
saturation after 12 months of intervention than C homozygotes. Interestingly, an equivalent trend 
was not observed in LPLI participants, which may reflect insufficient power or suppressed 
hepcidin-mediated regulation of gut iron absorption in the context of limited protein and haem iron 
intake. 
 
SNP rs855791 did not significantly affect serum ferritin in participants following either dietary 
intervention. While obesity and inflammation have been reported to elevate serum ferritin,
8
 the use 
of ferritin as a marker of iron stores is justified in this cohort (Chapter 4).
228
 As supported by the 
significant diet × time interaction observed across 12 months, dietary intake appeared to exert a 
greater relative impact on serum ferritin concentration than the SNP itself. This suggests that a 
higher-protein and haem iron diet can be beneficial for increasing iron stores during energy 
restriction regardless of rs855791 genotype. 
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In addition to assessing genotypic effects on longitudinal iron alterations, this study also confirms 
previous research reporting a significant effect of SNP rs855791 on iron status. Baseline outcomes 
from our cross-sectional cohort identified the T allele (coding for valine) as the minor, iron-
lowering allele. The minor allele frequency observed was reasonably consistent with the global 
minor allele frequency (0.40) reported on the National Center for Biotechnology Information SNP 
database,
255
 and with the frequency reported in Australian adolescents of European ancestry 
(0.42).
20
 
 
In line with previous research reporting an association between rs855791 and serum iron levels,
26
 a 
significant negative trend for serum iron was observed with each additional T allele in our cross-
sectional cohort. Although significant associations were not observed for other iron markers in this 
study, significant genome-wide relationships between rs855791, haemoglobin, transferrin 
saturation and sTfR have been reported.
20, 21, 172
 Contrary to our expectations, serum ferritin tended 
to be higher in T homozygotes despite adjustment for potential inflammatory effects. The reason 
for this is unclear although the majority of genetic studies do not support a significant link between 
this SNP and serum ferritin.
20, 22, 27, 171, 172
 The significant effect of diet on ferritin concentration in 
the longitudinal analysis suggests that external factors such as iron intake may have contributed to 
the contradictory baseline result. Future studies that incorporate additional dietary patterns such as 
vegetarianism (which can limit iron intake and bioavailability) can help to determine the relative 
impact of SNP rs855791 and dietary iron intake on ferritin variation between individuals. 
 
The trend for C homozygotes in the cross-sectional cohort to have lower hepcidin and 
hepcidin/transferrin saturation ratio (which was clearest in the dominant genetic model) 
corroborates recent findings reported in an Italian genetic isolate population.
29, 175
 These studies 
(which to date are the only studies to measure the association between rs855791 and serum 
hepcidin directly) found significantly higher hepcidin in T vs. C homozygotes,
29
 as well as 
associations between rs855791, serum iron and transferrin saturation.
29, 175
 Interestingly, serum 
hepcidin was only able to partially explain these significant genotype-iron associations, which 
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indicates the possibility of unidentified hepcidin-independent iron regulatory mechanisms at 
play.
175
 
 
This study is not without its limitations. As genetic analysis was not the primary study objective at 
the time of participant recruitment, the selected sample size was not powered to detect small 
biochemical differences between genotypes. The significance of our results may have also been 
compromised due to measurement of only one SNP which is often inadequate for detection of 
substantial phenotypic variation. Related polymorphisms including SNP rs4820268 are likely to 
have also contributed to iron variation.
21
 We were also unable to assess the effects of diet and 
rs855791 on hepcidin alteration as it was not measured longitudinally. 
 
In conclusion, the iron-lowering T allele of SNP rs855791 was associated with lower serum iron 
and higher hepcidin concentration at baseline. Lower serum iron and transferrin saturation 
observed in T hetero- and homozygotes following the HPHI diet suggest that rs855791-associated 
iron variability may be dependent on haem iron and/or protein intake. As overall iron marker 
concentrations were within normal range throughout the 12 months of the intervention, the clinical 
significance of these findings remain to be established. As young women are known to be at higher 
risk of iron inadequacy compared to other population groups,
32
 a greater understanding of how 
genetic variation affects iron metabolism can facilitate selection of suitable diets for minimising 
iron deficiency risk during weight loss. This exploratory study demonstrates the need for larger 
longitudinal studies that examine a wider range of iron-related SNPs and dietary patterns (e.g. 
vegetarianism) to more clearly evaluate gene-nutrient interactions that contribute to iron variation 
during weight management in young women. 
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SUMMARY OF FINDINGS 
A growing number of studies suggest that obesity is associated with disturbances to iron 
metabolism secondary to elevated inflammation and hepcidin. However, there is limited research 
incorporating the measurement of hepcidin and iron markers, such as sTfR and the sTfR-ferritin 
index (sTfR-F), which are appropriate for use under inflammatory conditions. This is presumably 
due to higher costs associated with analysis and the absence of standardised reference ranges. 
Existing studies have focussed on paediatric, mixed adult or morbidly obese populations with little 
research conducted in young women who are at increased risk of both weight gain and iron 
deficiency. To address the paucity of literature in this demographic, this thesis contains a series of 
studies investigating the impact of excess weight, weight loss and genetics on iron status in a 
cohort of healthy, free-living overweight and obese young women. 
 
The primary aims of the studies in this thesis were to: 
1. systematically review the evidence on the relationship between obesity, inflammation and 
iron status in adults; 
2. examine the prevalence of iron deficiency, severity of obesity-related iron disturbances, and 
hepcidin concentration in a community sample of young, healthy overweight and obese 
Australian women; 
3. assess the impact of two energy-restricted diets with contrasting protein and haem iron 
content, and weight loss on iron status during a clinical weight management trial; and 
4. investigate the influence of the common TMPRSS6 rs855791 polymorphism on iron and 
hepcidin status, as well as physiological iron responses to altered protein and haem iron 
intake during energy restriction. 
 
Findings from the systematic review in Chapter 3 support an association between obesity and iron 
disturbances. Existing literature of measurements in obese individuals, particularly those with BMI 
>35 kg/m
2
, showed higher ferritin concentration and lower transferrin saturation than non-obese 
comparison groups. This result was consistent with typical iron alterations observed in 
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inflammatory conditions. Higher haemoglobin in the obese also indicated that chronic tissue 
hypoxia syndromes, such as obstructive sleep apnoea, may influence haematological marker levels. 
No definitive conclusions could be drawn for sTfR and hepcidin due to the limited amount of data 
available. In the few studies that did measure these markers, higher levels of sTfR and hepcidin in 
the obese suggest that some degree of functional iron disruption may be present. 
 
To examine whether similar disruptions to iron metabolism also occur in young, healthy 
overweight and obese women, the cross-sectional study described in Chapter 4 was conducted to 
address the second aim of this thesis. Results from this study showed mild iron and inflammatory 
alterations with increasing obesity. This was reflected by the significant associations observed 
between increasing BMI and lower serum iron, lower transferrin saturation, and higher CRP. 
Despite this, the main finding of this study was the unexpectedly low ferritin and hepcidin 
concentrations observed in our cohort. Hypoferritinaemia was present in 17% of participants, with 
many also showing hepcidin concentrations below 5 ng/ml. Hence, simple iron deficiency and not 
obesity-related hypoferraemia, was found to be the main iron-related abnormality in this sample. 
 
Simple iron deficiency is often a result of inadequate iron intake, and obtaining sufficient iron may 
be even more challenging for young women undergoing energy restriction. As few studies have 
monitored iron status during diet-induced weight reduction, the study in Chapter 5 was conducted 
to explore the effects of manipulating protein and haem iron intake on iron status in a subset of the 
cross-sectional cohort undergoing a 12-month weight management intervention. Median serum 
ferritin levels were maintained within normal limits in both diet groups throughout the 12 months, 
although only participants on the higher-protein and haem iron diet were able to increase iron 
stores during the trial. Participants who lost ≥10% of initial weight tended to show a more 
favourable iron profile, and this was particularly evident in the lower-protein and haem iron diet 
group who showed higher serum iron and transferrin saturation, and lower sTfR concentration. 
While this observation may simply reflect greater diet quality and compliance in the more 
successful participants, it is possible that weight reduction itself (provided that the diet is 
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reasonably nutrient-rich) may be beneficial for improving iron status despite the absence of 
significant hepcidin elevation at baseline. 
 
As significant obesity-related iron disturbances were not observed in this sample of young women, 
a final exploratory study was conducted to examine the potential influence of genetics on 
individual iron variation. The rs855791 polymorphism in the TMPRSS6 gene was selected due to 
its significant association with various iron markers, its high frequency in the general population 
and evidence of its hepcidin-independent impact on iron status. Outcomes from this analysis 
revealed that participants who were homozygous for the C allele showed the most favourable iron 
profile. Furthermore, C homozygotes on the higher-protein and haem iron diet tended to have 
greater serum iron and transferrin saturation levels than those who were hetero- and homozygous 
for the alternative T allele. These findings suggest that the rs855791 polymorphism can 
significantly influence iron and hepcidin status at baseline, although its significance appears to be 
reduced when dietary protein and haem iron intake during energy restriction are limited. 
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NUTRITIONAL AND CLINICAL IMPLICATIONS 
The findings from this thesis highlight the importance of monitoring and appropriately managing 
simple iron deficiency in young overweight and obese women. The high prevalence of 
hypoferritinaemia in combination with low hepcidin observed in this sample suggest an aetiology 
of inadequate intake and/or excessive loss of iron. 
 
In spite of recent evidence showing iron disruptions with excess weight and inflammation, 
outcomes from the cross-sectional analysis suggest that the routine iron marker serum ferritin, with 
its cut-off value at <15 µg/l, appears to be a sound measure of iron deficiency in young women not 
burdened with significant obesity-related comorbidities. However, caution must be exercised when 
utilising ferritin in those with a BMI >35 kg/m
2
 as inflammatory-related iron disruptions may be 
more prominent. In order to more accurately assess true iron status in these individuals, analysis of 
additional biochemical markers including sTfR, sTfR-F and hepcidin should be considered in those 
with class II obesity and above. Moreover, potential confounding from elevated inflammation 
should also be accounted for when attempting to gauge iron status in any individual. This can 
include the measurement of acute phase proteins and proinflammatory cytokines such as CRP, α -
1-acid glycoprotein, IL-6 and TNF-α, or at minimum, avoiding iron assessment during periods of 
overt infection. 
 
Simple iron deficiency clearly remains an issue for a substantial proportion of young Australian 
women including those who are overweight and obese. Designing energy-restricted diets that 
provide sufficient iron to meet Australian recommended intakes for women at this age is also 
challenging. Therefore, it would be prudent in the clinical setting, to conduct initial screening for 
suboptimal iron status in young women who seek dietetic and medical advice for weight 
management. This is especially relevant for women with greater iron needs such as those with a 
history of iron deficiency, PCOS, heavy or prolonged menses and/or those who report marginal 
iron intake. 
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As demonstrated by the dietary intervention study described in Chapter 5, practical implementation 
of well-designed and nutrient-rich diets allow for reasonable preservation of iron status during 12 
months of energy restriction in most young women. Successful losses of ≥10% of initial weight 
may also have a positive impact on iron levels independent of significant hepcidin reduction. As 
weight loss is known to bring about other important health benefits such as reduced cardiovascular 
and metabolic disease risk, weight management using nutritionally balanced diet plans should be 
encouraged in this group. Young overweight and obese women who possess greater iron needs 
(such as those mentioned in the paragraph above) may particularly benefit from adopting energy-
restricted diets higher in protein and haem iron for superior maintenance of iron homeostasis. 
Practitioners should however, thoroughly assess iron status and needs before recommending these 
diets, given the possible link between haem iron intake and risk of colorectal cancer.
256
 
 
Exploration of the rs855791 polymorphism and its associations with various biochemical iron traits 
in Chapter 6 demonstrates the significant role of genetics in determining individual iron variability. 
The question of whether higher-protein and haem iron diets can be beneficial to those with the iron-
lowering T allele remains unclear as the significant effect of rs855791 on iron status appeared to 
diminish under conditions of limited protein and haem iron intake. Replication of this study using a 
larger sample and a greater range of SNPs is warranted to clarify the benefits of increasing iron 
intake for those genetically predisposed to having lower iron status, and to establish the clinical 
significance of findings reported in this exploratory analysis. 
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STUDY LIMITATIONS 
Low statistical power was a primary limiting factor in the studies described in Chapters 5 and 6. 
Various issues contributed to the small sample size of the 12-month dietary intervention study. A 
rigorous selection criterion was enforced at the recruitment stage to minimise confounding on the 
weight and iron outcomes. Hence, exclusion of some lifestyle choices common in young women 
such as vegetarianism and smoking made a number of volunteers ineligible to participate in the 
trial. High attrition was also experienced in this study. Illness and an inability to attend face-to-face 
sessions, particularly due to lack of time and frequent changes in living situation, were reported as 
common reasons for attrition. Few studies have attempted to examine weight management in this 
age group relative to paediatric and older cohorts. Difficulty with recruitment and retention of 
participants may explain the lack of studies, yet more research in young women is needed given the 
greater risk of weight gain and obesity compared to other populations. Similar issues to those 
reported in this research have been summarised in a recent systematic review of weight 
management studies in young adults.
37
 However, reasons for the recruitment and retention 
difficulties experienced in these studies were often not provided, making improvement to future 
weight management study designs for similar age groups more difficult. 
 
The cross-sectional design of Chapter 4, while providing some estimate of prevalence in this 
convenience sample, is not able to provide evidence of causality between obesity, iron, hepcidin 
and inflammatory status. Although an absence of significant hypoferraemia and inflammation in 
majority of the sample indicate that excess weight may precede the development of significant 
comorbidities and functional iron disturbances, larger longitudinal studies are required to examine 
the evolution of iron and hepcidin-related disruptions that accompany the development of obesity. 
Additionally, collection of baseline dietary iron intake in this cohort would have also allowed for a 
more thorough evaluation of possible contributors to simple iron deficiency. 
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Due to the high costs associated with measuring plasma hepcidin at present, the dietary 
intervention study in Chapter 5 is limited by the lack of longitudinal hepcidin measurement. As 
results from the cross-sectional study did not indicate the presence of substantial baseline hepcidin 
elevation, it was decided that hepcidin would not be analysed at the six- and 12-month time points 
as significant decreases accompanying weight loss (as hypothesised in Chapter 1) was deemed to 
be unlikely. Future measurement of hepcidin at these time points is possible, pending budgetary 
allowances, which will clarify the effect of diet-induced weight loss on hepcidin alterations in this 
group of young overweight and obese women. 
 
Low DNA yield from a number of frozen biological specimens also contributed to low statistical 
power observed in the genetic study (Chapter 6). As genetic investigation was not a primary 
objective of the cross-sectional and weight loss intervention studies, DNA was not extracted from 
fresh blood. Instead, a small aliquot of packed cells from each participant was frozen for potential 
genetic analysis at a later stage. Consequently, a number of these frozen samples may have 
contained insufficient white cells for extraction of adequate DNA. Strategies such as repetition of 
the extraction process on remaining blood and reducing the final rehydration volume to 20 µl were 
employed to maximise the yield and concentration of the final DNA sample. 
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FUTURE RESEARCH 
The outcomes of this thesis have implications for future directions in obesity and iron-related 
research. The systematic review in Chapter 3 argues for more widespread use of sTfR and 
hepcidin, as well as the appropriate controlling of confounders such as obstructive sleep apnoea 
which is common in obesity. Consideration of these factors is necessary in future studies as a more 
accurate assessment of true iron and haematological status allows for the development of suitable 
clinical care plans for overweight and obese individuals who exhibit abnormal and clinically 
significant biochemical profiles. 
 
Results from Chapter 4 suggest that obesity-related comorbidities may be more important than 
excess adiposity per se for the development of substantial inflammatory iron disruptions in this age 
group. Studies are required to identify these specific comorbidities and to clarify the causal 
relationships between obesity, inflammation and hepcidin elevation. Some studies have reported 
altered hepcidin and ferritin concentration with type 2 diabetes.
257
 However, the question of 
whether diabetes precedes the manifestation of iron and hepcidin abnormalities, or vice versa, 
remains to be established. More research is also required to examine potential relationships 
between iron, hepcidin and other comorbid conditions such as cardiovascular disease, the metabolic 
syndrome and non-alcoholic hepatosteatosis. Although total and abdominal body fat was not 
significantly associated with the iron biomarkers measured in the cross-sectional study, the role of 
body fat distribution and the relative contribution of abdominal/android vs. gynoid fat, particularly 
in respect to gender differences also merits further investigation. 
 
In healthy overweight and obese populations undergoing dietary weight management, larger studies 
including the measurement of hepcidin at longitudinal time points will provide further insight into 
how body iron regulation alters with energy restriction, weight loss and dietary macronutrient and 
iron manipulation. Research is also needed to evaluate the influence of other common iron-related 
polymorphisms such as the TMPRSS6 SNP rs4820268 under various dietary contexts including 
vegetarian- and veganism. A greater understanding of these gene-nutrient interactions may 
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potentially help to direct future nutrigenetic research into personalised nutrition, or the tailoring of 
dietary recommendations in accordance to individual iron needs. 
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1. MeSH – Anemia, Iron-deficiency 
2. Keyword – Anemi* 
3. Keyword – Anaemi* 
4. Keyword – Iron Deficien* 
5. Keyword – Iron Deple* 
6. MeSH – Obesity; abdominal obesity; morbid obesity 
7. Keyword – Obes* 
8. Keyword – Overweight 
9. 1 OR 2 OR 3 OR 4 OR 5 
10. 6 OR 7 OR 8 
11. 9 AND 10 
 
A1. Electronic search strategy used to search the MEDLINE database with no limits. 
Similar strategies were used for other electronic information sources, modified to comply with 
search rules of each database. (Asterisk denotes the use of truncation) 
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A2. Quality item checklist 
Author 
(Country) 
Study population 
sufficiently described? 
(age, gender, menopausal 
status) 
Sampling procedures 
sufficiently described? 
(sampling frame, sample 
size) 
Appropriate 
participant 
exclusion criteria? 
Outcomes collected using 
appropriate methods? 
(measured anthropometry, 
fasting status, blood 
collection by venipuncture) 
All important confounders accounted for (gender, 
age/menopausal status, ethnicity, dietary iron intake, oral 
contraceptive use, blood donation, iron treatment, alcohol 
consumption, menorrhagia or amenorrhoea, haemorrhage 
or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic 
disease) 
      
Aasheim et al, 2009 
(Sweden, Norway) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: height and 
weight) 
No (confounders accounted for: age) 
Ahmed et al, 2008 
(Australia) 
No (menopausal status 
assumed by age) 
Yes No (excluded 
subjects with 
elevated ferritin) 
Yes No (confounders accounted for: gender, age/menopausal status, 
haemochromatosis) 
Amaral et al, 1984 
(USA) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: height, 
weight, venipuncture) 
No (confounders accounted for: liver disease) 
Anna et al, 2009 
(USA) 
[Abstract] 
Yes Yes No exclusion criteria 
reported 
Yes No (confounders accounted for: gender)
 
Anty et al, 2008 
(France) 
No (menopausal status 
assumed by age) 
No (sample size 
determination not reported) 
Yes No (not reported: height, 
weight, venipuncture) 
No (confounders accounted for: gender, menorrhagia, 
gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis) 
Ausk & Ioannou, 2008 
(USA) 
Yes Yes Yes Yes No (confounders accounted for: gender, age, menopausal 
status, ethnicity, dietary iron intake, blood donation, alcohol 
consumption) 
Beard et al, 1997 
(USA) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes Yes No [confounders accounted for: gender, liver disease, chronic 
disease (insulin-dependent diabetes mellitus)] 
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Author 
(Country) 
Study population 
sufficiently described? 
(age, gender, menopausal 
status) 
Sampling procedures 
sufficiently described? 
(sampling frame, sample 
size) 
Appropriate 
participant 
exclusion criteria? 
Outcomes collected using 
appropriate methods? 
(measured anthropometry, 
fasting status, blood 
collection by venipuncture) 
All important confounders accounted for (gender, 
age/menopausal status, ethnicity, dietary iron intake, oral 
contraceptive use, blood donation, iron treatment, alcohol 
consumption, menorrhagia or amenorrhoea, haemorrhage 
or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic 
disease) 
      
Bekri et al, 2006 
(France) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: height, 
weight, venipuncture) 
No [confounders accounted for: non-alcoholic steatohepatitis, 
haemochromatosis, chronic disease (diabetes)] 
Belgaumkar et al, 2011 
(UK) 
[Abstract] 
No (gender and 
menopausal status not 
reported) 
No (sampling frame and 
sample size determination 
not reported) 
No exclusion criteria 
reported 
No data collection procedures 
reported 
No consideration or adjustment of confounders reported 
Brolin et al, 1998 
(USA) 
Yes No (sample size 
determination not reported) 
Yes No (none reported) No (confounders accounted for: gender, menopausal status) 
Cooper et al, 1999 
(Australia) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: fasting status, 
venipuncture) 
No consideration or adjustment of confounders reported 
Coupaye et al, 2009 
(France) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: venipuncture) No consideration or adjustment of confounders reported 
de Luis et al, 2013 
(Spain) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: venipuncture) No (confounders accounted for: gender, iron treatment/drugs, 
renal disease, thyroid disease) 
Ernst et al, 2009 
(Switzerland) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: venipuncture) No (confounders accounted for: gender) 
Fricker et al, 1990 
(France) 
Yes No (sample size 
determination not reported) 
Yes Yes No (confounders accounted for: gender, menopausal status, oral 
contraceptive use, blood donation, iron treatment/drugs, 
amenorrhoea, chronic disease) 
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Author 
(Country) 
Study population 
sufficiently described? 
(age, gender, menopausal 
status) 
Sampling procedures 
sufficiently described? 
(sampling frame, sample 
size) 
Appropriate 
participant 
exclusion criteria? 
Outcomes collected using 
appropriate methods? 
(measured anthropometry, 
fasting status, blood 
collection by venipuncture) 
All important confounders accounted for (gender, 
age/menopausal status, ethnicity, dietary iron intake, oral 
contraceptive use, blood donation, iron treatment, alcohol 
consumption, menorrhagia or amenorrhoea, haemorrhage 
or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic 
disease) 
      
Gasteyger et al, 2006 
(Switzerland) 
Yes No (sample size 
determination not reported) 
Yes No (not reported: venipuncture) No (confounders accounted for: gender, menopausal status, 
ethnicity, oral contraceptive use, liver disease) 
Hamalainen et al, 2012  
(Finland) 
No (menopausal status not 
available) 
No (sample size 
determination not reported) 
Yes Yes No (confounders accounted for: gender, age, smoking, physical 
activity, inflammation) 
Kretsch et al, 1998 
(USA) 
Yes No (sample size 
determination not reported) 
No (may have 
excluded subjects 
with anaemia) 
Yes No (confounders accounted for: gender, age/menopausal status, 
oral contraceptive use, menorrhagia or amenorrhoea, acute 
infection, liver disease, inflammatory disorders, chronic 
disease) 
Lecube et al, 2006 
(Spain) 
Yes No (sample size 
determination not reported) 
No (excluded 
subjects with ferritin 
<10 ng/ml) 
No (not reported: height, 
weight, venipuncture) 
No [confounders accounted for: gender, menopausal status, 
ethnicity, blood donation, iron treatment, alcohol consumption, 
haemorrhage, acute infection, haemochromatosis, chronic 
disease (type 2 diabetes)] 
Micozzi et al, 1989 
(USA) 
No (menopausal status not 
reported) 
Yes No (may have 
excluded subjects 
with anaemia) 
No (haemoglobin analysis by 
haemoglobinometer) 
No (confounders accounted for: gender, age, chronic disease) 
Murer et al, 2012 
(Switzerland) 
[Abstract] 
No (gender and 
menopausal status not 
reported) 
No (sampling frame and 
sample size determination 
not reported) 
No exclusion criteria 
reported 
No (not reported: fasting status, 
venipuncture) 
No (confounders accounted for: inflammation) 
Ortiz Espejo et al, 2011 
(Spain) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes None reported No consideration or adjustment of confounders reported 
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Author 
(Country) 
Study population 
sufficiently described? 
(age, gender, menopausal 
status) 
Sampling procedures 
sufficiently described? 
(sampling frame, sample 
size) 
Appropriate 
participant 
exclusion criteria? 
Outcomes collected using 
appropriate methods? 
(measured anthropometry, 
fasting status, blood 
collection by venipuncture) 
All important confounders accounted for (gender, 
age/menopausal status, ethnicity, dietary iron intake, oral 
contraceptive use, blood donation, iron treatment, alcohol 
consumption, menorrhagia or amenorrhoea, haemorrhage 
or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic 
disease) 
      
Palomar et al, 2005 
(Spain) 
Yes No (sample size 
determination not reported) 
Yes No (not reported: fasting status, 
venipuncture) 
No consideration or adjustment of confounders reported 
Payne & DeWind, 1969 
(USA) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: fasting status, 
venipuncture) 
No consideration or adjustment of confounders reported 
Skroubis et al, 2006 
(Greece) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes None reported No consideration or adjustment of confounders reported 
Smith et al, 2013 
(UK) 
[Abstract] 
No (gender and 
menopausal status not 
reported) 
No (sample size 
determination not reported) 
No exclusion criteria 
reported 
None reported No (confounders accounted for: gender, age, iron 
treatment/drugs, chronic disease) 
Świtoniak & Król, 1992 
(Poland) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
No exclusion criteria 
reported 
None reported No (confounders accounted for: age, gender) 
Thurnheer et al, 2012 
(Switzerland) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
No exclusion criteria 
reported 
No (not reported: 
venepuncture) 
No (confounders accounted for: gender) 
Toh et al, 2009 
(Australia) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes None reported No [confounders accounted for: gender (only for haemoglobin)] 
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Author 
(Country) 
Study population 
sufficiently described? 
(age, gender, menopausal 
status) 
Sampling procedures 
sufficiently described? 
(sampling frame, sample 
size) 
Appropriate 
participant 
exclusion criteria? 
Outcomes collected using 
appropriate methods? 
(measured anthropometry, 
fasting status, blood 
collection by venipuncture) 
All important confounders accounted for (gender, 
age/menopausal status, ethnicity, dietary iron intake, oral 
contraceptive use, blood donation, iron treatment, alcohol 
consumption, menorrhagia or amenorrhoea, haemorrhage 
or gastrointestinal bleeding, acute infection, liver disease or 
haemochromatosis, inflammatory disorders, chronic 
disease) 
      
Tussing-Humphreys 
et al, 2009 
(USA) 
Yes Yes Yes No (haemoglobin analysis by 
haemoglobinometer) 
No (confounders accounted for: gender, menopausal status, 
ethnicity, blood donation, alcohol consumption, amenorrhoea, 
gastrointestinal bleeding, acute infection, haemochromatosis, 
inflammatory disorders) 
Yanoff et al, 2007 
(USA) 
No (menopausal status not 
reported) 
No (sample size 
determination not reported) 
Yes No (not reported: venipuncture) No (confounders accounted for: gender, age, ethnicity, 
gastrointestinal bleeding, liver disease, inflammatory disorders, 
chronic disease) 
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A3. Summary of outcomes for non-bariatric surgery studies (age, BMI, haemoglobin and ferritin) 
Study 
(Country) 
Strata/Group 
Age (years) BMI (kg/m
2
) Haemoglobin (g/l) Ferritin (µg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Ahmed et al, 2008 
(Australia) 
Male               (Normal) 
Female <50 y (Normal) 
Female ≥50 y (Normal) 
Male               (Overweight) 
Female <50 y (Overweight) 
Female ≥50 y (Overweight) 
Male               (Obese) 
Female <50 y (Obese) 
Female ≥50 y (Obese) 
≥25 
25 – 49 
≥50 
≥25 
25 – 49 
≥50 
≥25 
25 – 49 
≥50 
≥25 
25 – 49 
≥50 
≥25 
25 – 49 
≥50 
≥25 
25 – 49 
≥50 
 
 
 
 
 
 
>30 
>30 
>30 
<25 
<25 
<25 
25 – 30 
25 – 30 
25 – 30 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
 
 
150 (130-172)
a
 
50.4 (42.1-60.3)
a
 
69.4 (59.7-78.8)
a
 
144 (118-144)
a
 
38.1 (33.8-43.1)
a
 
64.7 (57.8-73.3)
a
 
147 (134-160)
a
 
42.1 (35.8-49.7)
a
 
75.9 (68.0-85.0)
a
 
Anna et al, 2009 
(USA) 
[Abstract] 
BMI <25 
BMI 25.1 – 30 
BMI 30.1 – 35 
BMI >35 
 
 
48.1 ± 18.9 
45.5 ± 17.7 
42.4 ± 22.4 
48.5 ± 19.1 
 
 
 
 
32.1 ± 1.3 
40 ± 4.9 
22.3 ± 2.0 
27.4 ± 1.5 
 
 
 
 
140 ± 15 
138 ± 15 
140 ± 16 
139 ± 15 
 
 
 
 
− 
 
 
− 
Ausk & Ioannou, 2008 
(USA) 
BMI <25 
BMI 25 – 30 
BMI 30 – 35 
BMI 35 – 40 
BMI ≥40 
18 – >70 18 – >70  
 
30 – 35 
35 – 40 
≥ 40 
<25 
25 – 30 
 
 
 
 
 
143 ± 25 
140 ± 30 
139 ± 22 
140 ± 20 
145 ± 18 
 
 
 
 
 
145 ± 236 
147 ± 253 
146 ± 259 
106 ± 179 
144 ± 219 
 
 
 
Beard et al, 1997 
(USA) 
VLED 1758 kJ/day 
VLED 2763 kJ/day 
VLED 3349 kJ/day 
41 ± 37.4 
39 ± 37.1 
46 ± 22.6 
 
− 
 
38.1 ± 7.8 
 
− 
 
− 
 
− 
40.1 ± 25.0
b
 
26.7 ± 16.5
b
 
32.0 ± 23.1
b
 
 
− 
Fricker et al, 1990 
(France) 
N/A 30.8 ± 9.3 30.5 ± 7.0 31.9 ± 4.0 20.7 ± 1.4 137 ± 9 129 ± 10 48.0 ± 44.3 25.8 ± 19.5 
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Study 
(Country) 
Strata/Group 
Age (years) BMI (kg/m
2
) Haemoglobin (g/l) Ferritin (µg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Hamalainen et al, 2012  
(Finland) 
Female MetS 54.4 ± 5.7 − 30.8 ± 5.3 − 141 ± 10 − 94 ± 75 − 
Kretsch et al, 1998 
(USA) 
N/A 25 – 42 − 31.5 ± 4.1 − 131 ± 4 − 33.1 ± 24.8 − 
Lecube et al, 2006 
(Spain) 
N/A 56.9 ± 9.4 57.4 ± 11.1 39.7 ± 7.9 25.0 ± 2.7 135 ± 9 133 ± 8 70.5 ± 50.3 69.5 ± 61.5 
Micozzi et al, 1989 
(USA) 
BMI <27.4 
BMI 31.1 – 36.1 
BMI >36.1 
 
25 – 74 
 
25 – 74 
 
31.1-36.1 
>36.1 
< 27.4  
137 ± 0.3
c
 
138 ± 0.3
c
 
136 ± 0.3
c
  
− 
 
− 
Murer et al, 2012 
(Switzerland) 
[Abstract] 
N/A 40.7 ± 12.8 − 39.2 ± 7.5 − − − 35.8 ± 38.7 − 
Świtoniak & Król, 1992 
(Poland) 
Underweight 
Normal weight 
Overweight 
Obese 
 
 
 
40.2 ± 3.6 
27.4 ± 2.0 
38.0 ± 4.0 
39.6 ± 3.3 
 
 
 
32.1 ± 3.2 
17.7 ± 1.0 
21.8 ± 1.2 
26.4 ± 2.4 
 
 
 
137 ± 10 
132 ± 6 
130 ± 13 
137 ± 12 
 
− 
 
− 
Yanoff et al, 2007 
(USA) 
N/A 38.6 ± 9.7 37.2 ± 11.2 38.4 ± 6.3 25.6 ± 3.1 135 ± 11 135 ± 11 81.1 ± 88.8 57.6 ± 88.7 
Data presented as mean ± SD unless otherwise specified 
BMI, body mass index; MetS, metabolic syndrome; N/A, not applicable; VLED, very-low-energy diet 
aGeometric mean (95% confidence interval) 
bData obtained from measurement of plasma ferritin 
cMean ± standard error (conversion to mean ± SD was not possible due to lack of information regarding sample size) 
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A4. Summary of outcomes for bariatric surgery studies (age, BMI, haemoglobin and ferritin)  
Study 
(Country) 
Strata/Group 
Age (years) BMI (kg/m
2
) Haemoglobin (g/l) Ferritin (µg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Aasheim et al, 2009 
(Sweden, Norway) 
GBP group 
DS group 
35 ± 7 
36 ± 5 
 
− 
54.8 ± 17.8 
55.2 ± 18.8 
 
− 
143 ± 61 
143 ± 65 
 
− 
 
− 
 
− 
Amaral et al, 1984 
(USA) 
Male 
Female 
35.0 ± 6.8 
35.8 ± 6.2 
 
− 
103 ± 25.7% above 
ideal body weight 
 
− 
156 ± 15 
140 ± 10 
 
− 
 
− 
 
− 
Anty et al, 2008 
(France) 
N/A 39 (30.8-47.0)
a
 − 43.8 (40.9-47.9)a − 137 (128-142)a − 45.0 (22.0-78.5)a − 
Bekri et al, 2006 
(France) 
Lean controls 
Obese 
Obese with diabetes 
Obese with NASH 
 
37.5 (30.7-43.2)
b
 
47.0 (39.3-48.8)
b
 
34.5 (29.9-41.3)
b
 
29.0 (25-38)
b
 
 
 
 
 
46.2 (40.0-49.4)
b
 
42.3(37.8-49.6)
b
 
44.8 (40.8-48.9)
b
 
21 (20.5-21.5)
b
 
 
 
 
 
 
139 ± 15 
 
 
− 
 
 
112 ± 125 
 
 
− 
Belgaumkar et al, 
2011 (UK) 
[Abstract] 
N/A 45 ± 9 − 60.0 ± 11.3 − 134 ± 13 − 81.7 ± 66.7c − 
Brolin et al, 1998 
(USA) 
 
Placebo group 
Intervention group 
 
37.0 ± 8.0 
36.6 ± 8.0 
 
 
− 
Mean weight: 
129 ± 27 kg 
126 ± 21.6 kg 
 
 
− 
 
130 ± 10 
130 ± 10 
 
 
− 
 
56 ± 58 
87 ± 81 
 
 
− 
Cooper et al, 1999 
(Australia) 
N/A 23 – 59 − 31.6 – 52.7 − 135 ± 9 − 94 ± 90 − 
Coupaye et al, 2009 
(France) 
AGB group 
GBP group 
35 ± 10 
43 ± 10 
 
− 
43 ± 3 
49 ± 8 
 
− 
129 ± 10 
131 ± 12 
 
− 
86.3 ± 75.4 
96.4 ± 89.3 
 
− 
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Study 
(Country) 
Strata/Group 
Age (years) BMI (kg/m
2
) Haemoglobin (g/l) Ferritin (µg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
de Luis et al, 2013 
(Spain) 
BMI 35-40 
BMI 40-45 
BMI 45-50 
BMI >50 
43.4 ± 12.8 
43.1 ± 15.1 
44.7 ± 12.5 
45.1 ± 11.8 
− 
36.4 ± 4.1 
42.6 ± 1.5 
47.5 ± 1.3 
55.4 ± 5.3 
− 
142 ± 14 
138 ± 12 
139 ± 11 
140 ± 14 
− 
89.6 ± 15.1 
59.1 ± 84.3 
101.4 ± 97.0 
65.1 ± 51 
− 
Ernst et al, 2009 
(Switzerland) 
N/A 40.5 ± 11.6 − 44.9 ± 6.2 − 143 ± 15 − 73.5 ± 72.9 − 
Gasteyger et al, 2006 
(Switzerland) 
N/A 35.4 ± 6.5 − 43.8 ± 4.1 − 140 (no SD) − 61.3 (no SD)d − 
Ortiz Espejo et al, 
2011 
(Spain) 
Obese controls 48 − − − − − 64.8 ± 78.5 − 
Palomar et al, 2005 
(Spain) 
N/A 40.1 ± 11.6 − 46.9 ± 6.3 − 129 ± 22 − 49.0 ± 52.3 − 
Payne & DeWind, 
1969 
(USA) 
N/A 34.6 − Mean weight: 
140.9 kg 
− 14.2 ± 1.9e − − − 
Skroubis et al, 2006 
(Greece) 
RYGBP group 
BPD group 
32.6 ± 9.4 
36.1 ± 9.8 
 
− 
45.6 ± 4.9 
57.2 ± 6.1 
 
− 
140 ± 10 
140 ± 24 
 
− 
41.4 ± 45.0 
71.6 ± 82 
 
− 
Smith et al, 2013 
(UK) 
[Abstract] 
Normoglycaemic 
Pre-diabetic 
Diabetic 
36.5 ± 12.2 
44.4 ± 11.5 
50.9 ± 10.3 
 
− 
46.5 ± 6.8 
47.9 ± 7.4 
46.6 ± 7.7 
 
− 
 
− 
 
− 
105 ± 93 
118 ± 125 
129 ± 151 
 
− 
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Study 
(Country) 
Strata/Group 
Age (years) BMI (kg/m
2
) Haemoglobin (g/l) Ferritin (µg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Thurnheer et al, 2012 
(Switzerland) 
Male 
Female 41.4 ± 10.8 − 48.5 ± 11.5 ± 
151 ± 19 
140 ± 20 
− 174 ± 128 
62 ± 52 
− 
Toh et al, 2009 
(Australia) 
RYGBP group (male) 
RYGBP group (female) 
SG group (male) 
SG group (female) 
48 ± 10 
 
46 ± 12 
 
 
− 
43.1 ± 5.2 
 
51.0 ± 11.2 
 
 
− 
146 ± 13 
132 ± 7 
140 ± 14 
136 ± 9 
 
 
− 
170 ± 190 
 
152 ± 140 
 
 
− 
Tussing-Humphreys  
et al, 2009 
(USA) 
N/A 35.6 ± 7.2 37.0 ± 8.7 50.1 ± 11.0 21.9 ± 4.9 122 ± 12
f
 120 ± 11
f
 26.3 ± 19.7
f
 18.4 ± 17.8
f
 
Data presented as mean ± SD unless otherwise specified 
AGB, adjustable gastric banding; BPD, biliopancreatic diversion; BMI, body mass index; DS, duodenal switch; GBP, gastric bypass; N/A, not applicable; NASH, non-alcoholic 
steatohepatitis; RYGBP, Roux-en-Y gastric bypass; SG, sleeve gastrectomy 
aMedian (interquartile range) 
bMedian (95% confidence interval) 
cFerritin data likely reported in incorrect units (data originally reported in mg/l) 
dFerritin data likely reported in incorrect units (data originally reported in µmol/l) 
eHaemoglobin data reported in mg. per cent 
fGeometric mean (95% confidence interval) 
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A5. Summary of outcomes for non-bariatric surgery studies (transferrin saturation, soluble transferrin receptor, hepcidin and C-reactive protein) 
Study 
(Country) 
Strata/Group 
Transferrin saturation (%) sTfR (mg/l) Hepcidin (ng/ml) CRP (mg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Ahmed et al, 2008 
(Australia) 
Male               (Normal) 
Female <50 y (Normal) 
Female ≥50 y (Normal) 
Male               (Overweight) 
Female <50 y (Overweight) 
Female ≥50 y (Overweight) 
Male               (Obese) 
Female <50 y (Obese) 
Female ≥50 y (Obese) 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
 
 
 
 
− 
Anna et al, 2009 
(USA) 
[Abstract] 
BMI <25 
BMI 25.1 – 30 
BMI 30.1 – 35 
BMI >35 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
Ausk & Ioannou, 2008 
(USA) 
BMI <25 
BMI 25 – 30 
BMI 30 – 35 
BMI 35 – 40 
BMI ≥40 
 
 
24 ± 12 
22 ± 15 
20 ± 17 
28 ± 20 
27 ± 18 
 
 
 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
Beard et al, 1997 
(USA) 
VLED 1758 kJ/day 
VLED 2763 kJ/day 
VLED 3349 kJ/day 
18.0 ± 7.5 
22.3 ± 9.1 
20.0 ± 4.5 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Fricker et al, 1990 
(France) 
N/A 18 ± 8 20 ± 7 − − − − − − 
Hamalainen et al, 2012  
(Finland) 
Female MetS − − 2.8 ± 0.9 − − − 3.1 ± 3.4a − 
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Study 
(Country) 
Strata/Group 
Transferrin saturation (%) sTfR (mg/l) Hepcidin (ng/ml) CRP (mg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Kretsch et al, 1998 
(USA) 
N/A 23.4 ± 6.7 − − − − − − − 
Lecube et al, 2006 
(Spain) 
N/A 29.8 ± 10.8 30.8 ± 10.7 1.38 ± 0.38
b
 1.16 ± 0.34
b
 − − − − 
Micozzi et al, 1989 
(USA) 
BMI <27.4 
BMI 31.1 – 36.1 
BMI >36.1 
 
26.9 ± 0.3
c
 
24.1 ± 0.3
c
 
29.0 ± 0.3
c
 
 
 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Murer et al, 2012 
(Switzerland) 
[Abstract] 
N/A − − 3.9 ± 1.9 − 2.79 ± 2.93 − 3.81 ± 5.24 − 
Świtoniak & Król, 1992 
(Poland) 
Underweight 
Normal weight 
Overweight 
Obese 
 
 
 
28.4 ± 11.4 
26.7 ± 5.0 
24.5 ± 9.8 
27.2 ± 10.2 
 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
Yanoff et al, 2007 
(USA) 
N/A 20.3 ± 9.9 23.0 ± 9.9 1.92 ± 0.60 1.79 ± 0.61 − − 7.5 ± 6.7 3.4 ± 6.7 
Data presented as mean ± SD unless otherwise specified 
BMI, body mass index; CRP, C-reactive protein; MetS, metabolic syndrome; N/A, not applicable; sTfR, soluble transferrin receptor; VLED, very-low-energy diet 
aHigh sensitivity CRP results reported 
bsTfR data likely reported in incorrect units (data originally reported in mg/dl) 
cMean ± standard error (conversion to mean ± SD was not possible due to lack of information regarding sample size) 
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A6. Summary of outcomes for bariatric surgery studies (transferrin saturation, soluble transferrin receptor, hepcidin and C-reactive protein) 
Study 
(Country) 
Strata/Group 
Transferrin saturation (%) sTfR (mg/l) Hepcidin (ng/ml) CRP (mg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Aasheim et al, 2009 
(Sweden, Norway) 
GBP group 
DS group 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
14 ± 42.6
a
 
14 ± 31.0
a
 
 
− 
Amaral et al, 1984 
(USA) 
Male 
Female 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Anty et al, 2008 
(France) 
N/A 19 (46-26)
b
 − − − − − 10.0 (7.0-18.0)b,c − 
Bekri et al, 2006 
(France) 
Lean controls 
Obese 
Obese with diabetes 
Obese with NASH 
 
 
19.6 ± 8.3 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
8.7 (13.9-16.1)
d
 
10.0 (7.2-13.6)
d
 
9.0 (4.3-14.3)
d
 
1 (1-3.3)
d
 
 
 
 
Belgaumkar et al, 
2011 (UK) 
[Abstract] 
N/A − − − − − − − − 
Brolin et al, 1998 
(USA) 
Placebo group 
Intervention group 
23 ± 9 
27 ± 15 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Cooper et al, 1999 
(Australia) 
N/A − − − − − − − − 
Coupaye et al, 2009 
(France) 
AGB group 
GBP group 
21.6 ± 11.9 
19.6 ± 8.1 
 
− 
 
− 
 
− 
 
− 
 
− 
12.2 ± 8.8 
11.4 ± 7.9 
 
− 
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Study 
(Country) 
Strata/Group 
Transferrin saturation (%) sTfR (mg/l) Hepcidin (ng/ml) CRP (mg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
de Luis et al, 2013 
(Spain) 
BMI 35-40 
BMI 40-45 
BMI 45-50 
BMI >50 
− − − − − − − − 
Ernst et al, 2009 
(Switzerland) 
N/A − − − − − − − − 
Gasteyger et al, 2006 
(Switzerland) 
N/A − − − − − − − − 
Ortiz Espejo et al, 
2011 
(Spain) 
Obese controls − − − − − − − − 
Palomar et al, 2005 
(Spain) 
N/A 31.5 ± 19.2 − − − − − − − 
Payne & DeWind, 
1969 
(USA) 
N/A − − − − − − − − 
Skroubis et al, 2006 
(Greece) 
RYGBP group 
BPD group 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Smith et al, 2013 
(UK) 
[Abstract] 
Normoglycaemic 
Pre-diabetic 
Diabetic 
25.9 ± 10.2 
22.6 ± 9.6 
21.6 ± 9.3 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
Thurnheer et al, 2012 
(Switzerland) 
Male 
Female 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
 
− 
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Study 
(Country) 
Strata/Group 
Transferrin saturation (%) sTfR (mg/l) Hepcidin (ng/ml) CRP (mg/l) 
Obese Non-obese Obese Non-obese Obese Non-obese Obese Non-obese 
          
Toh et al, 2009 
(Australia) 
RYGBP group (male) 
RYGBP group (female) 
SG group (male) 
SG group (female) 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
− 
 
 
7.4 ± 5.8
e
 
 
 
− 
Tussing-Humphreys 
et al, 2009 
(USA) 
N/A 14.2 ± 8.3
f
 18.2 ± 10.7
f
 2.76 ± 0.82
f
 2.00 ± 0.57
f
 88.02 ± 100.77
f
 9.70 ± 13.33
f
 7.5 ± 5.4
f
 0.8 ± 1.5
f
 
Data presented as mean ± SD unless otherwise specified 
AGB, adjustable gastric banding; BPD, biliopancreatic diversion; CRP, C-reactive protein; DS, duodenal switch; GBP, gastric bypass; N/A, not applicable; NASH, non-alcoholic 
steatohepatitis; RYGBP, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; sTfR, soluble transferrin receptor 
aData obtained from a subgroup (n=15) 
bMedian (interquartile range) 
cData obtained from a subgroup (n=55) 
dMedian (95% confidence interval) 
eData obtained from RYGBP group (n=103) 
fGeometric mean (95% confidence interval) 
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APPENDIX B: SUPPLEMENTARY MATERIAL FOR CHAPTERS 4 AND 5
a
 
B1. Study protocol for the cross-sectional and longitudinal dietary intervention studies  
B2. Participant information sheet for the cross-sectional study 
B3. Participant consent form for the cross-sectional study 
B4. Participant information sheet for the longitudinal dietary intervention study 
B5. Participant consent form for the longitudinal dietary intervention study 
B6. Dietary prescription provided to participants randomised to the higher-protein, higher-haem 
iron diet 
B7. Dietary prescription provided to participants randomised to the lower-protein, lower-haem 
iron diet 
B8. Comparison of nutritional profiles of the higher-protein, higher-haem iron and lower-protein, 
lower-haem iron diets based on seven day models designed for a 23 year old female with 
light activity 
B9. Seven day model of the higher-protein, higher-haem iron diet 
B10. Seven day model of the lower-protein, lower-haem iron diet 
  
                                                   
aAcknowledgement: the materials presented in Appendix B were prepared by Dr Hayley Griffin 
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B1. Study protocol for the cross-sectional and longitudinal dietary intervention studies 
 
 
 
 
 
 
 
Weight Loss for Overweight 
Women (WOW) 
Study Protocol 
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A. Study Design 
 
The study is a randomised controlled trial comparing a higher-protein, red meat 
based “Total Wellbeing” style diet to an iso-energetic conventional higher 
carbohydrate, white meat based diet. 
 
Numbered envelopes containing the diet to be followed will be used to randomly 
allocate the diet status of each subject. These envelopes will be prepared by a 
researcher not involved in the recruitment or seeing of subjects according to a 
random block design per every four subjects. 
 
The subjects will not be told the explicit nature of the opposing diet (i.e. difference 
in protein and carbohydrate) in order to keep them blinded to the intervention. 
They will be told only that there are two different dietary plans, which are both 
nutritionally adequate, restricted in energy, low in fat and include low GI foods, 
however one is a red meat based diet and the other is a white meat based diet. 
 
They will be required to follow the diet and a standardised exercise plan for a 
period of 12 months (30 mins of brisk walking on most, preferably all, days), which 
is in line with the recommendations in the Australian National Physical Activity 
guidelines for Adults. 
 
The study is divided into three phases. The first phase is to recruit subjects and 
obtain baseline measures. In this phase subjects will attend an initial screening 
visit where their suitability and willingness to participate will be assessed, informed 
consent obtained, baseline tests organised and questionnaires completed. 
 
This is followed by a treatment phase of six months where subjects will be advised 
to follow the prescribed diets and standardised exercise programme and undergo 
further follow-up tests. During this six month phase, subjects will attend the clinic 
weekly for three months and then fortnightly until six months. 
 
The subjects will be requested to maintain their diet and exercise programmes for 
a further six months with monthly clinic follow-up so that post intensive treatment 
success can be evaluated. 
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B. Subjects 
 
Subjects will be recruited from a number of methods, including: 
 The Metabolism and Obesity Service (MOS) at Royal Prince Alfred Hospital 
(RPAH) Sydney. This service provides specialised assessment and treatment 
to approximately 500 new obese (Body Mass Index [BMI] >35 kgm-2) subjects 
annually. Subjects are referred by local general practitioners, specialist 
endocrinologists, other specialist clinicians and allied health practitioners. 
 Advertisements of the study via flyers in tertiary education campuses 
 Advertisement of the study via the Central Sydney Area Health Service Intranet 
 Advertisement of the study via the University of Sydney Student Intranet 
 Advertisement of the study in local newspapers 
 
Inclusion Criteria: 
 Healthy females aged 18-25 years  
 BMI  27.5 kgm-2 
 Able to attend scheduled visits at MOS (RPAH) 
 Willing to include red meat in the diet four or more times a week 
 Fluent in English  
 Adequate contraception maintained throughout the study 
 
Exclusion Criteria: 
 Significant medical conditions e.g. malignancy; cardiovascular, respiratory, 
gastrointestinal, renal or liver disease 
 Significant immune function conditions including auto-immune diseases e.g. 
lupus or subjects undergoing chemotherapy treatment 
 Diabetes mellitus  
 Secondary cause of obesity e.g. Cushing’s syndrome, hypothyroidism  
 Psychiatric illness 
 Severe untreated obstructive sleep apnoea (Epworth Sleepiness Scale 10) 
 Previous bariatric surgery 
 Medications known to affect appetite, metabolic rate, weight and immune 
function  
 Severe binge eating (Binge Eating Questionnaire 27) 
 Smoking 
 Vegetarianism 
 Pregnancy or breastfeeding 
 Severe mobility problems 
 Severe eating disorder such as bulimia nervosa or binge eating disorder 
 Use of certain dietary supplements 
 Iron deficiency anaemia i.e. Haemoglobin (Hb) must be normal 
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PROTOCOL FOR IRON LEVELS IN RANDOMISED CONTROL TRIAL:  
For newly recruited participants whose baseline iron levels are found to be 
suboptimal, they will require varying degrees of iron supplementation prior to 
starting the trial to ensure optimal health upon commencement of the diet. 
 
Protocol 1:   Hb normal, ferritin normal, but serum iron low 
Recruit subject as per normal method. 
 
Protocol 2:  Hb normal, but ferritin low (± low serum iron) 
Subject to take Herron Iron Complex (2 tablets, 5 days/week to 
reduce risk of gastrointestinal upset) for 3 months. If ferritin is just 
low (i.e. 13-14 µgL-1) then subject to take tablets for only 1 month 
and followed by review. 
 
Subject can be recruited for trial once ferritin levels are 
normalised. Ferritin levels will be reviewed again at 6 and 12 
months.  
 
Protocol 3:  Hb low  
Exclude and refer to local GP. 
 
Protocol 4:  Ferritin high (>200) 
Consider screening for haemochromatosis. 
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PROTOCOL FOR DIETARY SUPPLEMENTS IN RANDOMISED 
CONTROLLED TRIAL: 
 
Protocol 1:  Iron supplements 
A) Subjects that have been diagnosed with iron deficiency 
and are currently taking (or recently ceased) iron 
supplementation: 
These subjects can only be recruited once the treating doctor has 
ceased iron supplementation. Subjects will need to organise for 
their doctor to perform a blood test to ensure iron levels are 
normal. If levels are abnormal, they will need to continue the 
regimen and be tested again in the future. 
 
Once they have ceased supplementation and their iron levels are 
normal, they can be recruited. 
 
B) For subjects that HAVE been taking iron tablets without 
evidence of established iron deficiency: 
Recruit once they have ceased iron supplementation.  
 
Protocol 2:  Zinc supplements 
Exclude 
  
Protocol 3:  Multivitamin supplements 
Document exactly what supplement(s) they were taking (e.g. 
brand, dose, frequency) and record the contents. Exclude if 
tablets contain a high dose of zinc  (>20mg). If supplements 
contain a high dose of iron, follow the iron tablet protocol. If 
contain low doses of zinc and iron (<10mg and <5mg 
respectively), then recruit but allow a minimum of 2 weeks 
between last tablet taken and venepuncture. 
 
Protocol 4:  Vitamin e.g. B, C supplements 
Recruit, however allow a minimum of 2 weeks between when last 
taken and venepuncture. 
 
Protocol 5:  Fish oil supplements 
Exclude if taking 5 or more capsules per day (~1.5g n-3 fatty 
acids). If taking less than this then recruit, however allow a 
minimum of 2 weeks between when last taken and venepuncture. 
 
 
During the trial, all subjects are asked to not take any dietary supplements and 
avoid donating blood. Subjects are able to maintain their usual blood pressure or 
lipid management medication. However ANY changes to medication need to be 
reported to researchers.  
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C. Study Parameters  
 
1. Weight and Body Composition 
 
1.1 Weight and Body Mass Index (BMI) 
Body weight (light clothing, no shoes) will be recorded on an electronic 
digital platform scale (Teraoka DS-260; Teraoka Seiko, Tokyo, Japan) with 
a capacity of 300 kg and accuracy to 0.1 kg. Height will be measured to 
nearest 0.5 cm with a wall-mounted stadiometer (Hyssna Limfog AB, 
Hyssna, Sweden).  
 
1.2 Waist Circumference and Waist-to-Hip Ratio (WHR) 
Waist and hip circumference (light clothing) will be measured to nearest 0.5 
cm with a metal retractable tape (Lufkin W606PM; Cooper Industries, 
Sparks, USA). Waist circumference will be measured at the narrowest 
circumference above the level of the umbilicus (the midpoint between the 
last rib and the iliac crest). Hip circumference will be measured at the 
maximal gluteal protrusion (Lohman et al 1998). 
 
1.3 Blood Pressure 
Blood pressure will be measured using an automatic machine (OMRON 
Healthcare Co. Ltd., Kyoto, Japan) and manually (ACCOSON Dekamet, 
England) before the walking test at baseline, week 2, 3 months, 6 months 
and 12 months with a large cuff if necessary after the subject has been 
seated for 15-20 minutes. 
 
1.4 Bio-electrical Impedance Analysis (BIA) 
Body composition will be measured by bio-electrical impedance using the 
tetra-polar surface electrode technique. BIA involves the use of a small 
electrical current that is passed through the body for quick measurement of 
body composition.  It is approved for use during pregnancy and in 
neonates. BIA measurements will be taken after a four hour fast according 
to a strict standardised protocol used by the staff of MOS. 
 
Note: The initial BIA machine used broke mid-trial, and was replaced with a 
new one. 
 
1.5 Dual-energy X-ray Absorptiometry (DXA) 
Body composition will also be measured by DXA on a Lunar Prodigy (GE 
Healthcare, Giles, UK) using 8.6 software unless body shape or mass 
precludes the use of the DXA apparatus. The radiation dose subjects will be 
exposed to does not exceed 0.03mSv and side effects are negligible. DXA 
measurements will be performed by a trained technician in the metabolic 
unit at RPAH. 
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2. DIET AND EATING BEHAVIOURS 
 
2.1 24 Hour Recall 
This will be done “randomly” (subjects are unaware of scheduled 24 hour 
recall assessments) on the weeks that the food diary is to be analysed. The 
food diary will be analysed for the period that corresponds to weeks 4, 8, 
12, 25 and 51 therefore this will be done at weeks 5, 9, 13, 26 and 52. This 
is so that the recall will be completed after the diary to be analysed has 
been completed to minimise the risk of participants changing what they ate 
during the week that is to be analysed.  
 
It will be done using the multiple-pass method by a researcher trained in 
this methodology. Amounts will be quantified in household measures with 
the assistance of a photographic atlas of food portion sizes if required 
(Nelson, Atkinson & Meyer 1997).  
 
This information will then be analysed using FoodWorks Version 6.0.25175 
(Xyris Software, Brisbane, Australia) incorporating the AusNut (all foods) 
revision 18, AusFoods (brands) revision 11 and Nuttab 2006 revision 1 
databases. Analyses will be performed for a 23 year old female doing light 
activity by a trained researcher using a standard protocol for the entry of 
food items. Food selections will be made using the description closest to the 
item. Due to limitations in the database, modelling is not going to be 
performed for all nutrients (e.g. vitamin B12, fatty acids). 
 
2.2 3 Day Food Diary 
Although a weighed food diary is considered to be the ‘gold standard’ 
dietary method for recording food intake, these diaries are labour intensive 
for the respondent and compliance is a problem. The use of semi-
quantative household measures is much easier for the subject and similar 
results have been obtained using this method. Due to the length of the 
study and the respondent burden from other aspects of measurement, 
semi-quantative household measures have been selected for the recording 
of dietary information.  
 
The diary will be kept weekly (3 days/week) for the first three months, 
fortnightly (3 days/fortnight) for the following three months and once a 
month (3 days/month) for the last six months. Food diary analysis (two 
weekdays and one weekend day) will be undertaken at weeks 4, 8 12, 25 
and 51. Analysis will be as reported for the 24 hour recall above.  
 
Subjects will be completing more diaries than will be analysed, so that they 
gain benefits from completing a diary (i.e. being aware of what they are 
eating etc.) and are also unaware of the weeks selected for dietary analysis. 
To improve the completeness of food record keeping, subjects will be urged 
to report exactly what they eat and every effort will be made for them to feel 
comfortable reporting digressions from the diet. In addition, one set of 
electronic household scales and a brief training session on how to use 
household measures will be provided to subjects when the diary is 
introduced. 
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2.3 Daily Hunger and Desire to Eat Scores 
Subjects will rate hunger for the entire day on a 10 cm visual analogue 
scale (VAS) ranging from “not at all hungry” at one end to ‘”extremely 
hungry” at the other. Desire to eat will also be rated on a 10cm VAS from 
“not at all strong” to “extremely strong”. Subjects will be instructed to 
summarise their hunger/desire to eat into these rating scales to reflect how 
they felt over the day. The VAS will be placed at the bottom of each page in 
the food diary as a reminder for subjects to complete this on the days food 
intake is recorded. 
 
2.4 Health Log 
Subjects will be asked to record their health daily during the trial using the 
following criteria that have been used in studies measuring immune function 
(Nieman et al, 1990; Nieman et al, 1998). This provides some guide to the 
general health of the subjects during the study. 
 
1. No health problems today 
2. Cold symptoms (runny, stuffy nose, sore throat, coughing, sneezing, 
coloured discharge) 
3. Flu symptoms (fever, headache, general aches and pains, fatigue, 
weakness, chest discomfort, cough) 
4. Nausea, vomiting, diarrhoea 
5. Muscle, joint or bone problems, injury 
6.    Other health problem (describe). 
 
2.5 Infection Frequency 
Subjects will complete a subjective rating on how often they become sick 
with an infection (upper respiratory tract) such as a cold or flu using a 10 cm 
visual analogue scale (VAS) ranging from at one end “always sick with 
infections” to ”never sick with infections” (i.e. the ends of the scales 
represent the extremes that they only rarely experience). Subjects will be 
asked complete this scale at baseline, 6 months and 12 months.  
 
2.6 Three Factor Eating Questionnaire (TFEQ) 
The TFEQ measures restrained eating or the cognitive control of eating 
behaviour, the disinhibition of control (tendency to break restraint) and 
perceived hunger. It is a validated questionnaire that is used at MOS for 
obese patients. 
 
The TFEQ is estimated to take no more than twenty minutes to complete 
and will be completed at baseline, the end of 3, 6 and 12 months of 
treatment and finally at post-trial follow-up. 
 
2.7 Binge Eating Questionnaire 
The Binge Eating Questionnaire is a self-report measure designed to 
assess the extent and severity of binge eating problems in the obese. 
During the trial, use of this questionnaire will help to identify differences in 
the binge eating tendency between the two diets. It is a questionnaire that 
has been validated in obese patients (Gormally et al, 1982), and is 
estimated to take no more than twenty minutes to complete and will be 
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completed at baseline, the end of 3, 6 and 12 months of treatment and 
finally at post-trial follow-up. 
 
We will be excluding those subjects with a severe binge eating 
questionnaire score (27), but will discuss management options with them. 
             
2.8 Harter Self Perception Questionnaire 
Concepts such as self-esteem, self-image and perceived competence are 
central to an individual’s overall perception of their self-worth. Low levels of 
these constructs have been reported in obese individuals and are observed 
to improve with weight loss. 
 
The Harter Self Perception Assessment has been developed to assess 
global self-worth and the importance of success in each of eleven specific 
domains for the individual (sociability, job competence, nurturance, athletic 
abilities, physical appearance, adequate provider, morality, household 
management, intimate relationships, intelligence, sense of humour). 
 
The Harter Self Perception Questionnaire is a validated questionnaire that 
is used at MOS for obese patients. It is estimated to take no more than 
twenty minutes to complete and will be completed at baseline, the end of 3, 
6 and 12 months.  
 
2.9 Food Habits Questionnaire 
This questionnaire measures fat intake and food habits. It has been 
validated as suitable for assessing food habits relevant to controlling weight 
and is a questionnaire used at MOS as a part of clinical care. The food 
habits questionnaire is estimated to take no more than twenty minutes to 
complete and will be completed at baseline, the end of 3, 6 and 12 months. 
 
2.10 Weight Cycling Questions 
Weight cycling will be assessed by modifying the question used recently by 
Shade et al (2004) to ask “within the last two, five and ten years when you 
were not pregnant or sick, did you ever lose 5 kg or more on purpose?” In 
addition we will ask subjects to report their minimum and maximum (non-
pregnant) weight (if >18 years), the maximum amount of weight they had 
lost at one time and the methods used for weight loss. 
 
2.11 24 Hour Urea Nitrogen 
24 hour urea nitrogen will be measured as 24 hour urine urea excretion 
using the Roche Modular instrument with Roche kits at Laverty Pathology 
Laboratory, Sydney. This test will be done at baseline, 3, 6 and 12 months 
to assess kidney function and determine dietary compliance to the protein 
prescription. 
 
Participants will be provided with instructions for urine collection to ensure 
collection accuracy. 
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3. METABOLIC PARAMETERS  
 
i)  Collection and Processing  
 
3.1     Venepuncture 
Blood will be drawn at recruitment, 6 and 12 months by trained staff at 
Medical Centre Pathology RPAH. Recruitment blood samples will be used 
to confirm subject eligibility e.g. iron levels (iron deficiency anaemia), 
glucose (diabetes) and TSH (Thyroid Stimulating Hormone) (thyroid 
disease). 
 
Blood will be collected from the antecubital vein with the subject fasting and 
seated. The following criteria will also be used (specifically designed for the 
immune markers): no strenuous exercise or alcohol for 24 hrs, adequate 
sleep, no topical corticosteroids for 48 hrs, no symptoms of infection or 
systemic antihistamines or corticosteroids for a week, no aspirin for two 
days and no immunizations for 3 weeks prior to the draw.  
 
3.2 Plasma and Packed Red Cell Storage: The University of Sydney 
The study researcher will collect all blood samples and transport on ice to 
the Endocrine and Metabolic Unit at RPA for processing and distribution. 
Heparin and EDTA plasma samples will be stored in 1 mL aliquots within 
polypropylene tubes temporarily at -20ºC then transported in dry ice to The 
University of Sydney (Cumberland Campus) for long term storage at -80ºC 
in the School of Exercise and Sport Science. 
 
Blood samples for analysis at Laverty Pathology will be transported to the 
commercial laboratory via courier. 
 
   
ii)  Parameters to be Measured – Laverty Pathology 
 
3.4 Liver Function Tests (LFT), Urea, Creatinine, Glucose & Lipids 
 All chemistries (LFT, urea, creatinine, glucose) and lipids (total cholesterol, 
TG, LDL and HDL) will be measured from serum using the Roche Modular 
instrument with Roche kits. 
 
3.5 Routine Iron Studies 
Iron studies (including serum iron, transferrin and ferritin) will be done from 
serum using the Roche Modular E170 immunoassay analyser with Roche 
kits. 
 
3.6  Thyroid Stimulating Hormone (TSH) 
Serum TSH will be measured by Immunochemiluminometric assay (ICMA) 
using Siemens Advia Centaur immunoassay analyser with Siemens kits.  
 
3.7 Full Blood Count (FBC) 
FBC will be measured from serum using the Sysmex instrument being a 
Roche platform. 
Appendix B: Supplementary Material for Chapters 4 and 5 
175 
3.8 Zinc 
Zinc (a potential confounder for immune function) will be measured from 
plasma using the Perkin-Elmer instrument with Inductivity Coupled Plasma 
Mass Spectroscopy (instrument model Perkin-Elmer Elan DRC Plus). 
 
3.9 Immune Markers 
Lymphocyte subsets will be measured from whole blood by flow cytometry 
using the Multi IMK test (lyse no wash) method. 
  
 
iii)  Parameters to be Measured – The University of Sydney 
 
3.10 Inflammatory Markers 
Inflammatory markers such as C-Reactive Protein (CRP), Tumour Necrosis 
Factor-Alpha (TNF-) and Interleukin-6 (IL-6) will be measured from fasting 
plasma samples using a commercial enzyme-linked immunosorbent 
analysis (ELISA) kit. 
 
Note: ELISA results from the TNF- and IL-6 kits were invalid (absorbances 
for the standard curve and most samples were below the lower limit of 
detection) and hence were not used in the final analysis. 
 
3.11 Insulin 
Fasting plasma insulin will be measured using a commercial ELISA kit. 
 
3.12 Appetite Markers  
Adipocyte hormones Leptin and Adiponectin, as well as Ghrelin and Gastric 
Inhibitory Peptide (GIP) will be measured from fasting plasma samples 
using commercial ELISA kits. 
 
3.13 Soluble Transferrin Receptor (sTfR) 
sTfR will be measured from fasting plasma samples using commercial 
ELISA kits. 
 
3.14 Genetic Analysis 
DNA will be extracted from packed red blood cells. Single nucleotide 
polymorphism and polymerase chain reaction technologies will be applied 
by one of the researchers to identify potential candidate genes that may 
affect response to a particular diet (e.g. hepatic lipase gene [LIPC], PPAR 
gamma 2 and the leptin receptor gene) or iron metabolism (e.g. hepcidin 
and ferritin). 
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iv)  Parameters to be Measured – Other 
 
3.15 Resting Metabolic Rate (RMR) 
RMR will be measured with the subject in a semi-reclined position using a 
portable bedside metabolic monitor (Deltatrac II Metabolic Monitor, Datex-
Ohmeda, Helsinki, Finland) by a trained technician in the metabolic unit at 
RPAH. 
 
Subjects will be fasted for 12 hours (including no medications) and will not 
have performed any strenuous exercise 24 hours prior to the measurement. 
They will be rested for a minimum of 30 minutes prior to measurement. 
They will be made to feel comfortable and relaxed and will be familiarised 
with the procedure. 
  
Nitrogen excretion will be estimated to be 12g/24 hr for all subjects. 
Predicted energy expenditure is calculated using the Harris Benedict 
equation. Actual energy expenditure is calculated on the Deltatrac 
according to the equation derived by Weir (de V Weir 1949).  
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4. PHYSICAL FITNESS/ACTIVITY 
 
4.1 Sub-Maximal Oxygen Uptake (VO2) 
The cardiovascular fitness of subjects will be assessed using a sub-
maximal walk test on a treadmill (Technogym, Gambettola, Italy). Subjects 
are required to achieve three or four steady state heart rates when walking 
at 4 km/hr while the treadmill grade increases by 2% every 3 minutes. 
Ratings of perceived exertion will be collected at each steady state using 
the Borg Scale (Borg, 1982). 
 
The week 1 treadmill test will be used to familiarise subjects with the test, 
and determine the appropriate grades at which to test them. The test will be 
repeated at week 2 (to obtain a baseline reading following familiarisation), 6 
and 12 months to track fitness during and after the trial.   
 
4.2 Pedometer 
Subjects will be asked to wear a pedometer (Yamax SW-200, Yamax 
Corporation, Tokyo, Japan) to monitor daily activity for the first three 
months, then one week a month between 3 and 6 months. 
 
4.3 3 Day Activity Diary 
The energy expenditure of subjects will be assessed using a modified 
physical activity diary (Bouchard et al 1983). This is completed for 3 days 
(two weekdays and one weekend day). Subjects record their activity for 
every 15 minute period, which is converted into total metabolic activity. 
 
4.4 Exercise Record 
Subjects will record any physical activity (type and duration) daily during the 
trial. This is another method to assess the level of exercise subjects do 
while participating in the trial, and will also act as a behaviour modification 
tool as subjects will be more aware of their physical activity. 
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5. SLEEP 
 
 Epworth Sleepiness Questionnaire 
While a full sleep study is the best way to diagnose obstructive sleep 
apnoea, this is not practical for this trial in terms of time and cost. Therefore 
in order to identify subjects at higher risk of sleep apnoea (one of the 
exclusion criteria), the Epworth Sleepiness Scale (ESS) will be used to 
screen patients. The ESS is a measure of general daytime sleepiness, an 
important symptom of sleep apnoea. Subjects scoring 10 or more on the 
ESS will be excluded from the trial. 
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6.  CROSS-SECTIONAL STUDY (CSS) 
  
In addition to the longitudinal trial outlined above, we will determine the 
prevalence of iron deficiency, inflammation and measure 
immunocompetence in a wider sample of overweight and obese women 
aged 18-25 years.  
 
We plan to measure an additional 50 subjects over the duration of the 
study. Combining data with the longitudinal trial cohort provides a total of 
120 subjects. We will evaluate the effect of weight cycling/dieting behaviour 
on the abovementioned parameters as well as the relationships between 
excess weight, inflammation and differential iron markers. 
 
These women will fit all inclusion/exclusion criteria for the longitudinal trial 
with the exception of: 
 Being unable to participate in the trial due to their inability to attend 
scheduled visits 
 Being unwilling to include red meat in their diet  
 Being unable to maintain adequate contraception throughout the 
study  
 Having severe untreated obstructive sleep apnoea, severe eating 
disorder, iron deficiency anaemia or severe mobility problems 
 Have not donated blood in the past 3 months 
 Are not undergoing metformin treatment 
 
 
PROTOCOL FOR IRON LEVELS IN CSS 
 
Protocol 1:   Hb normal, ferritin normal, but serum iron low 
 Recruit subject as per normal method. 
 
Protocol 2:  Hb normal, but ferritin low (± low serum iron) 
 Refer to local GP and request treatment. 
 
Protocol 3:  Hb low  
 Refer to local GP and request treatment. 
 
Protocol 4:  Ferritin high (>200) 
Subject may need to be screened for 
haemochromatosis. 
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In addition, there is a separate protocol for dietary supplements for those 
included in the cross-sectional study: 
 
PROTOCOL FOR DIETARY SUPPLEMENTS IN CSS 
 
Protocol 1: Iron supplements 
Exclude. Note: If subject has been taking (or given after 
blood donation) normal iron supplements i.e. not Ferro-
Gradumet, and willing to wait, can be recruited after 3 
month “wash out” from last tablet. 
 
Protocol 2:  Zinc supplements 
  Exclude 
 
Protocol 3:  Multivitamin supplements 
Document the exact supplement(s) taken (e.g. brand, 
dose, frequency) and record the contents. Exclude if 
tablets contain a high dose of zinc or iron. Recruit if 
contain low doses of zinc and iron, however allow a 
minimum of 2 weeks between when last taken and the 
venepuncture. 
 
Protocol 4:  Vitamin e.g. B, C supplements 
Recruit, however allow a minimum of 2 weeks between 
when last taken and the venepuncture. 
 
Protocol 5:  Fish oil supplements 
Exclude if taking 5 or more capsules per day (~1.5g n-
3). If taking less than this then recruit, however allow a 
minimum of 2 weeks between when last taken and the 
venepuncture. 
 
 
Subjects in the cross-sectional study will be asked if they have a secondary 
cause of obesity, however they will NOT be screened for thyroid function as 
per the longitudinal trial. 
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6.1 Parameters to be Measured (Also Included in the Longitudinal Trial) 
As with the longitudinal trial participants, these subjects will provide a 
weight/dieting history in addition to a baseline blood test. Parameters to be 
collected include: 
 Weight, BMI, BIA, Waist circumference & WHR 
 TFEQ 
 Binge eating questionnaire 
 Food habits questionnaire  
 Weight cycling questions 
 FBC, routine iron studies & sTfR 
 Immune/Inflammatory markers 
 Epworth Sleepiness Scale 
 
6.2 Parameters to be Measured (Not Included in the Longitudinal Trial) 
Frozen plasma samples will be transported to the Princess Alexandria 
Hospital (Brisbane, Australia) for measurement of plasma hepcidin by an 
on-line extraction coupled to liquid chromatography-tandem MS method 
(Franklin et al, 2010) using the Xevo TQ MS (Waters Corporation, Milford, 
USA). 
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B2. Participant information sheet for the cross-sectional study 
 
 
The effect of weight cycling on iron status, inflammation 
and immune function in young, overweight and obese women 
 
INFORMATION FOR PARTICIPANTS 
 
 
Introduction 
 
You are invited to take part in a research study that examines the effect of weight cycling on iron 
status, inflammation and immune function. The objective is to measure iron levels, inflammation 
and the immune systems of young women and then investigate how weight cycling can affect these 
factors. This research study is part of larger trial that is comparing the effectiveness of a red meat 
based, low fat diet and a white meat based, low fat diet on weight loss, immune function, blood 
fats, glucose, insulin and iron levels. 
 
Weight gain in young women is often associated with frequent and unsuccessful dieting, yet not 
enough research has occurred on weight management strategies for this group. This research 
study will provide valuable information on how changes in weight can affect young women.  
 
The study is being conducted within this institution by the following researchers: 
 Dr Helen O’Connor, Lecturer, Department of Exercise and Sport Science, The University of 
Sydney 
 Prof Kate Steinbeck, Conjoint Professor University of Sydney, Faculty of Medicine & Senior 
Staff Specialist in Endocrinology & Adolescent Medicine, Royal Prince Alfred Hospital 
 Dr Kieron Rooney, Lecturer, Department of Exercise and Sport Science, The University of 
Sydney 
 Hayley Griffin, PhD student, The University of Sydney 
 Helen Cheng, Research Assistant, The University of Sydney 
 
This study is being sponsored by Meat and Livestock Australia, under a Red Meat and Human 
Nutrition Research and Development Grant. 
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Study Procedures 
 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You 
will then be asked to complete a number of procedures in order to determine your degree of 
obesity, your weight history and health status. Each procedure will need to be done only once for 
this study, and they should all be completed during one or two clinic visits. Each questionnaire 
should not take more than 20 minutes to complete (i.e. less than 1 1/2 hours to complete all of 
them). The procedures involved include: 
 Weight, height, waist and hip measurements 
 Three diet/eating behaviour questionnaires and weight cycling history 
 Sleep questionnaire 
 Bio-electrical impedance (BIA): This involves small electrodes being attached to your ankle 
and wrist that pass a current through your body and is pain and risk free. It is used in order 
to assess your body composition assess so we can determine how much of the body is 
comprised of fat and lean muscle.  
 Blood test: You will be asked to provide a 25 ml blood sample in order to measure your full 
blood count, iron status, immune and inflammatory markers. DNA will be isolated from your 
blood sample for gene analysis. This genetic analysis allows the researchers to study your 
genetic code in order to identify if you express specific genes that may relate to your weight. 
The blood would be taken from a vein in your arm by an experienced pathologist. 
 
Most of these tests are performed routinely at the Metabolism and Obesity Services regardless of 
your participation in this study. If you have a referral for the Metabolism and Obesity Services, you 
will be referred back for routine treatment after completing this study.  
 
Risks 
 
All medical procedures - whether for diagnosis or treatment, routine or experimental – involve some 
risk of injury.  In addition, there may be risks associated with this study that are presently unknown 
and unforeseeable.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
 
Blood collection involves some discomfort at the site from which the blood is taken. There is also a 
risk of some minor bruising at the site, which may last one to two days.  
 
It is also important that women participating in this study are not pregnant and do not become 
pregnant during the course of the study. If you are a woman of child-bearing potential and there is 
any possibility that you are pregnant, the researchers will perform a pregnancy (urine) test before 
you start in the study. If necessary, you should use reliable contraception (such as oral or 
implanted contraception, an IUD or have had a tubal ligation) during the course of the study.  If at 
any time you think you may have become pregnant, it is important to let the researchers know 
immediately. 
 
Participants will be able to maintain their usual blood pressure or lipid management medication 
during this study. However, any changes to medications should be reported to the researchers. 
 
Benefits 
 
While we intend that this research study furthers medical knowledge and may improve treatment 
options for weight gain in young women in the future, it may not be of direct benefit to you. 
 
Compensation for injuries or complications 
 
If you suffer any injuries or complications as a result of this study, you should contact the study 
doctor as soon as possible, who will assist you in arranging appropriate medical treatment. If you 
are eligible for Medicare, you can receive any medical treatment required to treat the injury or 
complication, free of charge, as a public patient in any Australian public hospital. In the unlikely 
event that you experience psychological distress during this study, an appropriate referral will be 
made. 
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In addition, you may have a right to take legal action to obtain compensation for any injuries or 
complications resulting from the study.  Compensation may be available if your injury or 
complication is sufficiently serious and is caused by unsafe drugs or equipment, or by the 
negligence of one of the parties involved in the study (for example, the researcher, the hospital, or 
the treating doctor).  You do not give up any legal rights to compensation by participating in this 
study.  
 
Costs 
 
Participation in this study will not cost you anything, nor will you be paid.  
 
Voluntary Participation 
 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you do take 
part, you can withdraw at any time without having to give a reason.  Whatever your decision, 
please be assured that it will not affect your medical treatment or your relationship with the staff 
who are caring for you.   
 
Confidentiality 
 
All the information collected from you for the study will be treated confidentially, and only the 
researchers named above will have access to it. The study results may be presented at a 
conference or in a scientific publication, but individual participants will not be identifiable in such a 
presentation. 
 
Further Information 
 
When you have read this information, Helen Cheng will discuss it with you further and answer any 
questions you may have.  If you would like to know more at any stage, please feel free to contact 
her on (02) 9515 4235 or 0434 362 515.  
 
This information sheet is for you to keep. 
 
Ethics Approval 
 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney South 
West Area Health Service, and by the Human Research Ethics Committee of The University of 
Sydney. Any person with concerns or complaints about the conduct of this study should contact 
either: 
 The Secretary of the Ethics Review Committee (RPAH Zone) of the Sydney South West Area 
Health Service on (02) 9515 6766 and quote protocol number X09-0107 
 The Manager of Ethics Administration at The University of Sydney on (02) 9351 4811 and 
quote reference number 8286 
  
Version No. : #11 
Date: 03/06/09 
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B3. Participant consent form for the cross-sectional study 
 
 
The effect of weight cycling on iron status, inflammation 
and immune function in young, overweight and obese women 
 
PARTICIPANT CONSENT FORM 
 
 
I, ........................................………….……................................................................................ [name]  
 
of 
.....................................………….......................…….....................................................…….[address]  
 
have read and understood the Information for Participants on the abovenamed research study 
 
and have discussed the study with ......…………..…..................................................………............... 
 
I have been made aware of the procedures involved in the study, including any known or expected 
inconvenience, risk, discomfort or potential side effect and of their implications as far as they are 
currently known by the researchers. 
 
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
NAME:    ..............................…….................................................................... 
 
SIGNATURE:   ..............................…….................................................................... 
 
DATE:    ......................................................................................................... 
 
NAME OF WITNESS:  ......................…………..................................................................... 
 
SIGNATURE OF WITNESS: .............................………….............................................................. 
 
Version No. : #9 
Date: 19/02/09  
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B4. Participant information sheet for the longitudinal dietary intervention study 
 
Comparison of red meat based, low fat diet versus white meat based, low fat diet 
on weight loss, immune function, hunger, metabolic parameters and iron status 
in young, overweight and obese women 
 
INFORMATION FOR PARTICIPANTS 
 
Introduction 
You are invited to take part in a research study comparing the effectiveness of a low fat red meat 
(RM) and white meat (WM) diet on weight loss, immune function, hunger, metabolic parameters 
and iron status. The objective is to investigate whether a RM or WM diet is more effective for 
weight loss and controlling hunger, as well as improving immune function, blood fats, glucose, 
insulin and iron levels in young women.  
 
Weight gain in young women is often associated with frequent and unsuccessful dieting, yet not 
enough research has occurred on weight management strategies for this group. This research 
study will provide valuable information on the wellbeing of young women who are consuming either 
a RM or WM based weight loss diet. In order to participate in this study, you will need to be 
prepared to eat either red or white meat at least four times each week.  
 
The study is being conducted within this institution by the following researchers: 
 Dr Helen O’Connor, Lecturer, Department of Exercise and Sport Science, The University of 
Sydney 
 Prof Kate Steinbeck, Conjoint Professor University of Sydney, Faculty of Medicine & Senior 
Staff Specialist in Endocrinology & Adolescent Medicine, Royal Prince Alfred Hospital 
 Dr Kieron Rooney, Lecturer, Department of Exercise and Sport Science, The University of 
Sydney 
 Hayley Griffin, PhD student, The University of Sydney 
 Helen Cheng, Research Assistant, The University of Sydney 
 
This study is being sponsored by Meat and Livestock Australia, under a Red Meat and Human 
Nutrition Research and Development Grant. 
 
Study Procedures 
If you agree to participate in this study, you will be asked to sign the Participant Consent Form. You 
will then be asked to complete a number of procedures to determine your weight, body composition 
(i.e. fat and lean muscle mass), health status, fitness, diet/eating/sleeping behaviours and resting 
metabolic rate. A description of these procedures is provided below. 
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These procedures will tell us if you are eligible to participate in this study. If you are not eligible, 
and have a referral for the Metabolism and Obesity Services, you will be referred back for routine 
treatment. If you are eligible and interested in participating, you will be allocated to one of the two 
dietary plans by a process called randomisation. The term randomisation means you have an equal 
chance of being allocated to either group, similar to tossing a coin. 
 
You will be asked to follow the prescribed dietary plan for 12 months, and to attend the clinic (for 
approximately 1 hour) once per week for the first 3 months, then once per fortnight from 3 to 6 
months, and finally once per month from 6 to 12 months. During these visits you will receive 
information on your diet and some of the study procedures will be performed. Each questionnaire 
on sleep and eating behaviours should not take more than 20 minutes to complete (i.e. less than 2 
hours to complete all of them) and you will be able to fill them out at home if this option is more 
convenient. However, you may be required to attend the clinic at other times for certain tests. You 
will also be advised to undertake some form of physical activity/exercise e.g. walking for 30 
minutes each day, and record in a diary your food intake and how you are feeling. You will be given 
appropriate log sheets to record these items.  
 
The following procedures will occur at the clinic: 
 Weight, height, waist and hip measurements 
 Diet history (including past weight cycling) and four diet/eating behaviour questionnaires  
 Physical activity and sleep questionnaires 
 Body composition via dual-energy x-ray absorptiometry (DEXA) scan and bio-electrical 
impedance (BIA): DEXA will be done three times and involves a whole body scan with x-
rays. BIA will be done four times and involves small electrodes being attached to your ankle 
and wrist that pass a current through your body. Both methods are pain free. 
 Blood test: A 35 ml blood sample will be taken at three different times in order to measure 
lipids (including cholesterol), glucose, insulin, liver function tests, creatinine, urea, full blood 
count, iron status, appetite markers, immune and inflammatory markers. DNA will be isolated 
from your blood sample for gene analysis. This genetic analysis allows the researchers to 
study your genetic code in order to identify if you express specific genes that may relate to 
your weight. The blood would be taken from a vein in your arm by an experienced 
pathologist. 
 Resting metabolic rate: This will be done three times and involves you lying still for around 
40 minutes under a clear plastic hood while your breathing is monitored.  
 Sub-maximal VO2 treadmill test: This will be done three times. This test involves supervised 
walking, not running, on a treadmill and having your heart rate monitored. 
 
You will be asked to complete the following procedures, outside the clinic: 
 Food and health diary: You will be asked to keep a 3-day record of your food and drink 
intake, a record of how hungry you feel and how well you are feeling regularly throughout the 
study. 
 Pedometer: You will need to wear a pedometer regularly during the first half of the study and 
to record the readings. A pedometer is a non-intrusive devise that is attached to your 
clothing. 
 Urine collection for 24hr Urea Nitrogen test: You will be asked to collect all of your urine for 
24 hours and then bring it into the clinic for processing four times during the study.  
 
Following completion of the study, you will be asked to attend a clinic visit (for approximately 2 
hours) 1 and 2 years post-trial where long-term sustainability of your diet will be assessed. 
The following procedures will occur during this clinic visit: 
 Weight, height, waist and hip measurements 
 Four diet/eating behaviour questionnaires 
 One physical activity questionnaire 
 Dieting and weight cycling history since completion of trial 
 Physical activity history since completion of trial 
 Sub-maximal VO2 treadmill test 
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Risks 
All medical procedures - whether for diagnosis or treatment, routine or experimental – involve some 
risk of injury.  In addition, there may be risks associated with this study that are presently unknown 
and unforeseeable.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
 
The risks of participating in this study are related to the following procedures: 
 Blood test: Blood collection involves some discomfort at the site from which the blood is 
taken. There is also a risk of some minor bruising at the site, which may last one to two days. 
If this occurs, you will be given suitable advice. 
 DEXA Scan: This involves exposure to a very small amount of radiation. As part of everyday 
living, everyone is exposed to naturally occurring background radiation and receives a dose 
of about 2 millisieverts (2 mSv) each year. The effective dose from this study is 0.03 mSv 
(i.e. 0.01 mSv from each DEXA scan). At this dose level, no harmful effects of radiation have 
been demonstrated and the risk is negligible. Any person who would like further information 
on radiation should contact Jocelyn Towson, Radiation Safety Officer at RPAH, on (02) 9515 
6023. 
 Resting metabolic rate (RMR): Some patients may feel slightly claustrophobic when placed 
under the clear plastic hood. If this is the case, the procedure will be stopped immediately.   
 
Please inform the researchers if you have participated in any other research studies using radiation 
in the last five years. Please keep this information sheet in a safe place for the next five years and 
show it to the researchers if you volunteer for any more studies using radiation. 
 
It is also important that women participating in this study are not pregnant and do not become 
pregnant during the course of the study.  If you are a woman of child-bearing potential and there is 
any possibility that you are pregnant, the researchers will perform a pregnancy (urine) test before 
you start in the study. If necessary, you should use reliable contraception (such as oral or 
implanted contraception, an IUD or have had a tubal ligation) during the course of the study.  If at 
any time you think you may have become pregnant, it is important to let the researchers know 
immediately. 
 
Participants will be able to maintain their usual blood pressure or lipid management medication 
during this study. However, any changes to medications should be reported to the researchers. 
 
Benefits 
As a participant of this study, you will receive regular dietary counselling and information sessions 
in a standard clinical setting. You will be supported to reduce your weight, improve any metabolic 
complications associated with excess weight and increase your physical activity. It is anticipated 
that both the RM and WM diet groups will lose weight during the study. You will also receive 
additional testing to the normal patients attending the Metabolism and Obesity Services, which 
includes body composition measurement by DEXA and blood tests which measure immune and 
inflammatory markers. This means that your treatment plan will be more holistic. 
 
Compensation for injuries or complications 
If you suffer any injuries or complications as a result of this study, you should contact the study 
doctor as soon as possible, who will assist you in arranging appropriate medical treatment. If you 
are eligible for Medicare, you can receive any medical treatment required to treat the injury or 
complication, free of charge, as a public patient in any Australian public hospital. In the unlikely 
event that you experience psychological distress during this study, an appropriate referral will be 
made. 
 
In addition, you may have a right to take legal action to obtain compensation for any injuries or 
complications resulting from the study. Compensation may be available if your injury or 
complication is sufficiently serious and is caused by unsafe drugs or equipment, or by the 
negligence of one of the parties involved in the study (for example, the researcher, the hospital, or 
the treating doctor).  You do not give up any legal rights to compensation by participating in this 
study.  
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Costs 
 
Participation in this study will not cost you anything, nor will you be paid. However, you will be 
given vouchers for Coles or Woolworths supermarkets in order to help cover the cost of meat or 
chicken purchases. Vouchers will be given out at regular intervals during the trial. If you complete 
the full 12 months of the trial, five vouchers each to the value of $20 will be given. Therefore, the 
maximum total value of the vouchers given to you during the trial will be $100. If you withdraw early 
from the trial, you will only be given vouchers for the period prior to withdrawal (i.e. you will not 
receive all five vouchers). 
 
In addition, you will be given a set of kitchen scales to use during the trial to help you measure food 
items. If you complete the full 12 months of the trial, you will be able to keep the scales. However if 
you withdraw early from the trial, you will be asked to return the scales so that other participants 
can use them.  
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If you do take 
part, you can withdraw at any time without having to give a reason.  Whatever your decision, 
please be assured that it will not affect your medical treatment or your relationship with the staff 
who are caring for you.   
 
Confidentiality 
 
All the information collected from you for the study will be treated confidentially, and only the 
researchers named above will have access to it. The study results may be presented at a 
conference or in a scientific publication, but individual participants will not be identifiable in such a 
presentation. 
 
Further Information 
 
This information sheet is for you to keep. When you have read this information, Helen Cheng will 
discuss it with you further and answer any questions you may have. If you would like to know more 
at any stage, please feel free to contact her on (02) 9515 4235 or 0434 362 515.  
 
Ethics Approval 
 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the Sydney South 
West Area Health Service, and by the Human Research Ethics Committee of The University of 
Sydney. Any person with concerns or complaints about the conduct of this study should contact 
either: 
 The Secretary of the Ethics Review Committee (RPAH Zone) of the Sydney South West Area 
Health Service on (02) 9515 6766 and quote protocol number X05-0085  
 The Manager of Ethics Administration at The University of Sydney on (02) 9351 4811 and 
quote reference number 8286. 
  
Version No. : #12 
Date: 16/04/09 
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B5. Participant consent form for the longitudinal dietary intervention study 
 
Comparison of red meat based, low fat diet versus white meat based, low fat diet 
on weight loss, immune function, hunger, metabolic parameters and iron status 
in young, overweight and obese women 
 
PARTICIPANT CONSENT FORM 
 
 
I, .......................................................………….…….........................................................[name]  
 
of .....................................................………….......................……............................….[address]  
 
have read and understood the Information for Participants on the abovenamed research 
study 
 
and have discussed the study with ......…………..…................................................................... 
 
I have been made aware of the procedures involved in the study, including any known or 
expected inconvenience, risk, discomfort or potential side effect and of their implications as 
far as they are currently known by the researchers. 
 
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
NAME:    ..............................……............................................................ 
 
SIGNATURE:   ..............................……............................................................ 
 
DATE:    ..............................……............................................................ 
 
NAME OF WITNESS:  ......................…………............................................................. 
 
SIGNATURE OF WITNESS: .............................…………...................................................... 
 
Version No. : #11 
Date: 24/02/09  
Level 6 West Main Building
Missenden Rd
Camperdown NSW 2050  AUSTRALIA
Phone: 61 2  95154220  Fax: 61 2  95155820
Email: mos@email.cs.nsw.gov.au
besity  ervices
etabolism &
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B6. Dietary prescription provided to participants randomised to the higher-protein, higher-haem 
iron diet 
Foods that you will need to eat each day 
 
 
Food type Units allowed Unit conversion 
 
HIGH FIBRE 1 unit per day 1 unit  = 1 weetbix plus ½ cup all bran 
CEREAL   = 40 g high fibre breakfast cereal 
    (eg Sultana Bran, Fibre Plus) 
   = 1 slice wholegrain bread 
 
DAIRY 2 units per day 1 unit  = 250 ml skim milk  
   = 200 g diet yoghurt 
   = 200 g low-fat custard or dairy dessert    
   = 25 g cheddar cheese or other full-fat  
       cheese 
   = 50 g reduced fat cheese (less than 10  
       percent fat) 
 
LEAN  2 units per day 1 unit = 100 g raw weight of lean meat 
PROTEIN   (for dinner)  
You should eat 2 units of lean red meat (beef, lamb, 
veal) for dinner 4 times each week. Eat 2 units of fish 
for dinner twice a week and 2 units of lean other white 
meats (chicken, turkey, pork) for dinner once per week. 
 
 1 unit per day  1 unit = 100 g raw weight of lean meat (tinned  
(for lunch)    or fresh fish, chicken, turkey, pork, 
    ham, beef, lamb)  
    = 2 eggs 
 
WHOLEGRAIN 3 units per day 1 unit = one 35 g slice of wholegrain bread  
BREAD     
You can replace one unit of bread each day with any of 
the following: 
   1 unit  = 2 crispbread, such as Ryvita 
    = 1 medium potato (150 g) 
    = 1/3 cup cooked rice or noodles 
    = 1/2 cup cooked pasta 
    = 1/3 cup baked beans, cooked lentils,  
     kidney beans or other legumes 
    = 3/4 cup cooked couscous 
 
FRUIT 2 units per day 1 unit = 150 g fresh or tinned, unsweetened 
    fruit 
   = 150 ml unsweetened fruit juice 
   = 20 g dried fruit 
 
** 
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VEGETABLES 2 ½ units per day 1 unit = 1 cup cooked vegetables (see list on  
following pages) 
 
It is recommended that you eat ½ cup of salad 
vegetables and 2 cups of cooked vegetables per day. 
Always include some green leafy vegetables such as 
broccoli, spinach, brussel sprouts etc. 
 
FATS AND 3 units per day 1 unit = 1 teaspoon canola or olive oil 
OILS   = 1 teaspoon canola or olive oil based 
    normal margarine 
   = 2 teaspoons canola or olive oil based 
    light margarine 
   = 1 teaspoon curry paste or pesto in oil 
   = 20 g avocado 
   = 7 g nuts or seeds 
 
SOUP LOW 1 unit per day 1 unit = 1 cup (250 ml) any packet soup that has 
KILOJOULE (optional extra)      less than approximately 40 kilocalories  
     (or 160 kilojoules) per serve (eg Home 
Brand Chicken Noodle soup mix, 
Continental French Onion Classic 
Recipe soup, Continental Spring 
Vegetable Classic Recipe soup) 
           
ALCOHOL 2 units per week 1 unit = 150 ml wine  
(optional extra)  = 300 ml bitter or draught beer (not stout) 
   = 400 ml reduced alcohol beer 
   = 50 ml spirits 
 
  If you prefer not to drink, you can replace your units 
  of alcohol for a treat or snack: 
  1 unit = 20 g chocolate 
   = 1 plain muesli bar 
   = 2 plain sweet biscuits 
   = other treat up to the value of 430 kJ 
 
** It is essential you eat the lean protein units daily – these are compulsory foods 
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Free Foods 
 
These foods contain minimal energy and will not affect your weight loss 
 
Vegetables/salad (up to 2 ½ cups per day) 
 
asparagus * artichoke * green beans * bean sprouts * broccoli  
brussel sprouts * beetroot * carrot * cabbage * capsicum * cauliflower  
celery * champignon * chilli * chives * choko * corn * cucumber * fennel  
lettuce * marrow * mushroom * onion * rhubarb * radish * peas * pumpkin  
silver beet * spinach * swede * tomato * turnip * zucchini  
 
Condiments 
 
artificial sweeteners * stock cubes * clear soups * diet topping  
diet jelly * no oil or oil free salad dressings * tomato sauce * BBQ sauce  
soy sauce * chilli sauce * pickles * mustard * vegemite * mint sauce * horseradish  
curry powder/paste * parsley * garlic * ginger * lemon * vinegar * herbs * spices 
 
Drinks 
 
water * diet cordial * diet soft drink   
mineral water (unflavoured) * tea/coffee * Bonox/Bovril  
 
 
 
A lot of energy can be consumed when drinking fluids 
Tea/coffee is allowed freely, but make sure you use artificial sweetener if you  
like to add sugar. A cappuccino is allowed but must be exchanged for 125 ml (½ unit)  
of your milk ration. You may only have fruit juice as part of your fruit ration. 
Wine, beer and other alcoholic beverages are allowed as per your alcohol quota. 
 
 
 
 
You may find that recipes normally prepared at home need to be  
modified to fit with the eating plan 
It could mean that you need to check the quantity of each ingredient. It is best to  
weigh any meat before eating it, unless it is already in a pre-weighed pack. Thickeners and gravies 
are allowed but are to be used in small amounts. Dressings and mayonnaise may be used on salad 
dishes as long as they are the low joule or no oil varieties.  
You can always add your own measured canola oil to these dressings. 
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B7. Dietary prescription provided to participants randomised to the lower-protein, lower-haem iron 
diet 
Foods that you will need to eat each day 
 
 
Food type Units allowed Unit conversion 
 
CEREAL 1 unit per day 1 unit  = 2 weetbix 
   = 40 g breakfast cereal 
    (eg Just Right, Sustain) 
   = 1 slice wholegrain bread 
 
DAIRY 2 units per day 1 unit  = 250 ml high calcium skim milk  
    (eg Shape No Fat, Pura Tone) 
   = 200 g diet yoghurt 
   = 200 g low-fat custard or dairy dessert    
   = 25 g cheddar cheese or other full-fat  
       cheese 
   = 50 g reduced fat cheese (less than 10  
       percent fat) 
    
LEAN  1 unit per day 1 unit = 80 g raw weight of lean meat 
PROTEIN     
You should eat 1 unit of lean white meat (chicken, 
turkey, pork) for dinner 4 times each week. Eat 1 unit 
of fish for dinner twice a week and 1 unit of lean red 
meat (beef, lamb, veal) for dinner once per week. 
 
WHOLEGRAIN 3 units per day 1 unit = one 35 g slice of wholegrain bread  
BREAD     
You can replace one unit of bread each day with any of 
the following: 
   1 unit  = 2 crispbread, such as Ryvita 
    = 1 medium potato (150 g) 
    = 1/3 cup cooked rice or noodles 
    = 1/2 cup cooked pasta 
    = 1/3 cup baked beans, cooked lentils,  
     kidney beans or other legumes 
    = 3/4 cup cooked couscous 
 
RICE or PASTA 1 unit 6 times 1 unit = 120 g cooked rice or pasta 
 per week 
 
FRUIT 2 units per day 1 unit = 150 g fresh or tinned, unsweetened 
    fruit 
   = 150 ml unsweetened fruit juice 
   = 20 g dried fruit 
 
** 
** 
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VEGETABLES 2 ½ units per day 1 unit = 1 cup cooked vegetables (see list on  
    following pages) 
 
It is recommended that you eat ½ cup of salad 
vegetables and 2 cups of cooked vegetables per day. 
Always include some green leafy vegetables such as 
broccoli, spinach, brussel sprouts etc. 
 
FATS AND 3 units per day 1 unit = 1 teaspoon canola or olive oil 
OILS   = 1 teaspoon canola or olive oil based 
    normal margarine 
   = 2 teaspoons canola or olive oil based 
    light margarine 
   = 1 teaspoon curry paste or pesto in oil 
   = 20 g avocado 
   = 7 g nuts or seeds 
 
SHORTBREAD 2 units per day 1 unit = 1 biscuit (eg Arnotts Glengarry, Arnotts  
BISCUITS       Arno Shortbread) 
 
SOUP LOW 1 unit per day 1 unit = 1 cup (250 ml) any packet soup that has 
KILOJOULE (optional extra)      less than approximately 40 kilocalories  
     (or 160 kilojoules) per serve (eg Home 
     Brand Chicken Noodle soup mix, 
Continental French Onion Classic 
Recipe soup, Continental Spring 
Vegetable Classic Recipe soup) 
          
ALCOHOL 2 units per week 1 unit = 150 ml wine  
(optional extra)  = 300 ml bitter or draught beer (not stout) 
   = 400 ml reduced alcohol beer 
   = 50 ml spirits 
 
If you prefer not to drink, you can replace your units 
of alcohol for a treat or snack: 
  1 unit = 20 g chocolate 
   = 1 plain muesli bar 
   = 2 plain sweet biscuits 
   = other treat up to the value of 430 kJ 
 
** It is essential you eat the lean protein and wholegrain bread units daily – these are 
compulsory foods 
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Free Foods 
 
These foods contain minimal energy and will not affect your weight loss 
 
Vegetables/salad (up to 2 ½ cups per day) 
 
asparagus * artichoke * green beans * bean sprouts * broccoli  
brussel sprouts * beetroot * carrot * cabbage * capsicum * cauliflower  
celery * champignon * chilli * chives * choko * corn * cucumber * fennel  
lettuce * marrow * mushroom * onion * rhubarb * radish * peas * pumpkin  
silver beet * spinach * swede * tomato * turnip * zucchini  
 
Condiments 
 
artificial sweeteners * stock cubes * clear soups * diet topping  
diet jelly * no oil or oil free salad dressings * tomato sauce * BBQ sauce  
soy sauce * chilli sauce * pickles * mustard * vegemite * mint sauce * horseradish  
curry powder/paste * parsley * garlic * ginger * lemon * vinegar * herbs * spices 
 
Drinks 
 
water * diet cordial * diet soft drink   
mineral water (unflavoured) * tea/coffee * Bonox/Bovril  
 
 
 
A lot of energy can be consumed when drinking fluids 
Tea/coffee is allowed freely, but make sure you use artificial sweetener if you  
like to add sugar. A cappuccino is allowed but must be exchanged for 125 ml (½ unit)  
of your milk ration. You may only have fruit juice as part of your fruit ration. 
Wine, beer and other alcoholic beverages are allowed as per your alcohol quota. 
 
 
 
 
You may find that recipes normally prepared at home need to be  
modified to fit with the eating plan 
It could mean that you need to check the quantity of each ingredient. It is best to  
weigh any meat before eating it, unless it is already in a pre-weighed pack. Thickeners and gravies 
are allowed but are to be used in small amounts. Dressings and mayonnaise may be used on salad 
dishes as long as they are the low joule or no oil varieties.  
You can always add your own measured canola oil to these dressings. 
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B8. Comparison of nutritional profiles of the higher-protein, higher-haem iron and lower-protein, 
lower-haem iron diets based on seven day models designed for a 23 year old female with light 
activity 
Nutrient intake per day HPHI diet LPLI diet EAR RDI AI UL 
       
Energy (kJ) 5614.64 5602.41 - - - - 
kJ from protein (%) 32.46 20.35 - - - - 
kJ from fat (%) 25.00 21.04 - - - - 
kJ from saturated fat (%) 7.53 6.86 - - - - 
kJ from carbohydrate (%) 41.49 57.56 - - - - 
kJ from alcohol (%) 1.05 1.05 - - - - 
kJ from others (%) 0.09 ? - - - - 
Protein (g) 107.1 67.09 37 46 - - 
Total fat (g) 37.91 31.86 - - - - 
Saturated fat (g) 11.41 10.39 - - - - 
Polyunsaturated fat (g) 5.69 4.75 - - - - 
Monounsaturated fat (g) 16.23 12.83 - - - - 
Fat as polyunsaturated (%) 17.07 16.99 - - - - 
Fat as monounsaturated (%) 48.69 45.87 - - - - 
Fat as saturated (%) 34.24 37.13 - - - - 
Cholesterol (mg) 297.67 87.06 - - - - 
Carbohydrate (g) 137.85 190.58 - - - - 
Sugars (g) 73.09 83.24 - - - - 
Starch (g) 63.58 106.11 - - - - 
Alcohol (g) 2.04 2.04 - - - - 
Dietary fibre (g) 22.68 23.83 - - 25 - 
Thiamin (mg) 1.63 1.76 0.9 1.1 - - 
Riboflavin (mg) 2.54 2.5 0.9 1.1 - - 
Niacin equivalents (mg) 47.44 31.68 11 14 - 35 
Vitamin B6 (mg) ? ? 1.1 1.3 - 50 
Vitamin B12 (µg) ? ? 2 2.4 - - 
Vitamin C (mg) 156.43 159.67 30 45 - - 
Total folate (µg) 332.45* 355.2* 320 400 - 1000 
Total vitamin A equivalents (µg) 1057.79 1307.11 500 700 - 3000 
Sodium (mg) 2186.23 1939.55 - - 460-920 2300 
Potassium (mg) 3554.05 3095.82 - - 2800 - 
Magnesium (mg) 318.36 268.11* 255 310 - 350 
Calcium (mg) 907.51* 876.95* 840 1000 - 2500 
Phosphorus (mg) 1725.45 1282.3 580 1000 - 4000 
Iron (mg) 12.19* 9.85* 8 18 - 45 
Zinc (mg) 11.74 7.63* 6.5 8 - 40 
AI, adequate intake; EAR, estimated average requirement; HPHI, higher-protein and higher-haem iron; 
LPLI, lower-protein and lower-haem iron; RDI, recommended dietary intake; UL, upper limit of intake 
?Nutrients that were unable to be computed using FoodWorks Version 6.0.25175 
*Nutrients that were below the recommended dietary intake (RDI) 
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B9. Seven day model of the higher-protein, higher-haem iron diet 
Day  Meal  Food  Quantity  
    
Monday Breakfast Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   200g   
        Bread,Mixed Grain   35g   
        Banana,common,raw,peeled   150g   
        Tea,black,brewed from leaf/teabags,regular   600 ml   
                
    Lunch Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Salmon,Pink,Canned In Water,No Added Salt,Drained   100g   
        Cheese,Cheddar(Mild,Tasty,Vintage)   25g   
        Tomato,Raw   30g   
        Cucumber,Lebanese,Raw   20g   
        Spinach,English,Raw   6g   
        Apple,Green,Raw,Unpeeled   150g   
        Water,plain,drinking   600 ml   
    
    Dinner Beef,Steak,Fillet,Raw,Fat Trimmed   200g   
        Oil,Canola(Include Rape Seed Oil)   1 tsp   
        Potato,Boiled,Without Added Salt,With Skin(Unpeeled),Fat Not 
Added   
150g   
        Broccoli,Cooked,Fat Not Added   65g   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   50g   
        Squash,Button,Cooked,Fat Not Added In Cooking   75g   
        Salad,Side,Without Dressing,NFS   1 cup   
        .Diet coke [Soft drink]   500 ml   
    
Tuesday Breakfast .Sanitarium Weet-Bix(regular) [Breakfast cereal]   1 biscuit   
        .Kellogg's All bran [Breakfast cereal]   0.5 cup   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   250 ml   
        Pineapple,raw,peeled   150g   
        Water,plain,drinking   500 ml   
                
    Lunch Soup,Tomato,Smooth,Red Energy,Fr Dry Mix,Reconst W/Water   1 cup   
        Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Ham,Leg(Separable Fat),Fat Trimmed   100g   
        Tomato,Raw   90g   
        Juice,orange,commercial,unsweetened   150 ml   
        Water,plain,drinking   500 ml   
        .Cadbury dairy milk [Chocolate]   20g   
                
    Dinner Lamb,Trim Lamb(No Separable Fat),Raw   200g   
        Garlic,raw,peeled   0.5 Clove   
        Oil,Sesame   0.5 tsp   
        Shallot,Raw   1 serve (2 shallot bulbs)   
        Chili,red,raw   5g   
        Cabbage,Bok Choy,Cooked,Fat Not Added In Cooking   1 cup (cooked)   
        Snowpea(Pea Pod),Cooked,Fat Not Added In Cooking   75g   
        Sauce,Oyster,Asian,Commercial   0.08 cup   
        Sauce,Chili,Asian,Commercial   0.06 cup   
        Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   0.5 tsp   
        Yoghurt,Skim/Low Fat,Vanilla,Artificially Sweetened   200g   
        Cordial,other fruit juice,artif sweetened,rec dilution   600 ml   
    
Wednesday Breakfast    Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Vegemite   2 tsp   
        Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   200g   
        Coffee,black,from instant,regular,NS strength   250 ml   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   20 mL   
        Water,plain,drinking   400 ml   
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Day  Meal  Food  Quantity  
    
Wednesday Lunch Beef,Steak,Fillet,Raw,Fat Trimmed   100g   
        Oil,Olive   1 tsp   
        Lettuce,Mignonette,Raw   2 leaf   
        Capsicum,Red,Raw   20g   
        Bean Sprout,Raw   15g   
        Onion,Spring,Raw   15g   
        Chili,red,raw   10g   
        Juice,lime   10 ml   
        Sauce,Fish,Asian,Commercial   0.25 tsp   
        Sauce,soy,commercial   0.25 tsp   
        Garlic,raw,peeled   0.4g   
        Bread,Mixed Grain   70g   
        Custard,Low Fat,Vanilla,Commercial   200g   
        Water,plain,drinking   500 ml   
                
    Dinner Snapper,Raw   200g   
        Broccoli,Cooked,Fat Not Added   0.5 cup (nfs)   
        Carrot,Cooked,Fat Not Added In Cooking   0.5 cup (nfs)   
        Bean,Green,Cooked,From Raw,Fat Not Added In Cooking   0.25 cup (chopped)   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   0.25 cup (chopped)   
        Fruit salad,fresh   300g   
        Water,plain,drinking   500 ml   
                
Thursday    Breakfast    .Kellogg's Sultana bran [Breakfast cereal]   40g   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   250 ml   
        Peach,Canned In Natural Juice,Drained   150g   
        Tea,black,brewed from leaf/teabags,regular   500 ml   
                
    Lunch .Westons ryvita(original whole rye) [Biscuit]   2 biscuit (crispbread)   
        Tuna,Canned In Water,Drained   100g   
        Onion,Mature,Raw   1 thin slice   
        Tomato,Raw   0.5 cup (chopped/sliced)   
        Cucumber,Lebanese,Raw   0.5 cup (chopped/diced)   
        Cheese,Feta,Reduced Fat   50g   
        Oil,Olive   1 tsp   
        Mineral Water,Natural   500 ml   
                
    Dinner Beef,Steak,Fillet,Raw,Fat Trimmed   200g   
        Oil,Olive   2 tsp   
        Pepper,Black/White   0.5 tsp   
        Fennel,Cooked,Fat Not Added In Cooking   0.25 cup   
        Zucchini,Cooked,Fat Not Added In Cooking   0.5 cup (nfs)   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   0.5 cup (chopped)   
        Mushroom,Cooked/Canned,Fat Not Added In Cooking   0.25 cup (sliced)   
        Juice,lemon,fresh   0.06 cup   
        Bread,Mixed Grain   70g   
        Apple,Red,Raw,Unpeeled   150g   
        Water,plain,drinking   600 ml   
                
Friday Breakfast    Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        Egg,poached   1 Average   
        Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   200g   
        Juice,apple   150 ml   
        Water,plain,drinking   600 ml   
                
    Lunch Bread,Mixed Grain   70g   
        Ham,Leg(Separable Fat),Fat Trimmed   50g   
        Pickle,Mixed,In Brine,NFS   1 tsp   
        Cheese,Cheddar,Reduced Fat(50%Reduction)   50g   
        Lettuce,Cos,Raw   0.5 cup (nfs)   
        Banana,common,raw,peeled   150g   
        .Diet coke [Soft drink]   1 bottle(500ml)   
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Day  Meal  Food  Quantity  
    
Friday Dinner  Barramundi,Raw   200g   
        Oil,Olive   1 tsp   
        Garlic,raw,peeled   0.5 Clove   
        Juice,lemon,commercial   1 tsp   
        Capers   1 tb   
        Lettuce,Common,Raw   0.5 cup (nfs)   
        Carrot,Raw   0.5 cup (chopped)   
        Tomato,Cherry,Raw   0.5 cup (cherry tomato)   
        Snowpea Sprout,Raw   0.5 cup   
        Vinegar   1 tb   
        Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        Water,plain,drinking   600 ml   
                
Saturday Breakfast .Uncle Tobys Fibreplus [Breakfast cereal]   40g   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   250 ml   
        Apricot,Dried,Raw   20g   
        Coffee,black,from instant,regular,NS strength   250 ml   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   20 mL   
        Water,plain,drinking   300 ml   
                
    Lunch Bread,Mixed Grain   105g   
        Turkey,Breast,Deli-Sliced   100g   
        Rocket,Raw   0.25 cup (shredded/chopped)   
        Tomato,Raw   0.25 cup (chopped/sliced)   
        Custard,Low Fat,Vanilla,Commercial   200g   
        Water,plain,drinking   500 ml   
                
    Dinner    Chicken,Breast,Raw,Without Skin   200g   
        Oil,Olive   3 tsp   
        Tomato Puree   1 tb   
        Garlic,raw,peeled   0.5 Clove   
        Asparagus,Cooked,Fat Not Added In Cooking   0.5 cup   
        Carrot,Cooked,Fat Not Added In Cooking   0.5 cup (nfs)   
        Pumpkin,Boiled,Without Added Salt,Fat Not Added In Cooking   0.5 cup (nfs)   
        Cauliflower,Cooked,Fat Not Added In Cooking   0.5 cup   
        Grape,Green,No Seeds,Raw   150g   
        Wine,Red   150 mL   
        Water,plain,drinking   300 ml   
                
Sunday Breakfast Egg,Scrambled,Fat Not Added In Cooking   2 medium egg (55-64g)   
        Tomato,Grilled   0.25 cup (chopped)   
        Mushroom,Cooked/Canned,Fat Not Added In Cooking   0.25 cup   
        Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        Coffee,black,from instant,regular,NS strength   250 ml   
        Milk,Fluid,Skim/Nonfat(Fat<0.16%)   20 mL   
        Water,plain,drinking   500 ml   
                
    Lunch Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   1.5 tsp   
        Chicken,Breast,Raw,Without Skin   100g   
        Lettuce,Common,Raw   1 medium leaf   
        Tomato,Raw   3 thin slice   
        Beetroot,canned,drained   2 Slices   
        Cucumber,Lebanese,Raw   3 slice (2.5cm dia,0.5cm thick)   
        Apple,Green,Raw,Unpeeled   150g   
        Mineral Water,Natural   500 ml   
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Day  Meal  Food  Quantity  
    
Sunday Dinner Lamb,Trim Lamb(No Separable Fat),Raw   100g   
        Snowpea(Pea Pod),Cooked,Fat Not Added In Cooking   50g   
        Pea,Green,Cooked,From Raw,Fat Not Added In Cooking   50g   
        Rocket,Raw   25g   
        Mint,Raw   0.25 cup   
        Cheese,Feta,Reduced Fat   50g   
        Vinegar   0.25 tb   
        Oil,Canola(Include Rape Seed Oil)   0.5 tsp   
        Mustard,Cream Type,Commercial   0.25 tsp   
        Yoghurt,Skim/Low Fat,Vanilla,Artificially Sweetened   200g   
        Date,Dried   20g   
        Cordial,citrus fruit juice,artif sweetened,rec dilution   600 ml   
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B10. Seven day model of the lower-protein, lower-haem iron diet 
Day  Meal  Food  Quantity  
    
Monday Breakfast Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   200g   
        Apple,Green,Raw,Unpeeled   150g   
        Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        .Vegemite [Yeast extract]   1 tsp   
        Tea,black,brewed from leaf/teabags,regular   500 mL   
                
    Lunch Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Baked Beans,Canned In Tomato Sauce   0.33 cup   
        Cheese,Cheddar(Mild,Tasty,Vintage)   25g   
        Carrot,Raw   0.25 cup (chopped)   
        Celery,Raw   0.25 cup (strips)   
        .Cadbury dairy milk [Chocolate]   20g   
        .Diet coke [Soft drink]   500 mL   
                
    Dinner Chicken,Breast,Raw,Without Skin   80g   
        Broccoli,Cooked,Fat Not Added   65g   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   50g   
        Squash,Button,Cooked,Fat Not Added In Cooking   75g   
        Salad,Side,Without Dressing,NFS   1 cup   
        Rice,white,boiled   120g   
        Juice,orange,commercial,unsweetened   150 ml   
        Water,plain,drinking   500 mL   
        .Arnotts glengarry [Biscuit]   2 biscuit   
                
Tuesday Breakfast .Sanitarium Weet-Bix(regular) [Breakfast cereal]   2 biscuit   
        .Shape [Milk]   250 ml   
        Strawberry,Raw   150g   
        Water,plain,drinking   500 ml   
                
    Lunch  Soup,Tomato,Smooth,Red Energy,Fr Dry Mix,Reconst W/Water   1 cup   
        Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Lettuce,common,raw   1 Leaf   
        Tomato,Raw   2 thin slice   
        Carrot,Raw   1 large strip (7.5cm long)   
        Beetroot,canned,drained   1 Slices   
        .Arnotts glengarry [Biscuit]   2 biscuit   
        Banana,common,raw,peeled   150g   
        Water,plain,drinking   500 ml   
                
    Dinner Pork,butterfly steak,raw,lean   80g   
        Garlic,raw,peeled   0.5 Clove   
        Oil,Sesame   1 tsp   
        Shallot,Raw   1 serve (2 shallot bulbs)   
        Chili,red,raw   5g   
        Cabbage,Bok Choy,Cooked,Fat Not Added In Cooking   1 cup (cooked)   
        Snowpea(Pea Pod),Cooked,Fat Not Added In Cooking   75g   
        Sauce,Oyster,Asian,Commercial   0.08 cup   
        Sauce,Chili,Asian,Commercial   0.06 cup   
        Noodle,Asian,NS Type,Cooked,Fat Not Added In Ckg   0.33 cup   
        Yoghurt,Skim/Low Fat,Vanilla,Artificially Sweetened   200g   
        Cordial,other fruit juice,artif sweetened,rec dilution   600 ml   
                
Wednesday Breakfast Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Honey,All Types   2 tsp   
        Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   200g   
        Coffee,black,from instant,regular,NS strength   250 ml   
        .Shape [Milk]   20 mL   
        Water,plain,drinking   400 ml   
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Day  Meal  Food  Quantity  
                
Wednesday Lunch Bean,Red Kidney,Canned,Drained   0.33 cup (drained)   
        Pasta,Regular,Cooked,Fat Not Added In Cooking,With Added Salt   120 g (dry)   
        Carrot,Raw   0.3 cup (chopped)   
        Capsicum,Red,Raw   0.3 cup (nfs)   
        Corn,Canned,Fat Not Added   0.3 cup (baby corn,chopped)   
        Onion,Spring,Raw   0.1 cup (chopped)   
        Dressing,Salad,Fat Free,Vinegar-Based,NFS   0.25 cup   
        Apple,Green,Raw,Unpeeled   150g   
        Custard,Low Fat,Vanilla,Commercial   200g   
        Water,plain,drinking   500 ml   
                
    Dinner Snapper,Raw   80g   
        Broccoli,Cooked,Fat Not Added   0.5 cup (nfs)   
        Carrot,Cooked,Fat Not Added In Cooking   0.5 cup (nfs)   
        Bean,Green,Cooked,From Raw,Fat Not Added In Cooking   0.25 cup (chopped)   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   0.25 cup (chopped)   
        Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        .Arnotts shortbread [Biscuit]   2 biscuit   
        Apricot,dried   20g   
        Water,plain,drinking   500 ml   
                
Thursday Breakfast .Kellogg's Just right [Breakfast cereal]   40g   
        .Shape [Milk]   250 ml   
        Peach,Canned In Natural Juice,Drained   150g   
        Tea,black,brewed from leaf/teabags,regular   500 ml   
                
    Lunch .Westons ryvita(original whole rye) [Biscuit]   2 biscuit (crispbread)   
        Cheese,Cheddar(Mild,Tasty,Vintage)   25g   
        Onion,Mature,Raw   1 thin slice   
        Tomato,Raw   0.4 cup (chopped/sliced)   
        Cucumber,Lebanese,Raw   0.4 cup (chopped/diced)   
        Lettuce,Cos,Raw   0.2 cup (nfs)   
        Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        .Vegemite [Yeast extract]   2 tsp   
        Juice,apple   150 ml   
        Water,plain,drinking   500 ml   
                
    Dinner Beef,Steak,Fillet,Raw,Fat Trimmed   80g   
        Oil,Olive   1 tsp   
        Pepper,Black/White   0.5 tsp   
        Fennel,Cooked,Fat Not Added In Cooking   0.25 cup   
        Zucchini,Cooked,Fat Not Added In Cooking   0.5 cup (nfs)   
        Capsicum,Red,Cooked/Canned,Fat Not Added In Cooking   0.5 cup (chopped)   
        Mushroom,Cooked/Canned,Fat Not Added In Cooking   0.25 cup (sliced)   
        Juice,lemon,fresh   0.06 cup   
        Rice,white,boiled   120g   
        .Arnotts glengarry [Biscuit]   2 biscuit   
        Mineral Water,Natural   500 ml   
                
Friday Breakfast Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        Baked Beans,Canned In Tomato Sauce   0.33 cup   
        Banana,common,raw,peeled   150g   
        Water,plain,drinking   600 ml   
                
    Lunch Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Cheese,Cheddar,Reduced Fat(50%Reduction)   50g   
        Tomato,Raw   0.25 cup (chopped/sliced)   
        Salad,Side,Without Dressing,NFS   0.75 cup   
        .Arnotts shortbread [Biscuit]   2 biscuit   
        .Diet coke [Soft drink]   1 bottle(500ml)   
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Day  Meal  Food  Quantity  
                
Friday Dinner Chicken,Breast,Raw,Without Skin   80g   
        Tomato Puree   3 tb   
        Garlic,raw,peeled   0.5 Clove   
        Asparagus,Cooked,Fat Not Added In Cooking   0.5 cup   
        Carrot,Cooked,Fat Not Added In Cooking   0.25 cup (nfs)   
        Pumpkin,Boiled,Without Added Salt,Fat Not Added In Cooking   0.5 cup (nfs)   
        Cauliflower,Cooked,Fat Not Added In Cooking   0.25 cup   
        Pasta,Regular,Cooked,Fat Not Added In Cooking,With Added Salt   120g   
        Yoghurt,Skim/Low Fat,Vanilla,Artificially Sweetened   200g   
        Grape,Green,No Seeds,Raw   150g   
        Water,plain,drinking   600 ml   
                
Saturday Breakfast .Kellogg's Sustain [Breakfast cereal]   40g   
        .Shape [Milk]   250 ml   
        Watermelon,raw,peeled   300g   
        Water,plain,drinking   500 mL   
                
    Lunch Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Rocket,Raw   0.25 cup (shredded/chopped)   
        Tomato,Raw   0.25 cup (chopped/sliced)   
        Carrot,Raw   0.25 cup (grated)   
        Beetroot,Canned,Drained   0.25 cup (slices)   
        Potato,Dry-Baked,With Skin(Unpeeled)   150g   
        Oil,Olive   1 tsp   
        Custard,Low Fat,Vanilla,Commercial   200g   
        Water,plain,drinking   500 ml   
                
    Dinner Barramundi,Raw   80g   
        Garlic,raw,peeled   0.5 Clove   
        Juice,lemon,commercial   1 tsp   
        Capers   1 tb   
        Lettuce,Common,Raw   0.5 cup (nfs)   
        Carrot,Raw   0.25 cup (chopped)   
        Tomato,Cherry,Raw   0.5 cup (cherry tomato)   
        Snowpea Sprout,Raw   0.25 cup   
        Vinegar   1 tb   
        Pasta,Regular,Cooked,Fat Not Added In Cooking,With Added Salt   120g   
        .Arnotts glengarry [Biscuit]   2 biscuit   
        Wine,Red   150 mL   
        Water,plain,drinking   300 ml   
                
Sunday Breakfast Bread,Mixed Grain   70g   
        Margarine Spread,Monounsaturated,Canola   2 tsp   
        Tomato,Grilled   0.5 cup (chopped)   
        Mushroom,Cooked/Canned,Fat Not Added In Cooking   0.5 cup   
        Coffee,black,from instant,regular,NS strength   250 ml   
        .Shape [Milk]   20 mL   
        Water,plain,drinking   500 ml   
                
    Lunch Rice,white,boiled   120g   
        Pea,Green,Cooked,From Frozen,Fat Not Added In Cooking   0.2 cup   
        Carrot,Cooked,Fat Not Added In Cooking   0.2 cup (diced fr fresh)   
        Corn,Canned,Fat Not Added   0.1 cup   
        Bread,Mixed Grain   35g   
        Margarine Spread,Monounsaturated,Canola   1 tsp   
        Apple,Green,Raw,Unpeeled   150g   
        Yoghurt,Skim/Low Fat,Fruit,Artificially Sweetened   300g   
        Mineral Water,Natural   500 ml   
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Day  Meal  Food  Quantity  
    
Sunday Dinner Pork,butterfly steak,raw,lean   80g   
        Juice,apple   0.06 cup   
        Sauce,Cranberry,Commercial   0.125 cup (sauce)   
        Honey   1 tsp   
        Juice,orange,commercial,unsweetened   1 tsp   
        Couscous,Cooked,Fat Not Added In Cooking   0.75 cup (cooked)   
        Broccoli,Cooked,Fat Not Added   0.33 cup (nfs)   
        Snowpea(Pea Pod),Cooked,Fat Not Added In Cooking   0.33 cup   
        Pumpkin,Dry-Baked   0.33 cup   
        .Arnotts shortbread [Biscuit]   2 biscuit   
        Date,Dried   20g   
        Cordial,citrus fruit juice,artif sweetened,rec dilution   600 ml   
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APPENDIX C: SUPPLEMENTARY MATERIAL FOR CHAPTER 6 
C1. Detailed methods used for genetic analysis 
C2. Background information on the TaqMan® SNP Allelic Discrimination technique 
C3. Background information on interpreting the TaqMan® SNP Allelic Discrimination output 
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C1. Detailed methods used for genetic analysis 
DNA extraction 
The procedures outlined below were largely in accordance with the specified protocol for 
extracting DNA from frozen blood samples (Promega Corporation, Madison, USA). 
 
Cells were lysed in sterile 1.5ml microcentrifuge tubes containing 300 µl of thawed (from frozen 
storage) heparin packed red blood cells and 900 µl of cell lysis solution. Tubes were incubated for 
10 minutes at room temperature. After incubation, cell nuclei were isolated by centrifugation at 
13,000 × g for 20 seconds (room temperature) with removal of as much supernatant as possible. 
The cell lysis and nuclei isolation procedures were then repeated to maximise removal of cell 
debris. Tubes were then vortexed vigorously for 15 seconds to resuspend the isolated nuclei. 
 
Following resuspension, cell nuclei were lysed by adding 300 µl of nuclei lysis solution, mixed (by 
repeated pipetting) and incubated for approximately 60 minutes at 37 ºC. During this step, 1.5 µl of 
RNAse solution was also added to each tube to eliminate RNA contaminants. Subsequently, 100 µl 
of protein precipitation solution was added to each tube of nuclear lysate and centrifuged at 13,000 
× g for 3 minutes (room temperature) to induce precipitation and separation of unwanted protein 
contaminants. The supernatant (containing solubilised genomic DNA) from each tube were 
transferred into new sterile 1.5 ml microcentrifuge tubes (correspondingly labelled) containing 300 
µl of room temperature isopropanol and inverted several times to induce precipitation of DNA 
strands. Tubes were then centrifuged at 13,000 × g for 60 seconds (room temperature) and the 
isopropanol supernatant discarded carefully (to ensure that the precipitated DNA pellet does not 
dislodge from the wall of the tubes). 
 
A final wash of the DNA pellets was performed by adding 300 µl of 70% ethanol to each tube and 
gently inverting several times. Tubes were centrifuged at 13,000 × g for 60 seconds (room 
temperature) again with the ethanol supernatant discarded carefully. Each tube was then inverted 
and the DNA pellet (lodged on the wall of each tube) was air-dried for 15 minutes. Finally, the air-
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dried DNA samples were rehydrated in 10mM Tris-HCl (pH 7.4) and 1mM EDTA (pH 8.0) (1× TE 
buffer) and incubated overnight at 4 ºC (see note below). Rehydrated DNA samples were 
transferred to longer term storage at -20 ºC the following day. Concentration of the rehydrated 
DNA was determined using a NanoDrop spectrophotometer (NanoDrop Technologies, 
Wilmington, USA). 
 
N.B. DNA pellets were initially rehydrated in 100 µl of 1× TE buffer as per the kit protocol. 
However, due to low DNA yield from some of the blood samples that were initially isolated (likely 
due to low white cell concentration), the rehydration volume was adjusted to 20 µl so as to 
maximise the concentration of the rehydrated DNA. 
 
DNA target sequence amplification 
PCR was employed to amplify the 167 base pair target sequence containing the SNP rs855791. The 
custom primer and target sequences are shown in Appendix Table C1.1, with details of the PCR 
reaction set-up outlined in Appendix Table C1.2. 
 
Appendix Table C1.1. Custom oligonucleotide primer and target sequences 
 Tm (ºC) Any SC 3’ SC Sequence (5’ to 3’) 
Primers     
     TMPRSS6fwd 64.1 8.00 2.00 TCTGCAGAAAGTGGATGTGC 
     TMPRSS6rev 63.5 2.00 0.00 GCATCCTTTCTCCCTCCTCT 
Target sequence  6.00 2.00 TCTGCAGAAAGTGGATGTGCAGTTGATC
CCACAGGACCTGTGCAGCGAGG[C/T]C
TATCGCTACCAGGTGACGCCACGCATGC
TGTGTGCCGGCTACCGCAAGGGCAAGAA
GGATGCCTGTCAGGTGAGTCCCCCGGGC
ATGGGAGGGAGAGAGGAGGGAGAAAGGA
TGC 
Tm, melting temperature; SC, self-complementarity 
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Appendix Table C1.2. PCR reaction set-up and thermal cycler program 
PCR reaction set-up (total volume 50 µl) Thermal cycler program 
- 5 µl genomic DNA 95 ºC × 5 min 
- 1.5 µl TMPRSS6fwd primer (5 µM)a 95 ºC × 1 min 
- 1.5 µl TMPRSS6rev primer (5 µM)a 60 ºC × 1 min 
- 5 µl 10× PCR bufferb 72 ºC × 1 min 
- 5 µl dNTPs (2 mM) 72 ºC × 7 min 
- 1 µl Taq polymerase (5 units/µl) 4 ºC × ∞ 
- 31 µl sterile nuclease free water  
DNA, deoxyribonucleic acid; dNTPs, deoxyribonucleotide triphosphates; PCR, polymerase chain 
reaction; ∞, indefinite period of time 
arehydrated in 10mM Tris-HCl (pH 7.4) and 1mM EDTA (1× TE buffer) 
b10× PCR buffer contains 200 mM Tris-HCl (pH 8.4) and 500 mM KCl 
 
PCR product (amplicon) purification 
Following amplification, 10 µl of 6× Orange G loading dye was added to each PCR product and 
then loaded onto 3.5% agarose gels made in 1× TAE buffer (40 mM Tris-acetate, pH 8.0; 20 mM 
sodium acetate; 1 mM EDTA) and containing 50 µl of 500 µg/ml ethidium bromide solution. DNA 
purification was performed by running gel electrophoresis in 1× TAE buffer at 80 volts for 30 
minutes (or when loading dye bands had travelled approximately halfway across the gel). DNA 
bands of the purified amplicons were visualised using an ultraviolet (UV) transilluminator as 
shown in Appendix Figure C1.1. 
  
repeated for 
35 cycles 
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Appendix Figure C1.1. Agarose gel-purified amplicons visualised under ultraviolet (UV) light 
(Four samples, each taking three wells, were loaded onto gel A with each sample divided by a 
minimum of one empty lane to ensure clear separation of DNA; one sample was loaded onto gel B 
for logistical reasons) 
 
Purified DNA bands were cut out and recovered by Spin-X centrifuge filtration (Corning 
Incorporated, Corning, USA) at 13,000 × g for 15 minutes. To precipitate the amplicons from 
solution, 3 M sodium acetate (1/10
th
 of the volume of each amplicon solution), 100% ethanol (2½ 
volumes of each amplicon solution) and 2 µl of 1 mg/ml glycogen (carrier) were added to each tube 
and stored at -20 ºC for overnight precipitation. Samples were centrifuged the following day at 
13,000 × g for 15 minutes (at 4 ºC) and the supernatant was discarded (ensuring the amplicon pellet 
does not dislodge from the wall of the tube). A final wash with 500 µl of 70% ethanol and 
centrifugation (13,000 × g for 15 minutes at 4 ºC) was performed before the amplicon pellets were 
air-dried and rehydrated in 10 µl of sterile nuclease free water. 
 
Amplicon sequencing 
Amplicons were prepared for sequencing in accordance with the sample submission requirements 
outlined by the Australian Genome Research Facility Ltd, Sydney, Australia. Results showed one 
participant as homozygous for the C allele, another as homozygous for the T allele, and the 
remaining three participants as heterozygotes. The sequencing results of three participants (one of 
each zygosity) are presented in Appendix Figure C1.2. 
167bp 
A 
  1    2     3    4     5    6     7     8    9    10   11  12  13  14   15   16 
B 
17   18    19    20    21    22    23 
Appendix C: Supplementary Material for Chapter 6 
211 
 
 
Appendix Figure C1.2. Amplicon sequencing results from three participants [C allele 
homozygosity as reflected by the blue cytosine signal spike on the (A) forward and (B) reverse 
complement sequences; T allele homozygosity by the red thymine signal spike on the (C) forward 
and (D) reverse complement sequences; and CT heterozygosity by the mixed blue cytosine and red 
thymine signal spikes on the (E) forward and (F) reverse complement sequences]  
C D 
E F 
A B
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Verification of sequencing results 
To ensure that the SNP rs855791 was captured within the amplicons generated from the two 
custom oligonucleotide primers, sequencing results were verified against online published data. 
The sequence alignment results from one amplicon sample are shown in Appendix Figure C1.3. 
 
 
 
Appendix Figure C1.3. Sequence alignment and verification results (Amplicons generated from 
one DNA sample showing a 99% match with published data on the TMPRSS6 gene; the 1% 
mismatch reflects the rs855791 polymorphism as highlighted by the red box) 
 
TaqMan® SNP Allelic Discrimination set-up 
Three of the five participants with known rs855791 genotype (from sequencing) were selected as 
positive controls for genotyping analysis on the remaining participants (n=71). Prior to analysis, 
genomic DNA samples were diluted to a concentration of 30 ng/µl with sterile nuclease free water. 
Reactions were arranged on 96-well PCR reaction plates (Life Technologies Australia Pty Ltd, 
Mulgrave, Australia) based on the diagram shown in Appendix Figure C1.4. Details of the 
genotyping reaction set-up are outlined in Appendix Table C1.3. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A NTC NTC U01 U01 U09 U09 U17 U17 U25 U25 U33 U33 
B NTC NTC U02 U02 U10 U10 U18 U18 U26 U26 U34 U34 
C 
+ve 
(CC) 
+ve 
(CC) 
U03 U03 U11 U11 U19 U19 U27 U27 U35 U35 
D 
+ve 
(CC) 
+ve 
(CC) 
U04 U04 U12 U12 U20 U20 U28 U28 U36 U36 
E 
+ve 
(CT) 
+ve 
(CT) 
U05 U05 U13 U13 U21 U21 U29 U29 U37 U37 
F 
+ve 
(CT) 
+ve 
(CT) 
U06 U06 U14 U14 U22 U22 U30 U30 U38 U38 
G 
+ve 
(TT) 
+ve 
(TT) 
U07 U07 U15 U15 U23 U23 U31 U31 U39 U39 
H 
+ve 
(TT) 
+ve 
(TT) 
U08 U08 U16 U16 U24 U24 U32 U32 U40 U40 
 
Appendix Figure C1.4. Real-time PCR plate set-up for genotyping analysis (Four wells were 
assigned to positive controls of each zygosity and the no template control/blank; reactions for all 
unknown DNA samples were performed in duplicate; NTC, no template control; +ve, positive 
controls; U, unknown samples) 
 
Appendix Table C1.3. Genotyping reaction set-up and thermal cycler program 
Genotyping reaction set-up (total volume 25 µl) Thermal cycler program 
- 2.5 µl genomic DNA (30 ng/µl) 60 ºC × 1 min 
- 1.25 µl 20× TaqMan® SNP Genotyping Assay 95 ºC × 10 min 
- 12.5 µl 2× TaqMan® Universal PCR Master Mix 95 ºC × 15 sec 
- 8.75 µl sterile nuclease free water 60 ºC × 1 min 
 60 ºC × 1 min 
DNA, deoxyribonucleic acid; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism 
  
repeated for 
40 cycles 
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C2. Background information on the TaqMan® SNP Allelic Discrimination technique 
TaqMan® SNP Allelic Discrimination technique 
TaqMan® SNP genotyping is an allelic determination technique that uses a real-time PCR system 
platform (Applied Biosystems, Foster City, USA) and relies primarily on the activity of two 
reagents: (1) 20× SNP Genotyping Assay; and (2) 2× TaqMan® Universal PCR Master Mix (Life 
Technologies Australia Pty Ltd, Mulgrave, Australia). The 20× SNP Genotyping Assay contains 
two primers for amplifying the sequence surrounding the SNP rs855791 (similar to the custom 
oligonucleotide primers used for target sequence amplification) and two TaqMan® Minor Groove 
Binder (MGB) probes. The TaqMan® MGB probes are small amplicons that bind to their 
complementary sequence directly on the SNP site of the DNA strand. These specialised probes are 
attached to one of two reporter dyes (FAM™ or VIC® corresponding to the C or T allele 
respectively) and a dye-quencher that inhibits fluorescence of the reporter dye whilst it is still 
attached to the probe. The 2× TaqMan® Universal PCR Master Mix contains a specialised Taq 
DNA polymerase, deoxyribonucleotide triphosphates (dNTPs), as well as dye-signal reference and 
buffer components for optimal allelic determination performance. The theoretical concept of this 
genotyping technique is outlined below and illustrated visually in Appendix Figure C2.1. 
 
During real-time PCR, DNA denaturation occurs resulting in formation of single-stranded DNA 
templates that are free to bind (anneal) with the primers and probes from the SNP Genotyping 
Assay reagent. The probes anneal directly to the SNP site (which is between the two primers) on 
the DNA strand. Depending on genotype, an individual may only have C or T allele DNA 
templates (indicating that only the FAM™ or VIC® probes can anneal to the SNP sites) or they 
may have a combination of both DNA template types (indicating that both probes can anneal to 
their complementary SNP sites). Taq polymerase, which has both DNA synthesising (3’→5’ 
polymerase activity) and degrading (5’→3’ exonuclease activity) properties, subsequently attaches 
to the 3’ end of the primers on the DNA template and generates a short amplicon sequence up to 
the location where the probe is annealed to the SNP site. At this stage, Taq polymerase 5’ 
exonuclease activity cleaves the probe resulting in separation of the FAM™ or VIC® reporter dye 
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from its quencher. Once the FAM™ or VIC® dye is released from its quencher, it fluoresces at a 
specific frequency which is detected by the real-time PCR system. Hence, if fluorescence is only 
detected from the FAM™ reporter dye, this indicates homozygosity for the C allele. Conversely, T 
allele homozygosity is reflected by fluorescence from the VIC® reporter dye only. If fluorescence 
is detected from both reporter dyes, this indicates heterozygosity.  
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Appendix Figure C2.1. An illustrated summary of the TaqMan® SNP genotyping technique [(A) 
the Minor Groove Binder (MGB) probe anneals directly to the SNP site of the DNA template while 
the primer binds nearby; (B) once the primer and probe are attached, Taq polymerase (in yellow) 
binds to the 3’ end of the primer; (C) Taq polymerase generates an amplicon sequence (in orange) 
up to the SNP site; (D) Taq polymerase cleaves the MGB probe leading to the detachment of the 
FAM™ reporter dye (in blue) from its quencher (in red) resulting in fluorescence of FAM™]  
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C3. Background information on interpreting the TaqMan® SNP Allelic Discrimination output 
TaqMan® SNP Allelic Discrimination outputs 
A number of results are provided by the real-time PCR system following genotype analysis, with 
important outputs being the change in fluorescent signals, the ‘call’ and the allelic discrimination 
plot. 
 
As the reporter dyes fluoresce at two distinct frequencies, an increase in fluorescence at the FAM™ 
or VIC® specific frequency indicates the presence of the C or T allele respectively (Appendix 
Figure C3.1). 
 
 
 
 
Appendix Figure C3.1. Amplification and multicomponent plots [(A) amplification and (B) 
multicomponent plots showing detectable increases in fluorescent signals from the 20
th
 cycle of the 
real-time PCR system; increases in FAM™ (in blue) and VIC® (in green) signals are shown in the 
multicomponent plot on the right]  
Multicomponent Plot 
Amplification Plot 
B A 
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Theoretically, the detection of both signals in one DNA sample indicates heterozygosity for the 
SNP. However, results from analysing the sequenced DNA samples show the presence of some 
background VIC® fluorescence despite C homozygosity. This suggests some inappropriate binding 
of the VIC® probe to non-complementary SNP sites. Although the cause of this is not entirely 
clear, we believe that it may be due to a phenomenon known as the ‘wobble’ where pairing of non-
complementary bases occasionally occurs during translation.
a
 This phenomenon is observed in 
natural DNA replication and partly explains redundancy in the genetic code.
b
 It is known to be a 
cause of DNA mutation.
a
 
 
Despite the presence of the ‘wobble’ phenomenon, the inclusion of sequenced positive controls on 
each PCR plate provides a benchmark of expected FAM™ and VIC® signal sizes for each 
zygosity. The genotype of the unknown DNA samples is determined (or ‘called’) based on how 
closely their signals match those of the positive controls (Appendix Figure C3.2). Information on 
the size of each fluorescent signal and the call made is then visually summarised in the allelic 
discrimination plot (Appendix Figure C3.3). 
 
  
                                                   
aPray L. DNA Replication and Causes of Mutation. Nature Education 2008; 1. 
bArdell DH, Sella G. On the evolution of redundancy in genetic codes. J Mol Evol 2001; 53: 269-81. 
Appendix C: Supplementary Material for Chapter 6 
219 
 
 
Appendix Figure C3.2. A snapshot of the real-time PCR genotyping output (Columns ‘Allele1 
∆Rn’ and ‘Allele2 ∆Rn’ denote the magnitude of the change in VIC® and FAM™ fluorescent 
signals respectively; the ‘Call’ column shows the genotype of the unknown DNA samples 
determined according to the fluorescence patterns of the positive controls) 
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Appendix Figure C3.3. Allelic discrimination plot [The X and Y axes indicate the size of the 
VIC® and FAM™ fluorescent signals respectively; the coloured markers signify successful 
genotype determination (blue: C homozygote; green: heterozygote; red: T homozygote) whereas 
the black crosses indicate undetermined calls; the black markers represent the no template controls 
or blanks] 
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